Document 6BXYLNRd8djmma6xap8yZwGp6
RECYCLED
T
-hUtf - 9 V * W
\ 04r5^o
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
TRADE SECRET Study Title
H-24678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
Volume 2 of 4
Laboratory Project ID: DuPont-6554
DuPont-6554
Test Guidelines: U.S. EPA Health Effects Test Guidelines OPPTS 870.3100 (1998)
Author: Don A. Delker, Ph.D Study Completed on: April 22,2002 Performing Laboratory: EEHl.aIk.stkodenullRPLooanabtdod,rPea.tNOoer.myBfooouxrrH5s0aeanldthCaonmdpEannvyironmental Sciences
Newark, Delaware 19714-0050 Work Request Number I Service Code Number
ClinicSatludPyatNhuomlboegry:,
Page 216 of 1022 Cmpy Sanitized. Does no! contagli TSCACBI
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE42 INCIDENCES OF LESION G(9R0-ADNDOAENYS-ENOXEFPOMOPISLCUARRSOTESIECCVOLAPEILSCUIOOANBTSSIOERNV) ATIONS IN MALE RATS-
LESION INCIDENCE (NUMERIC) Males
| 1
LESIONS DIGESTIVE SYSTEM
| TREATMENT 1 1 1
0 60 10 60, 300 mg /kg mg/kg mg/kg mg/kg1 mg/kg /day /day /day /day /day
I III a V b VII b IX b
LIVER
(10) (10) (10) (10) (11)
NECROSIS, FOCAL. minimal total observations per lesion
43 43
INFLAMMATION, SUBACUTE/CHRONIC. minimal total observations per lesion
10 10 10 10 10 10 10 10
9 9
HYPERTROPHY, HEPATOCYTE, CENTRILOBULAR. minimal mild moderate total observations per lesion
1 9 1
1 10
HYPERPLASIA, BILE DUCT. minimal total observations per lesion
11 11
FATTY CHANGE, MEDIAN CLEFT. minimal mild
21 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified wras not identified a 60 mg/kg/day Isopropano b H-24678 is
217
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats___________
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
(90-DNOANY-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
LESIONS
DIGESTIVE SYSTEM
LIVER FATTY CHANGE, MEDIAN CLEFT. total observations per lesion FATTY CHANGE, CENTRILOBULAR. minimal mild moderate total observations per lesion
TREATMENT
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mg/kg mg/kgj mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
(10) (10) (10) (10) (ID
32
31 21 1
332
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 i s T ~ ~
>
DuPont-6554
Cempany Sanitized. Does no! contain TSCA CBi
218
)/
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
1/
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRANDOENS-NOEFOMPILCARSOTSICCOLPEISCIOONBSSERVATIONS IN MALE RATS-
(90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
1 Males
| TREATMENT
1 1 1
o 60 10 I 60 300 mg /kg mg/kg mg/kgI mg/kg mg/kg /day /day /day |/day /day
I III a V b 1 VII b IX b
PANCREAS
NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC. minimal total observations per lesion
HYPERPLASIA, FOCAL, ACINAR CELL. minimal total observations per lesion
ATROPHY. minimal total observations per lesion
ALTERATION, BASOPHILIC, FOCAL. minimal total observations per lesion
(10) 6 1 3.
4 4
(ID 7
3 3
1 1
2 2
1 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 if
/1
DuPont-6554
Company Sanitized. Does not contain TSCACSI
219
Sanitized Does not contain TSCACBf
>
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
(90-DNOAYN-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
Males
TREATMENT
0 60 10 60 300 1 mg/kg mg/kgi mg/kg| mg/kg mg/kg /day /day /day /day /day
1 I III a V b VII b IX b
ESOPHAGUS NO ABNORMALITY DETECTED
(10) 10
(10) 10
STOMACH NO ABNORMALITY DETECTED
(10) 10
(11) 11
DUODENUM NO ABNORMALITY DETECTED
JEJUNUM NO ABNORMALITY DETECTED
(10) 10
(10) 10
(11) 11
(11) 11
ILEUM
GO)
NO ABNORMALITY DETECTED
10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 i s l "
(11) 11
220
)
DuPont-6554
)
9H0--2D4a6y78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
'
| TREATMENT 1 1 1
LESION INCIDENCE (NUMERIC)
.
Males
0 I 60 10 60, 300 mg/kg| mg/kg mg/kg mgj/kg mg/kg /day I/day /day /day /day 1 | III a v b VII b IX b
CECUM NO ABNORMALITY DETECTED
(10) 10
(ID 11
COLON NO ABNORMALITY DETECTED
(10) 10
(11) 11
RECTUM NO ABNORMALITY DETECTED
SALIVARY GLANDS NO ABNORMALITY DETECTED
(10) 10
(10) 10
(11) 11
(ID 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
b H-24678 is
P
" 'L
>
DuPont-6554
Company Sanitized. Does not contain TSCCBI
221
))
H90-2-D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats___________________________________________________________________________ _______________ DuPont-6554
TABLE 42 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATSNON-NEOPLASTIC LESIONS
(90-DAY EXPOSURE EVALUATION)
| LESION INCIDENCE (NUMERIC)
|
LESIONS URINARY SYSTEM
Males
TREATMENT
| 0 60 10 60 300 1 mg/kg mg/kg mg/kg mg/kg mg/kg 1/day /day /day /day /day
1 I III a V b VII b IX b
KIDNEYS
NO ABNORMALITY DETECTED
NEPHROPATHY, CHRONIC PROGRESSIVE, minimal total observations per lesion
HYPERTROPHY, TUBULAR, minimal total observations per lesion
HYDRONEPHROSIS, UNILATERAL, mild total observations per lesion
CYST. minimal total observations per lesion
(10) 5
(10) 8
(10) 5
(10) 5
(11)
52448 52448
11 11
1 1
1 1
URINARY BLADDER
(10)
NO ABNORMALITY DETECTED
10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
(11) I ! il
Company Sanitized. Does not contain TSCACBI
222
Company Sanitized. Does not contain TSCA CB1
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
_________
TABLE 42 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATSNON-NEOPLASTIC LESIONS
(90-DAY EXPOSURE EVALUATION)
| LESIONS
i | | RESPIRATORY SYSTEM | LUNGS | NO ABNORMALITY DETECTED
| TREATMENT
1 1
LESION INCIDENCE (NUMERIC)
Males
0 | 60
10 | 60 | 300
mg/kg| mg/kg mg/kgj mg/kg! mg/kg
/day j/day /day |/day /day
I j III a V b j VII b IX b
(10) 10
(11) 10
| FOREIGN MATERIAL. | mild | total observations per lesion
| EDEMA. | minimal | total observations per lesion
1 1
1 1
| TRACHEA | NO ABNORMALITY DETECTED
(10) 10
(11) 11
\
| PHARYNX/LARYNX
(10)
j NO ABNORMALITY DETECTED
9
| INFLAMMATION, SUBACUTE/CHRONIC. | minimal | total observations per lesion
1 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day .Isopropanol b H-24678 is|
(11) 11
223
)
DuPont-6554
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats________
)
TABLE 42 (CONTINUED)
INCIDENCES OF LESION G(9R0-ADNDOAENYS-ENOXEFPOMOPILSCUARRSOTESIECCVOLAPEILSCUIOOANBTSSIOERNV) ATIONS IN MALE RATS-
1 11 1 1i 1 LESIONS 1 1
1 1\ 1 1 RESPIRATORY SYSTEM 1 1 1 NOSE
1 NO ABNORMALITY DETECTED
1 ODONTODYSPLASIA. 1 minimal 1 total observations per lesion
1 LESION INCIDENCE (NUMERIC)
! Males
| TREATMENT
1 1 1
|o
60 I 10
60 | 300
1 mg/kg| mg/kg mg/kg mg/kg j mg/kg 1/day /day /day /day /day
1 I III a V b VII b | IX b
(10) lI
9
1 1
(11)
1 7
1 INFLAMMATION, SUBACUTE/CHRONIC. 1 minimal
total observations per lesion
2 2
1 FOREIGN MATERIAL. 1 mild
1 total observations per lesion
1 1
1 DEGENERATION/NECROSIS, OLFACTORY, EPITHELIUM. 1 minimal 1 total observations per lesion
1
1 1
Figure in parentheses is number of animals microscopically examined for this tissue
)
DuPont-6554
Company Sanitized. Does
224
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NBOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
LESIONS
LESION INCIDENCE (NUMERIC) 11
Males
TREATMENT
0 ' 60 10 60 j 300 mg/kg mg/kg mg/kg mg/kgj mg/kg /day /day /day /day /day
I - III a V b VII b IX b
CARDIOVASCULAR SYSTEM
HEART
NO ABNORMALITY DETECTED
CARDIOMYOPATHY. minimal total observations per lesion
(10) 9
1 1
(11) 7
4 4
AORTA NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 "
DuPont-6554
Sanitized,, Does not contain TSCA
225
IOB
Company Sanitized. Does not contain TSCA CB
>
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
(90-DNOANY-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Males
0 60 10 1 60 300 mg/kg mg/kg mg/kgI mg/kg mg/kg /day /day /day 1/day /day 1 III a V b j VII b IX b
SPLEEN NO ABNORMALITY DETECTED
(10) 10
(11) 11
THYMUS NO ABNORMALITY DETECTED
(10) 10
(11) 11
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(10) 10
(11) 11
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(10) 10
(11) 11
BONE MARROW
(10)
NO ABNORMALITY DETECTED
10
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 60 mq/kq/dav.Isonropanol
b H-24678 M
'
(11) 11
226
)
DuPont-6554
Company Sanitized. Does not contain TSCA CB
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATSNON-NEOPLASTIC LESIONS
(90-DAY EXPOSURE EVALUATION)
LESION INCIDENCE (NUMERIC) Males
1 1
LESIONS ENDOCRINE SYSTEM
TREATMENT
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg /kg /day /day /day /day /day
I III a V b VII b IX b
PITUITARY GLAND NO ABNORMALITY DETECTED
(10) 10
(11) 11
THYROID GLAND
(10) (10) (10)
NO ABNORMALITY DETECTED
522
HYPERTROPHY, FOLLICULAR. minimal mild total observations per lesion
ALTERATION, COLLOID. minimal mild moderate severe total observations per lesion
368 11
11 588
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. minimal total observations per lesion
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
(10) 5 2 2 4
4
(11)
1
6 1 7
3 1 3 3 10
11 1 11 11
DuPont-6554
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyR a ts _____________________ ______________________________________ ______________________
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
LESIONS ENDOCRINE SYSTEM
LESION INCIDENCE (NUMERIC)
. Males
| TREATMENT |
1 1
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
PARATHYROID GLANDS NO ABNORMALITY DETECTED
(9) (9) 99
ADRENAL GLANDS NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dav Isopropanol b H-24678 is]
)
DuPont-6554
Company Sanitized. Does not contain TSCACBI
228
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
LESIONS NERVOUS SYSTEM
| TREATMENT
! 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 | 60 300 mg/kg mg/kg mg/kg| mg/kg mg/kg /day /day /day j/day /day 1 III a V b | VII b IX b
BRAIN NO ABNORMALITY DETECTED
(10) 10
(11) 11
SPINAL CORD NO ABNORMALITY DETECTED
(10) 10
(11) 11
SCIATIC NERVE NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dgy Isopropanol b H-24678 i L
DuPont-6554
Company Sanitized, Does notcontain TSCACB1
229
H90--2D4>6ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRANDOENS-NOEFOMPILCARSOTSICCOLPEISCIOONBSSERVATIONS IN MALE RATS-
(90-DAY EXPOSURE EVALUATION)
1 1 1 |
| LESIONS
I 1
1 l_ _ __
1 | MUSCULAR AND SKELETAL SYSTEM
1 1 | SKELETAL MUSCLE I1 | NO ABNORMALITY DETECTED
____
------------| TREATMENT
1 1 1 _ __
LEE5ION INCIDENCE (NUMERIC)
|
------------ 1
Males
1
------------ |
0
60 | 10
60 | 300 |
mg /kg mg/kg[ mg/kg mg/kg| mg/kg
/day /day |/day /day j/day
1 III a| V b VII b| IX b
(10) 10
(11! 11
1 | FEMUR/KNEE JOINT 1I [ NO ABNORMALITY DETECTED
1
1 | STERNUM I1 | NO ABNORMALITY DETECTED
l
(10) 10
(10) 10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
(11) 11
(11) 11
)
DuPont-6554
no| eonlaintSC<6<
230
Company Sanitized. Does not contain TSCA CBI
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRANDOENS-NOEFOMPILCARSOTSICCOLPEISCIOONBSSERVATIONS IN MALE RATS-
(90-DAY EXPOSURE EVALUATION)
LESIONS REPRODUCTIVE SYSTEM
| TREATMENT
1 1 1
1 LESION INCIDENCE (NUMERIC)
|
1
! Males 1
1 j 0 60 10 60 300 |
mg/kg mg/kg mg/kg mg /kg mg/kg|
/day /day /day /day /day |
I III a V b VII b IX b
TESTES
NO ABNORMALITY DETECTED
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL. minimal total observations per lesion
(10) 10
(11) 10
1 1
EPIDIDYMIDES NO ABNORMALITY DETECTED
(10) 10
(11) 11
PROSTATE
(10)
NO ABNORMALITY DETECTED
7
INFLAMMATION, SUBACUTE/CHRONIC. minimal mild total observations per lesion
2 1 3
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 ilT
(11) 9
1 1 2
231
)
DuPont-6554
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
))
________________________________________________________________DuPont-6554
TABLE 42 (CONTINUED) INCIDENCES OF LESION G(9R0-ADNDAOEYNS-ENOXEFPOMOPISLCUARRSOTESIECCVOLAPEILSCUIOOANBTSSIOERNV) ATIONS IN MALE RATS-
LESIONS REPRODUCTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
Males
1 TREATMENT
1i
1
| 0 60 1 10 60 300 1 mg/kg mg/kg1 mg/kg mg/kg mg/kg 1/day /day 1/day /day /day
1 I III a| V b VII b IX b
SEMINAL VESICLES NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day,Isopropanol b H-24678 isf
Company Sanitized. Does not contain TSC CBI
232
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
(90-DNOAYN-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
LESIONS CUTANEOUS SYSTEM
LESION INCIDENCE (NUMERIC)
Males
| TREATMENT
1 1 1
| 0 | 60 | 10
60 | 300
mg/kg| mg/kg| mg/kg mg/kg| mg/kg
/day I/day |/day /day |/day
I | III a| V b VII b | IX b
SKIN NO ABNORMALITY DETECTED
(10) 10
(11) 11
SPECIAL SENSES SYSTEM
EYE(S) WITH OPTIC NERVE
NO ABNORMALITY DETECTED
FOLD/ROSETTE, RETINAL. minimal total observations per lesion
ATROPHY, RETINAL. minimal total observations per lesion
(10) 8
1 1
1 1
(ID 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
DuPont-6554
ISO VQSl umuQQ jou S0OQ paziipB S Xueduioo
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats________________________________________________________________
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH EXPOSURE EVALUATION)
| LESIONS i 1
!
1 j DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
| TREATMENT 1 1
1
Males
j 0 300 |
1 mg/kg mg/kg| /day /day |
I IX a |
1
| LIVER
| NO ABNORMALITY DETECTED
| NECROSIS, FOCAL. | minimal j total observations per lesion
j INFLAMMATION, SUBACUTE /CHRONIC. | minimal | total observations per lesion
| HYPERTROPHY, HEPATOCYTE, CENTRILOBULAR. | minimal I total observations per lesion
| FATTY CHANGE, MEDIAN CLEFT. | minimal j mild | total observations per lesion
| FATTY CHANGE, CENTRILOBULAR. | minimal
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a_number indicates the lesion specified was not identified a H-24678 il
(10) 1
9 9
2 1 3 1
(9)
1 1
9 9
6 6
1 1
234
)
DuPont-6554
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
|
j 1! LESIONS
1
1 I_ _
_
_
| DIGESTIVE SYSTEM
_ __
_
1 1
l|| LIVER
I
FATTY CHANGE, CENTRILOBULAR. 1 total observations per lesion
1
|1 URINARY SYSTEM
1
|I11 KIDNEYS
| NO ABNORMALITY DETECTED
| LESION INCIDENCE (NUMERIC)
|
1-------------------------i Males
_____
| TREATMENT
I 1 1 _____
| 0 | 300
1 j|I mg/kg| mg/kg /day /day
IX a
(10)
(9)
1
(10) 3
(9) 4
j NEPHROPATHY, CHRONIC PROGRESSIVE.
|j minimal total observations per lesion
|1 HYDRONEPHROSIS, UNILATERAL. minimal
| total observations per lesion
1
74 74
11
11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of. a number indicates t;he lesion specified was not identified a H-24678 is
)
DuPont-6554
iy Santtl26d- Doe* not contain TSCACBf
235
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH RECOVERY EVALUATION)
DuPont-6554
LESIONS ENDOCRINE SYSTEM
| LESION INCIDENCE (NUMERIC) 1
| Males
TREATMENT
o 300 I mg/kg| mg/kg 1/day /day
1 I IX a
THYROID GLAND
(10)
(9)
NO ABNORMALITY DETECTED
5
Company Sanft?2ed. Does
HYPERTROPHY, FOLLICULAR. minimal total observations per lesion
6 6
ALTERATION, COLLOID. minimal mild moderate severe total observations per lesion
33 11 11
4 59
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
minimal
3 O
total observations per lesion
i Figure in parentheses is number of animals microscopically examined for this tissue
S The absence a -number indicates the lesion specified Was not identified
3 a H-24678 is
o01
>
o &
1 1
236
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (THREE-MONTH RECOVERY EVALUATION)
LESIONS DIGESTIVE SYSTEM
| LESION INCIDENCE (NUMERIC)
Males
1 l
i
TREATMENT
0 10 60 300 mg/kg mg/kg\ mg/kg mg/kg /day /day /day /day
I V a VII a IX a
LIVER
(5) (5) (5) (5)
NO ABNORMALITY DETECTED
11
NECROSIS, FOCAL.
minimal
moderate
m total observations per lesion
N INFLAMMATION, SUBACUTE/CHRONIC.
minimal a total observations per lesion
12 1
13
3455 3455
HYPERPLASIA, BILE DUCT. minimal total observations per lesion
11 11
FIBROSIS, BILE DUCT. moderate total observations per lesion
FATTY CHANGE, MEDIAN CLEFT. minimal
1
Figure in parentheses is number of animals microscopically examined for this tissue
1 1
1 1 1 I1 1 1
DuPont-6554
LDoes no! contain TSCA Cfj
237
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (THREE-MONTH RECOVERY EVALUATION)
LESIONS DIGESTIVE SYSTEM
| LESION INCIDENCE (NUMERIC)|
| TREATMENT
!
1
] Males
-- :--------- l j 0 10 60 1 300 1
mg/kg mg/kg mgVkgl mg/kg| /day /day /day 1/day |
1 V a VII a| IX a 1
LIVER
FATTY CHANGE, MEDIAN CLEFT. mild total observations per lesion
FATTY CHANGE, CENTRILOBULAR. minimal total observations per lesion
ECTASIA, BILE DUCT. severe total observations per lesion
(5) (5) (5) (5)
11 21
1 1
1 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of, number indicates the lesio.n specified yras not identified a H-24678 isl
DuPont-6554
)) )
H90--2D4a6y78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________________________________________________________ _________________ __________ DuPont-6554
TABLE 42 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS-
NON-NEOPLASTIC LESIONS (THREE-MONTH RECOVERY EVALUATION)
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC)
Males
o 10 60. 300 mg/kg| mg/kg mg/kg mg/kg /day 1/day /day /day
I 1 v a VII a IX a
ENDOCRINE SYSTEM
THYROID GLAND
ALTERATION, COLLOID. minimal mild severe total observations per lesion
(5) (5) (5) (5)
4542 1 12
1 5555
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a mnnber indicates .t-.he lesion snecifipn was not_identified a H-24678 is
Company Sanitized. Does
S28T.
5"
239
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________________________________________________
DuPont-6554
TABLE43 INCIDENCES OF LESION GRADNEOSNO-NFEMOIPCLRAOSSTCICOPLIECSOIOBNSSERVATIONS IN FEMALE RATS-
(90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
| Females
| TREATMENT
1 1 1
0 mg/kg /day
II
60 10 60 mg/kg| mg/kg| mg/kg /day /day /day
IV a 1 VI b VIIIb
300 mg/kg /day
Xb
LIVER
NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/ CHRONIC. minimal total observations per lesion
FATTY CHANGE, MEDIAN CLEFT. minimal mild total observations per lesion
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. minimal total observations per lesion
(10)
9 9 3 3
(11) 4
7 7
1 1
1 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
ova&i
240
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
))
_________________________________ _____________________DuPont-6554
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATSNON-NEOPLASTIC LESIONS
(90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
11 LESION INCIDENCE (NUMERIC) 1 1 Females
| TREATMENT
1 1 1
0 mg/kg /day
II
60 10 60 mg/kgj mg/kg| mg/kg /day /day /day
IV a VI b VIIIb
300 mg/kg /day
Xb
PANCREAS
NO ABNORMALITY DETECTED
HYPERPLASIA, FOCAL, ACINAR CELL. minimal mild total observations per lesion
DEGENERATION/NECROSIS, ACINAR CELL. minimal total observations per lesion
ATROPHY. minimal total observations per lesion
(10) 7
1 1
1 1
2 2
(11) 9
1 1 2
1 1
1 1
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 60 mg/Kg/day Isopropanol
b H-24678 i s l "
^
c o n * * * Sonmz,. Does no, corns* TSCAcm
241
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
DuPont-6554
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC)
|
--------------------------------- |
Females
|
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
DIGESTIVE SYSTEM
ESOPHAGUS
NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC. minimal mild total observations per lesion
(10) 9
1 1
(ID 9
1 1 2
Company Sanfized.
STOMACH NO ABNORMALITY DETECTED
(10) 10
(ID X*1 X1
DUODENUM
(10)
(11)
NO ABNORMALITY DETECTED
10 11
iQ AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED, mild cat total observations per lesion
1 1
a3
Figure in parentheses is number of animals microscopically examined for this tissue
a The absence of a number indicates the lesion specified was not identified
5 a 60 mg/kg/day, Isopropanol
S' b H-24678 isl
S
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats________________________________ ___________________________________ DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(90-DNOANY-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
LESIONS DIGESTIVE SYSTEM
| TREATMENT
1 1
LESION INCIDENCE (NUMERIC)
Females
0 1 60 | 10 I 60 I 300 mg/kgI mg/kg! mg/kg| mg/kg| mg/kg /day /day /day | /day | /day II IV a | VI b | VIIIb| X b
JEJUNUM
NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. mild total observations per lesion
(10) 10
(11) 11
1 1
ILEUM
NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. moderate total observations per lesion
(10) 10
(11) 11
1 1
CECUM NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/ b H-24678 i
Company Sanitized. Does not contain TSCA Wf
243
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS(90-DNOAYN-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
)
DuPont-6554
1 1 1 1 j LESIONS 1 1 1
1 | DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
______________ TREATMENT
o mg /kg /day
II
Females
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
| COLON 1
| NO ABNORMALITY DETECTED 1 1 | RECTUM 1 | NO ABNORMALITY DETECTED 1 1 | SALIVARY GLANDS
| NO ABNORMALITY DETECTED 1
(10) 10
(10) 10
(10) 10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dgy Isopropanol b H-24678 is
(11) 11
(11) 11
(11) 11
Company Sanitized. Does not contain TSCA CBI
244
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION G(R9A0-DDNEAOSYNO-ENFXEMPOOIPCSLRUAORSSTECIECOVPLAIECLSUOIOABNTSSEIORNV)ATIONS IN FEMALE RATS-
DuPont-6554
LESIONS URINARY SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
|
--------------------------------- |
Females
|
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 1 300 mg/kgS mg/kg /day 1 /day
VIIIb1 X b
KIDNEYS
NO ABNORMALITY DETECTED
NEPHROPATHY, CHRONIC PROGRESSIVE. minimal total observations per lesion
INFARCT. minimal total observations per lesion
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. mild total observations per lesion
(10) 6
4 4
1 1
(11) 8 3 3
1 1
URINARY BLADDER NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/ b H-24678 i
Company Sanitized. Does not contain TSCACBI
245
)H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS(90-DNOAYN-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
)
DuPont-6554
LESIONS RESPIRATORY SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 | 60 | 10 | 60: mg/kg | mg/kg | mg/kg| mg;/kg /day [ /day | /day j /day
II | IV a | VI b | VI;IIb
300 mg/kg /day
Xb
LUNGS NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC. minimal total observations per lesion
TRACHEA
NO ABNORMALITY DETECTED
PHARYNX/LARYNX NO ABNORMALITY DETECTED INFLAMMATION, SUBACUTE/CHRONIC. minimal total observations per lesion
(10) 9
1 1
GO) 10
(10) 9
1 1
(11) 11
(11) 11 (10) 10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanc
b H-24678 iij
Sanitized, Dctesrnot contain TSCA CB
246
)H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS(90-DNOANY-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
)
DuPont-6554
LESIONS RESPIRATORY SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 j 60: mg/kgj mg/kg /day j /day
VI b | VIIIb
300 mg/kg /day
Xb
NOSE
NO ABNORMALITY DETECTED
REGENERATION, OLFACTORY, EPITHELIUM. minimal total observations per lesion
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. mild total observations per lesion
(10) 10
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified Was not identified a 60 mg/kg/cjgy Isopropanol b H-24678 iE
(11) 10
1 1
1 11
1
CompanySanitized. Does not contain TSCACBi
247
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(90-DNOAYN-ENXEPOOPSLUARSTEIECVLAELSUIOANTSION)
DuPont-6554
LESIONS CARDIOVASCULAR SYSTEM
1 LESION INCIDENCE (NUMERIC)
1 Females
|
| TREATMENT 1 1 1
o mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60) mg/kg /day
VIIIb
300 mg/kg /day
Xb
HEART
NO ABNORMALITY DETECTED
CARDIOMYOPATHY. minimal total observations per lesion
(10) 9
1 I
(11) 9
2 2
AORTA NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number o animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dav Isopropanol b H-24678 is
Company Sanitized. Does notcontain TSCA
248
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
DuPont-6554
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 | 10 | 60 mg/kgj mg/kgj mg/kg /day | /day | /day
IV a | VI b j VIIIb
300 mg/kg /day
Xb
LYMPHATIC AND HEMATOPOIETIC SYSTEM
SPLEEN NO ABNORMALITY DETECTED
(10) 10
(ID 11
THYMUS NO ABNORMALITY DETECTED
(10) 10
(ID 11
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(10) 10
(11) 11
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(10) 10
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified vas not identified a 60 mg/kg/ b H-24678 i
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats_____________ ,
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY EXPOSURE EVALUATION)
DuPont-6554
1 11 1 11 | LESIONS
l 1
1 { ,, __
____________
_
- -| TREATMENT
1 !
1 ___ _
1 | LYMPHATIC AND HEMATOPOIETIC SYSTEM
1 1 | BONE MARROW I| | NO ABNORMALITY DETECTED i1 | AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. | mild
| total observations per lesion
1
LESION INCIDENCE (NUMERIC) 1
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 300 mg/kgI mg/kg /day /day
VIIIb X b
(10) 10
(11) 11
1 1
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified a 60 mo/kg/cjgy Tsnnrnnannl.
b H-24678 is cy
Company Sanitized,
Q
250
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRate__________________ _____________________________________________ ___________ __________
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADNEOSNO-NFEMOIPCLRAOSSTCICOPLIECSOIOBNSSERVATIONS IN FEMALE RATS-
(90-DAY EXPOSURE EVALUATION)
DuPont-6554
1 LESIONS
ENDOCRINE SYSTEM
1 LESION INCIDENCE (NUMERIC) 11 1 Females
|
TREATMENT
I o 60 10 60 j mg/kgj mg/kgj mg/kgj mg/kg
1 /day /day /day /day
1 II
IV a I VI b VIIIb
300 mg/kg /day
Xb
PITUITARY GLAND
NO ABNORMALITY DETECTED
CYST. minimal total observations per lesion
(10) 10
(11) 10
1 1
THYROID GLAND
(10) (10) (10)
NO ABNORMALITY DETECTED
587
HYPERTROPHY, FOLLICULAR. minimal total observations per lesion
ALTERATION, COLLOID. minimal total observations per lesion
523 523
| AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED. | moderate | total observations per lesion
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/ko/dav Isopropanol b H-24678 isl
(10) 6
4 4
(11! 8
1 1
3 3
1 1
251
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION G(R9A0-DDNEOASYNO-ENFXEMPOOIPCSLRUAORSSTECIECOVPLAIECLSUOIOABNTSSEIORNV)ATIONS IN FEMALE RATS-
)
DuPont-6554
LESIONS ENDOCRINE SYSTEM
LESION INCIDENCE (NUMERIC) 11
Females
| TREATMENT
1 1 1
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 300 mg/kg1 mg/kg /day /day
VIIIb X b
PARATHYROID GLANDS NO ABNORMALITY DETECTED
(8) (7) 87
ADRENAL GLANDS NO ABNORMALITY DETECTED
(10) 10
(ID 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dav Isopropanol b H-24678 is
252
)H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATSNON-NEOPLASTIC LESIONS
(90-DAY EXPOSURE EVALUATION)
)
DuPont-6554
LESIONS NERVOUS SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV.a
10 1 60 mg/kgj mg/kg /day | /day
VI b j VIIIb
300 mg/kg /day
Xb
BRAIN NO ABNORMALITY DETECTED
SPINAL CORD NO ABNORMALITY DETECTED
SCIATIC NERVE NO ABNORMALITY DETECTED
(10) 10
(10) 10
(10) 10
(11) 11
(11) 11
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 Tnrr/ka/f^gy Tgnpropanol
b H-24678 is
253
9H0--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION G(R9A0-DDNEAOSYNO-ENFXEMPOOIPCSLRUAORSSTECIECOVPLAIECLSUOIOABNTSESIORNV)ATIONS IN FEMALE RATS-
DuPont-6554
LESIONS
LESION INCIDENCE (NUMERIC) I-------------------------------- 1
| Females
| TREATMENT
I I I
0 j 60 | 10 | 60 mg/kg| mg/kgj mg/kgj mg/kg /day 1 /day | /day | /day
II | IV a | VI b | VIIIb
300 mg/kg /day
Xb
MUSCULAR AND SKELETAL SYSTEM
SKELETAL MUSCLE NO ABNORMALITY DETECTED
(10) (11) 10 11
FEMUR/KNEE JOINT NO ABNORMALITY DETECTED
(10) 10
(11) 11
STERNUM NO ABNORMALITY DETECTED
(10) 10
(ID !
u
Figure in parentheses is number of animals microscopically examined for this tissue
T'FlCS s F e o n r 1 n f s> n i t m h o r 4 ri "44 r-i=ai- o c?
1 n c i n-n
^ 4 r.ra o -w-rf- 4 d S I l t Xf X@d
'p " * w |'8 `< w t a a
B>?
254
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
/)
TABLE 43 (CONTINUED)
INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS(90-DNAOYN-RNEECOOPVLEARSTYICEVLAELSUIOANTSION)
/| DuPont-6554
LESIONS REPRODUCTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 | 300 mg/kg1 mg/kg /day j /day
VIIIb| X b
OVARIES NO ABNORMALITY DETECTED
UTERUS NO ABNORMALITY DETECTED DILATATION, GLAND/LUMEN. minimal mild total observations per lesion
MAMMARY GLAND (FEMALE) NO ABNORMALITY DETECTED
GO) 10
(10) 6
1 3 4
(8) 8
(11) 11
(11) 9
1 1 2
(11) 11
Figure in parentheses is number of animals microscopically examined for this tissue 2$ The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/daifc Isopropanol b H-24678 is o.
o
255
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (90-DAY RECOVERY EVALUATION)
DuPont-6554
LESIONS
CUTANEOUS SYSTEM SKIN
NO ABNORMALITY DETECTED SPECIAL SENSES SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
... .
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 i mg/kg /day VIIIb
300 mg/kg /day
Xb
(10) 10
(11) 11
Company Sanitized.
EYE(S) WITH OPTIC NERVE
NO ABNORMALITY DETECTED
OPTIC NERVE NOT PRESENT.
I AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED, severe total observations per lesion
(10) 10
1
(11) 11
1 1
9 Figure in parentheses is number of animals microscopically examined for this tissue
o The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/^fiy Isopropanol
b H-24678 i s P
^
p
256
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________ _____ _______________
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
)
DuPont-6554
LESIONS
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
0 mg/kg /day
II
300 mg/kg /day
Xa
DIGESTIVE SYSTEM
LIVER
FATTY CHANGE, MEDIAN CLEFT, mild total observations per lesion
PANCREAS
NO ABNORMALITY DETECTED
( 1)
1 1
(1 )
1
ESOPHAGUS NO ABNORMALITY DETECTED
(1 ) 1
STOMACH NO ABNORMALITY DETECTED
(1 )
Figure in parentheses is number of animals microscopically examined for this tissue The absence of. a n m nber .indicates .the_lesion specified was noJ: identiied a H-24678 is
d. Does not contain TSCCt
257
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADNEOSNO-NFEMOIPCLRAOSSTCICOPLIECSOIOBNSSERVATIONS IN FEMALE RATS-
(ONE-MONTH RECOVERY EVALUATION)
') DuPont-6554
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
1 Females
| TREATMENT 1 1 1
|0 mg /kg /day
II
300 mg/kg /day
Xa
DUODENUM NO ABNORMALITY DETECTED
(1) 1
JEJUNUM
NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED, moderate total observations per lesion
(1) 1
1 1
ILEUM
NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED, mild total observations per lesion
(1) 1
1 1
Figure in parentheses is number of animals microscopically examined for this tissue
The absence o-|^numbe:^^idicatfes the lesion specified was n o ^ ^dentif ied
a H-24678 if
:"
Company S a n to * Dona no. eonla/o TSc CM
258
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
LESIONS DIGESTIVE SYSTEM
| LESION INCIDENCE (NUMERIC) 11
| Females
| TREATMENT
1 1 1
0 | 300 mg/kg| mg/kg /day 1 /day
II | X a
CECUM NO ABNORMALITY DETECTED
COLON NO ABNORMALITY DETECTED
(1) 1
(1) 1
RECTUM NO ABNORMALITY DETECTED
(1) 1
SALIVARY GLANDS NO ABNORMALITY DETECTED
(1) 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence ofa number indicates the lesion specified was not identified a H-24678 is
Company Sanitized. Does not contain TSCA CEft
259
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
___________________________________________________ _____
)
DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH RECOVERY EVALUATION)
1 1
1 ii j LESIONS
1
l II _ ^ l | URINARY SYSTEM
1
_
1 LESION INCIDENCE (NUMERIC) l1_ __
1 Females ......
TREATMENT
0 300 mg/kg mg/kg /day /day
__
__
__
II X a
| KIDNEYS }1 | NO ABNORMALITY DETECTED
i
l | URINARY BLADDER 11 | NO ABNORMALITY DETECTED
1
(1) 1
(1) 1
Figure in parentheses is number of animals microscopically examined for this tissue
The absence
icates the lesion specified was not identified
a H-24678 i
Company Sanitized. Does not contain TSCACBl
260
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH RECOVERY EVALUATION)
| LESIONS
RESPIRATORY SYSTEM
| LESION INCIDENCE (NUMERIC)
1-
Females
| TREATMENT
I 1 1
0 | 300 mg/kg| mg/kg /day | /day
II | X a
LUNGS NO ABNORMALITY DETECTED
(1) 1
TRACHEA NO ABNORMALITY DETECTED
(1) 1
PHARYNX/LARYNX NO ABNORMALITY DETECTED
NOSE NO ABNORMALITY DETECTED
Figure in parentheses is number of animals microscopically examined for this tissue
The absence
indicates the lssion sDeci-fcigd was not., identified
(1) 1
(1) 1
1 !1I 1 1
Company Sanitized. Does not contain TSCACBS
261
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats _______
_______
)
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH RECOVERY EVALUATION)
)
DuPont-6554
LESIONS
| LESION INCIDENCE (NUMERIC) l1 __
Females
TREATMENT
0 mg/kg /day
II
300 mg/kg /day
Xa
CARDIOVASCULAR SYSTEM
HEART NO ABNORMALITY DETECTED
a i
AORTA NO ABNORMALITY DETECTED
a i
Figure in parentheses is number of animals microscopically examined for this tissue The absence o_a number indicat,es the lesion specified was not identified a H-24678 is|
iso vosi Ww**3s**1sa W 8
262
3
j 3 < S9
J*
i>
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADNEOSNO-NFEMOIPCLRAOSSTCICOPLIECSOIOBNSESRVATIONS IN FEMALE RATS-
(ONE-MONTH RECOVERY EVALUATION)
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
| LESION INCIDENCE (NUMERIC)
l | Females
TREATMENT
0 mg /kg /day
II
300 mg/kg /day
Xa
SPLEEN NO ABNORMALITY DETECTED
(1) 1
THYMUS NO ABNORMALITY DETECTED
(1) 1
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(1) 1
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(1) 1
BONE MARROW
NO ABNORMALITY DETECTED
Figure in parentheses is number of animals microscopically examined for this tissue The absence of^a^number indicates the lesion specified was not identified a H-24678
(1) 1
263
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
>
DuPont-6554
LESIONS
LESION INCIDENCE (NUMERIC)
I Females
TREATMENT
0 mg/kg /day
II
300 mg/kg /day
Xa
ENDOCRINE SYSTEM
PITUITARY GLAND NO ABNORMALITY DETECTED
(1) 1
THYROID GLAND
NO ABNORMALITY DETECTED
ALTERATION, COLLOID. minimal mild total observations per lesion
(10) 8
(9)
28 1
29
ADRENAL GLANDS NO ABNORMALITY DETECTED
a) i
Figure in parentheses is number of animals microscopically examined for this tissue The absence of^a-nmabae-indicatbs the lesion specified was not identified a H-24678 is
Company Sanitized. Dow notcontain TSCACBi
264
)))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats_____________________________________________________________________ _____________________ DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
LESIONS NERVOUS SYSTEM
| LESION INCIDENCE (NUMERIC)
| Females
| TREATMENT
1 1 1
0 mg/kg /day
II
300 mg/kg
x/daay
BRAIN NO ABNORMALITY DETECTED
(1) 1
SPINAL CORD NO ABNORMALITY DETECTED
(1) 1
SCIATIC NERVE NO ABNORMALITY DETECTED
(1) 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence oh a number indicates the lesion specified w;as not identified a H-24678 isj
n wot e n n W m T8CA 81
265
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
(ONE-MNOONNT-NHEROEPCLOAVSTEIRCYLEEVSAIOLNUSATION)
)
DuPont-6554
LESIONS
| LESION INCIDENCE (NUMERIC)
| Females
TREATMENT
0 | 300 mg/kg| mg/kg /day j /day
II I X a
MUSCULAR AND SKELETAL SYSTEM
SKELETAL MUSCLE MO ABNORMALITY DETECTED
(1) 1
FEMUR/KNEE JOINT NO ABNORMALITY DETECTED
(1) 1
STERNUM NO ABNORMALITY DETECTED
(1) 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of,a number indicates the lesion specified was not identified a H-24678 isf
Doenotcontain TSCA-CBI
266
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (ONE-MONTH RECOVERY EVALUATION)
1 i1 1 1
| LESIONS
1 1
1 I
_
1 | REPRODUCTIVE SYSTEM
1
1 | OVARIES I1 | NO ABNORMALITY DETECTED
1
1 | UTERUS 11 | NO ABNORMALITY DETECTED
1
1 | MAMMARY GLAND (FEMALE) 11 | NO ABNORMALITY DETECTED
1
1 LESION INCIDENCE (NUMERIC)
1
Il __ __ ... 1I
1 Females |
.. . . . . 1
TREATMENT
0 300 mg/kg mg/kg
/day /day
II X a __
(1) 1
(1) 1
(1) 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of_a number indicates the lesion specified was not identified a H-24678 is
Company Sanitized. Does notcontain TSCACBt
267
H90--2D46)ay78O: raSluGbcahvraogneicStTuodxyicinityR
)
a
ts
__________________________________ DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADNEOSNO-NFEMOIPCLRAOSSTCICOPLIECSOIOBNSESRVATIONS IN FEMALE RATS-
(ONE-MONTH RECOVERY EVALUATION)
LESIONS CUTANEOUS SYSTEM
| LESION INCIDENCE (NUMERIC) 11 __
| Females
| TREATMENT
1 1 1
0 | 300 mg/kg| mg/kg /day | /day
II | X a
SKIN NO ABNORMALITY DETECTED
(1) 1
SPECIAL SENSES SYSTEM
EYE!S) WITH OPTIC NERVE NO ABNORMALITY DETECTED
1) 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence o^ a number indicates the lesion specified Was not identified a H-24678 is
)
. Doss notwts**! tSCA CBI
268
)) )
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats___________________________________________________________________________________________ DuPont-6554
TABLE 43 (CONTINUED) INCIDENCES OF LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS-
NON-NEOPLASTIC LESIONS (THREE-MONTH RECOVERY EVALUATION)
LESIONS ENDOCRINE SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
0 1 mg/kg 1 /day
1 II
10 mg/kg /day
VI a
60 mg/kg /day
VIIIa
300 mg/kg /day
Xa
THYROID GLAND
NO ABNORMALITY DETECTED
ALTERATION, COLLOID. minimal mild total observations per lesion
(5) (5) (5) (5)
11
5423 121
5544
Figure in parentheses is number of animals microscopically examined for this tissue
saoa piMueS Auettooo
3
o4
m >
2
269
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44
MICROSCOPIC OBSERVATIONENOSPINLAMSTAILCEARNADTSNLOINS-TNIENOGPILNADSITVIICDUAL ANIMALS AFFECTED(90-DAY EXPOSURE EVALUATION)
LESIONS
| TREATMENT
1 1 1
1j LESION INCIDENCE (NUMERIC)
| 1
Males
_I
0 60 10 60 300 j mg /kg mg/kg mg/kg| mg/kg mg/kgI /day /day >/day /day /day j
I III a v b VII b IX b 1
digestive system
LIVER
(10) (10) (10) (10) (11)
NECROSIS, FOCAL.
648221 648244 648273 648259 648301 648266 648309
INFLAMMATION, SUBACUTE/CHRONIC.
648220 648227 648221 648223 648218 648225 648232 648224 648237 648235 648238 648252 648245 648243 648236 648246 648258 648273 648244 648239 648247 648269 648286 648259 648248 648255 648274 648288 648266 648275 548256 648290 648301 648270 648289 648294 648299 648309 648280 648293 648307 648302 648312 648300 648308 648315 648303 648313 648305
HYPERTROPHY, HEPATOCYTE, CENTRILOBULAR.
648266 648217 648218 648231 648235 648236
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dg-V Isonrnnannl b H-24678
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 1 1 1 Males
|
| TREATMENT
1 1 1
o 60 10 60 300 mg/kg mg/kg mg/kg| mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
LIVER HYPERTROPHY, HEPATOCYTE, CENTRELOBULAR.
HYPERPLASIA, BILE DUCT. FATTY CHANGE, MEDIAN CLEFT.
FATTY CHANGE, CENTRILOBULAR.
(10)
(10)
(10)
(10)
(11) 648248 648275 648289 648293 648308
648288
648275
648269 648290 648302
648237 648305
648273 648223 648239 648286 648237 648293 648313 648266
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dg-v Ison b H-24678 is
m m m i w B m n not contain TSGACBf
271
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44(C0NT1NUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC) |
Males
TREATMENT
o 60 10 60 300 S mg/kg mg/kg mg/kg mg/kg mg/kg I/day /day /day /day /day
1 I III a V b VII b IX b
PANCREAS
(10)
(ID
NO ABNORMALITY DETECTED
648220 648246 648247 648255 648294 648307
648217 648218 648231 648235 648236 648293 648308
INFLAMMATION, SUBACUTE/CHRONIC.
!
HYPERPLASIA, FOCAL, ACINAR CELL.
648238
648239 648248 648275
648248
ATROPHY.
648225 648238 648256 648315
648239 648289
ALTERATION, BASOPHILIC, FOCAL.
648275
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dav is
b H-24678 is
272
Powrngfcontain TSCCB1
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________ ___
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
1 1 1
LESIONS
LESION INCIDENCE (NUMERIC) 1 1
Males
| TREATMENT
1 1 1
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
X III a V b VII b IX b
DIGESTIVE SYSTEM
ESOPHAGUS NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(10)
648217 648218 648231 648235 648236 648248 648275 1 648289 1 648293 1 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dav Isopropanol b H-24678 is
Smlfeed, Doesnot contain TSCACBI
273
H90--2D4) 6ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
11 LESION INCIDENCE (NUMERIC) 1 1 Males
| 1
TREATMENT
0 60 10 60: 300 [ mg/kg mg/kgI mg/kg| mg/kg| mg/kg 1/day /day /day /day /day
1 I III a v b VII b IX b
STOMACH NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/ctev Isonrdt b H-24678 i?
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 6482931 6483081
!
Sanitized. Does not contain TSCACBI
274
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSADUTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS
DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 1
Males
| i
j
| TREATMENT
1 1 1
0 60 10 60. 300 mg/kg mg/kg| mg/kg mg/kg| mg/kg /day /day /day /day /day
I III a V b VII b IX b
DUODENUM NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ll)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/kg/ctey Isooropanol b H-24678 isl
4%jnu fcowy `p&gfljMIgg UedlUOO
83 W3JU
275
)H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
1
} 1 | LESIONS l 1 1 I1
_ ___ __
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
|
Males
1 1
I 0 60 10 60! 300 j
mg /kg mg/kg mg/kg| mg/kg mg/kg|
/day /day /day /day /day j
I III a V b VII b IX b
| DIGESTIVE SYSTEM
1 1 | JEJUNUM I1 | NO ABNORMALITY DETECTED
l 1 l
|
1 1 1 1 1 l
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 548293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/(jay Isoprd b H-24678 is
180 V0S1 ii.Eico au seoQ *p0^(||u@gAinduioo
276
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
))
________________________________DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSADUTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 11 ____
Males
| 1i
1
| TREATMENT
1 1 1
0 60 10 601 300 mg/kg mg/kg mg/kg mg/kg mg /kg /day /day /day /day /day
I III a V b VII b IX b
ILEUM NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
ISS VOSJ. uiBjuea m s see p sz^u es Ausduwo
277
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
_____________________
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDINLAAMYSTAEILXCEPAORNSAUDTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS DIGESTIVE SYSTEM
| TREATMENT 1 1 1
LESION INCIDENCE (NUMERIC)
|
------------ |
Males
1 1
0 60 10 60 300 | mg/kg mg/kg mg/kg mg/kg mg/kg| /day /day /day /day /day 1
I III a V b VII b IX b |
CECUM NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ill
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dffl Isopropanpl b H-24678 is
Sanitised, Does not contain TBCA CD!
278
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
>
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEQPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
1 Males
|
TREATMENT
o 60 10 60, 300 mg /kg mg /kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
COLON MO ABNORMALITY DETECTED
GO)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/c^ Isoprgpanol b H-24678 isj
j,,> Wa u,|uiu3|ou #@o 'pezihus
279
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
')
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS DIGESTIVE SYSTEM
j TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a v b VII b IX b
RECTUM NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/kg/dau Isonropanol b H-24678 isf
Does not contain TSCA CBI
280
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats____________________________________ _______
)
__________________________________ DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
1
j
| LESIONS I 1 1
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mq/kq mg/kg mg/kg| mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
1 | DIGESTIVE SYSTEM
1
| SALIVARY GLANDS |1 | NO ABNORMALITY DETECTED l 1 l l 1 l l 1 l !
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mrr/ki-r/dav Tgnnrnnannl
b H-24678 is
180 VOSi,
281
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats_______
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
Company Sanitized. Does noi contain TSCACBJ
LESION INCIDENCE (NUMERIC)
Males
LESIONS URINARY SYSTEM
TREATMENT
o 60 10 60 300 1 mg/kg mg/kg mg/kg mg/kg mg/kg 1/day /day /day /day /day
1 I III a v b VII b IX b
KIDNEYS
(10) (10) (10) (10) (11)
NO ABNORMALITY DETECTED
648220 648227 648224 648237 648246 648232 648245 648243 648255 648252 648286 648266 648294 648258 648309 648280 648315 648274 648313 648305
648290 648299 648303
NEPHROPATHY, CHRONIC PROGRESSIVE.
648225 648269 648273 648244 648217
648238 648302 648288 648259 648231
648247
648301 648270 648235
648256
648312 648300 648236
648307
648239
648289
648293
648308
HYPERTROPHY, TUBULAR.
648217 648218 648231
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dau- Tsonropanol b H-24678 isj
282
Si XH
Company Sanitized. Does not contain TSCACBI
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS URINARY SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b
KIDNEYS HYPERTROPHY, TUBULAR.
HYDRONEPHROSIS, UNILATERAL. CYST.
(10)
(10)
(10)
(10)
di) 648235 648236 648239 648248 648275 648289 648293 648308
648221
648223
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/rlg^ Tsopropano1 b H-24678 is
283
)
H90--2D46a7y8O: raSlsGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS URINARY SYSTEM
LESION INCIDENCE (NUMERIC) j1
Males
| i
j
| TREATMENT
1 1 1
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
URINARY BLADDER NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kq/day Isopropanol b H-24678 is
Sanitized. Does not contain TSCACBI
284
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats________________
))
_______________________________________ DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS RESPIRATORY SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 | 60
10 | 60 | 300
mg/kg| mg/kg mg/kg| mg/kg| mg/kg
/day 1/day /day 1/day |/day
I | III a V b | VII b | IX b
LUNGS NO ABNORMALITY DETECTED
FOREIGN MATERIAL. EDEMA.
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanc b H-24678 is
(11)
648217 648218 648235 648236 648239| 648248| 648275j 648289| 648293| 648308!
1 1 648231|
648231j
1
Company Sanitized. Does not contain TSCACBI
285
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
1
1 1t | LESIONS
! i
i 1-
-
i | RESPIRATORY SYSTEM
i
__
__ _
LESION INCIDENCE (NUMERIC)
|
. __ _ | TREATMENT
i i i
Males
0 60 10 60 300 mg/kg mg /kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a v b VII b IX b
| TRACHEA 11 | NO ABNORMALITY DETECTED
l l 1 l l l
l ! 1 1
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/daji Isoprbpanol b H-24678 isj
Company Sanitized. Does not ormfa*n TSCACBI
286
))
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyicinityRats______________________________________
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS RESPIRATORY SYSTEM
1 LESION INCIDENCE (NUMERIC) Males
|
TREATMENT
o 60 1 10 60 300 mg/kgj mg/kg| mg/kgj mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
PHARYNX/LARYNX NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC.
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648315
648307
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/kg/dan-- Lsopronanol b H-24678 isl
Sanitized. Does not contain TSCA CBt
287
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________________________________
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
Company Sanitized. Does not aemWn TSOA CBF
LESIONS RESPIRATORY SYSTEM
LESION INCIDENCE (NUMERIC) 1--------------------------------- 1
| Males |
| TREATMENT
1 1 1
0 1 60 | 10
60: 1 300
mg/kg mg/kg j mg/kg mg/kg| mg/kg
/day /day |/day /day |/day
I III a V b VII b IX b
NOSE NO ABNORMALITY DETECTED
ODONTODYSPLASIA. INFLAMMATION, SUBACUTE/CHRONIC.
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307
648315
FOREIGN MATERIAL. DEGENERATION/NECROSIS, OLFACTORY, EPITHELIUM.
11 1 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/ b H-24678 i
(11) 648217 648235 648236 648248 648275 648289 648308
648218 648239
648231
648293
288
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS CARDIOVASCULAR SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mg/kgj mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I h i a V b VII b IX b
HEART NO ABNORMALITY DETECTED
CARDIOMYOPATHY.
(10)
648220 648225 648238 648246 648247 648256 648294 648307 648315
648255
(11)
648217 648236 648239 648248 648275 648289 648293
648218 648231 648235 648308
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanc
b H-24678 is*
Company San!**,. Boos no. contain TSCACBI
289
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats_______
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS CARDIOVASCULAR SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
'
AORTA NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/da^..Isopropanol b H-24678 isl
Company Sanitized. Does not contain TSCA CBI
290
.)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
LESION INCIDENCE (NUMERIC) i
Males
| TREATMENT
1 1 1
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
SPLEEN NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified wpas not identified a 60 mcr/kq/dav Isopropanol b H-24678 isf
Company Sanitized. Does not contain TSCA CBS
291
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________________________________ _____________________________________________
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDINLAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLQGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
LESION INCIDENCE (NUMERIC)
11 Males
| TREATMENT
1 1 1
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
THYMUS NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kq/dgit.Isopropanol b H-24678
Company Sanitized, Does not contain TSCACBi
292
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day 1 III a V b VII b IX b
Company Sanitized. Does
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is nuiriber of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
S'oo a 60 mcr/ka/dav Isooronanol
3 b H-24678 i e T
S' ~f m
$
293
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
1 LESIONS
LYMPHATIC AND HEMATOPOIETIC SYSTEM
( TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
|
------------ 1
Males
0 60 10 1 60 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
POPLITEAL LYMPH NODE HEMANGIOSARCOMA [M] .
(1) 648232
[M] Malignant tumour Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kq/da^ Isoprooanol b H-24678 is
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308|
! 1 1 I 1 1
Company Sanitized.&m mi eontan TSCACBI
294
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSADUTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
j TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
o 60 10 60 300 mg/kg| mg/kg mg/kg| mg/kgj mg/kg /day /day /day /day /day I III a V b VII b IX b
BONE MARROW NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dav Tsonrnnannl
b H-24678 isj
Company Sanitized. Does not contain TSCACBS
295
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS ENDOCRINE SYSTEM
) TREATMENT 1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kg I mg/kg /day /day /day /day /day I III a V b VII b IX b
PITUITARY GLAND NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESION INCIDENCE (NUMERIC) 1'
Males
j LESIONS
1 1
1 !
j ENDOCRINE SYSTEM 1I | THYROID GLAND 1{ | NO ABNORMALITY DETECTED
1 1 1 1 11 | HYPERTROPHY, FOLLICULAR.
1 1 |
11 1 1 11 | ALTERATION, COLLOID.
1 1 1 1 1 1
TREATMENT
0 60 10 60 300 j mg/kg mg/kg mg/kg mg/kg mg/kg j/day /day /day /daY /day
1 I III a V b VI b IX b
(10) (10) (10) (10) (11)
648220 648232 648221 648223 648231
648247 648252 648301 648237
648255
648243
648256
648259
648294
648300
648j244 648217 648280 648218
648236 648239 648248 648289 648308
648225 648227 648224 648266 648217
648238 648258 648245 648270 648218
648246 648269 648273 648280 648235
648307 648274 648286 648305 648236
648315 648290 648288
648239
648299 648309
648248
648302 648312
648275
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kq/d ay ,Isopropanc b H-24678 is
297
calata T S C A C 8 1
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS ENDOCRINE SYSTEM
| TREATMENT
1 1 i
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60; 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day 1 III a V b VII b IX b
THYROID GLAND ALTERATION, COLLOID.
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
PARATHYROID GLANDS NO ABNORMALITY DETECTED
(10)
(10) (10) 648303 648313
(IP)
(11) 648289 648293 648308
648231
(9)
648220 648225 648238 648246 648247 648255 648294 648307 648315
(9)
648217 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/da.v Isopropanol :
___
L
1 8 0 V S X UJBiuoo
298
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS ENDOCRINE SYSTEM
| TREATMENT 1 1
1
LESION INCIDENCE (NUMERIC)
|
Males
0 60 10 60 300 mg/kg mg /kg mg/kg mg/kg mg/kg /day /day /day /day /day
I III a V b VII b IX b
ADRENAL GLANDS NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isoproc b H-24678 is|
lo u s e c G -paJ3iaestedii(oo
f )
g> 299
)H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS NERVOUS SYSTEM
| TREATMENT 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60; 300 mg /kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
BRAIN NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dayIsopropanol b H-24678 is'
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Company Sanitized. Does not contai TS, en
300
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats_______________ _
)
)
__________________ DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAI; ANIMALS AFFECTED-
LESIONS NERVOUS SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60; 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
SPINAL CORD NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day;Isopropanol b H-24678 isj
Company Sanitized. Dees mi cental TSCAC il
301
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNEOLEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS
NERVOUS SYSTEM SCIATIC NERVE
NO ABNORMALITY DETECTED
| TREATMENT
! 1 1
LESION INCIDENCE (NUMERIC)
Males
0
60
10 | 60;
300
mg/kg mg/kg mg/kg| mg;/kg mg/kg
/day /day /day 1/day /day
1 III a V b | VII b IX b
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
1 1
1 1 (11)
648217
1 648218 1 648231 1 648235 1 648236 1 648239 1 648248 1 648275 1 648289 1 648293
648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/kc/d av ,Isonrooanol, b H-24678 is
180
302
)
);
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats_______ _______________________________________________________ ____________________________ DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDILNAAMYSTAEILXCEPAORNSAUDTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
LESIONS
| LESION INCIDENCE (NUMERIC) i1 __ __ l Males
| TREATMENT 1 I
1
| 0 60 10 60| 300 | mg/kg mg/kg mg/kg mgj/kg mg/kg I/day /day /day /day /day
1 I III a V b VII b IX b
MUSCULAR AND SKELETAL SYSTEM
SKELETAL MUSCLE NO ABNORMALITY DETECTED
1 i 1
1 | (10)
1 |648220 648225 |648238 648246 648247 648255 648256 648294 648307 648315
!
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day.Isopropano]_ b H-24678 if '
(ID
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Sanitized. D o e s no! contain T S C A CB I
303
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATINO(EN9O0S-PDINLAAMYSTAEILXCEPAORNSADUTRSNELOEINSV-TNAIENLOGUPAILNTADIOSITVNII)CDUAL ANIMALS AFFECTED-
Company Sanitized. Does
8
3,
ST S'
8
8
LESIONS MUSCULAR AND SKELETAL SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
|
Males
o 60 10 60 300 mg/kg mg/kg mg/kg mg/kgI mg/kg /day /day /day /day /day
I III a V b VII b IX b
FEMUR/KNEE JOINT NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/ b H-24678 is]
304
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS MUSCULAR AND SKELETAL SYSTEM
| TREATMENT 1
LESION INCIDENCE (NUMERIC)
Males
0
60 j 10 | 601
300
mg/kg mg/kg| mg/kgj mg./kg mg /kg
/day /day j/day |/day /day
I III a| V b j VII b IX b
STERNUM NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 i s ^ ^
Company Sanitized. Does not contain TSCACBI
305
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONENOSPILNAMSTAILCEARNADTSNOLINS-TNIENOGPILNADSITVIICDUAL ANIMALS AFFECTED-
(90-DAY EXPOSURE EVALUATION)
LESIONS
1 LESION INCIDENCE (NUMERIC)
I -1
Males
1 TREATMENT 1 1
1
I 0 60 10 60; 300 j mg/kg| mg/kg mg/kg mg/kg mg/kg 1/day /day /day /day /day
I I III a V b VII b IX b
REPRODUCTIVE SYSTEM TESTES
NO ABNORMALITY DETECTED
DEGENERATION/ATROPHY, SEMINIFEROUS TUBULES, BILATERAL.
1 |
|
! | (10) | ! |648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
1 j
l
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dgjf Isopropanol b H-24678 isF '
(11)
648217 648218 648231 648236 648239 648248 648275 648289 648293 648308
648235
Sanitized. Doesnot confalo TSCCBf
306
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS REPRODUCTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
1 Males
j TREATMENT
1 1 1
0 60 10 60 300 mg/kg mg/kg mg/kg mg/kgj mg/kg /day /day /day /day /day
I III a V b VII b IX b
EPIDIDYMIDES NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 m g / k g / I s o D r o n a n o l b H-24678 isl
Company San^f!e<f. no *w TSC CBI
307
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS REPRODUCTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 1
Males
| TREATMENT
1 1 1
0 60 10 60 300 mg/kg| mg/kg| mg/kgj mg/kg mg/kg /day 1/day |/day |/day /day
I | III a| V b | VII b IX b
PROSTATE NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC.
(10)
648220 648246 648255 648256 648294 648307 648315
648225 648238 648247
(ID
648218 648231 648235 648236 648239 648248 648289 648293 648308
648217 648275
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kq/day .Isopronanol b H-24678
Company Sanded. Doss not contain TSCA CBS
308
) )
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
______
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS REPRODUCTIVE SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60; 300 mg/kg mg/kg mg/kg mg/kg mg/kg /day /day /day /day /day I III a V b VII b IX b
SEMINAL VESICLES NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
3 Figure in parentheses is number of animals microscopically examined for this tissue 0 The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/
3 b H-24678 i
a
0) O > o
Company Sanitized. Ooes
309
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS CUTANEOUS SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Males
0 60 10 60; 300 mg/kg mg/kg mg/kg| mg/kg mg/kg /day /day /day /day /day I III a v b vili b IX b
SKIN NO ABNORMALITY DETECTED
(10)
648220 648225 648238 648246 648247 648255 648256 648294 648307 648315
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/kcr/dait Tsonropanol b H-24678 il
Sanitized, Does not contain TSCA CBf
310
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyR a t s ______________________________
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS SPECIAL SENSES SYSTEM
LESION INCIDENCE (NLjMERIC)
Males
TREATMENT
o 60 10 6q 300
1 mg/kg| mg/kg| mg/kg mg|/kg mg/kg
v b]/day
1I
/day /day hi a
/day /day VII b IX b
EYE(S) WITH OPTIC NERVE NO ABNORMALITY DETECTED
FOLD/ROSETTE, RETINAL. ATROPHY, RETINAL.
(10}
648220 648225 648246 648247 648255 648256 648294 648307
648315
648238
(11)
648217 648218 648231 648235 648236 648239 648248 648275 648289 648293 648308
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/^g^Isogropanol b H-24678 is
Sanit?2Sd. Doss enrstaln TSCCBI
311
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAR ANIMALS AFFECTED-
(ONNEEO-MPLOANSTTHICEAXNPDOSNUORNE-NEEVOAPLLUAASTTIIOCN)
Company SanFtteed. P not contata TSCA C8I
LESIONS DIGESTIVE SYSTEM
1 LESION INCIDENCE (NUMERIC) 1 1" - - " - -
1 Males
TREATMENT
0 300 j mg/kgj mg/kg 1/day /day
1 I IX a
LIVER
(1:0)
(9)
NO ABNORMALITY DETECTED
648216
NECROSIS, FOCAL,
648249
INFLAMMATION, SUBACUTE/CHRONIC.
648;222 648230 648*233 648241 648250 648249 648|257 648261 648j260 648262 648*264 648277 648;271 648282 648278 648284 648311 648306
HYPERTROPHY, HEPATOCYTE, CENTRILOBULAR.
648230 648241 648262 648277 648284 648306
Figure in parentheses is number of animals microscopically examined for this tissue
LThe absence of_a number indicates the lesion specified was not identified
312
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________________________________________________________ _ ______ DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
(ONNEEO-MPLOANSTTHICEAXNPODSNUORNE-NEEVOAPLLUAASTTIIOCN)
LESIONS DIGESTIVE SYSTEM
1 LESION INCIDENCE (NUMERIC) I1
Males
1 TREATMENT
1 1 1
0 1 300 mg/kgj mg/kg /day ]/day
1 1 IX a
LIVER FATTY CHANGE, MEDIAN CLEFT.
FATTY CHANGE, CENTRILOBULAR.
Figure in parentheses is number of animals microscopically examined for this tissue The absence oJL a number indicates the lesion specified was not.identified a H-24678 isi
(10)
(9)
648250 648249 648257 648278
648260
.
JS9 954. |ou smg >
313
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
DuPont-6554
TABLE 44 (CONTINUED) MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
(ONNEEO-MPLOANSTTHICEAXNPODSNUORNE-NEEVOAPLLUAASTTIIOCN)
LESIONS URINARY SYSTEM
1 LESION INCIDENCE (NUMERIC)
Males
1 TREATMENT
1 1 1
0 300 mg/kg| mg/kg /day /day
I IX a
KIDNEYS NO ABNORMALITY DETECTED NEPHROPATHY, CHRONIC PROGRESSIVE.
HYDRONEPHROSIS, UNILATERAL.
(10)
(9)
648264 648241 648271 648261 648311 648277
648306
648216 648249 648222 648262 648233 648282 648250 648284 648257 648260 648278
648233 648230
Figure in parentheses is number of animals microscopically examined for this tissue a H-24678 i f utnber mdioatUs th loHmn sDec' led was
`P w * s UBdluoQ
iao v o s * w *
314
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 44 (CONTINUED)
MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTEDNEOPLASTIC AND NON-NEOPLASTIC
(ONE-MONTH RECOVERY EVALUATION)
Company Sanitized* Does not contain TSCACBI
LESIONS
| LESION INCIDENCE (NUMERIC)
|1 _
_ _ __
Males
|
| TREATMENT
1 1 1
0 | 300 mg/kg| mg/kg /day j/day
1 | IX a
ENDOCRINE SYSTEM
THYROID GLAND NO ABNORMALITY DETECTED
HYPERTROPHY, FOLLICULAR.
ALTERATION, COLLOID.
(10)
(9)
648222 648233 648264 648271 648278
648230 648249 648261 648277
648284 648306
648216 648230 648250 648241 648257 648249 648260 648261 648311 648262
648277 648282 648284
Figure in parentheses is number of animals microscopically examined for this tissue
The absence gjM<mumbai^fls|^ga^lgs_the lesion specified was not, identified a H-24678 isl
315
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 44(CONTINUED)
MICROSCOPIC OBSERVATIONS IN MALE RATS LISTING INDIVIDUAL ANIMALS AFFECTEDNEOPLASTIC AND NON-NEOPLASTIC
(ONE-MONTH RECOVERY EVALUATION)
LESIONS
LESION INCIDENCE (NUMERIC)
Males
I TREATMENT | 0 | 300 I I mg/kgj mg/kg I I/day I/day I I 1 I IX a
ENDOCRINE SYSTEM
THYROID GLAND ALTERATION, COLLOID. AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
| (10) j
I 1
(9)
648306 648249
Figure in parentheses is number of animals microscopically examined for this tissue
JfSpypfM* u i>u 9,jv9* # o <|
316
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats____________________________________________________________________________________________ DuPont-6554
TABLE 44(CONTINUED) MICROSCOPIC OBSERVA(TTHIONRENEOSEP-IMNLAOMSNTATILHCERARENACDTOSNVOLEINRS-TYNIENEOGVPAILNLAUDSAITVTIICIDOUNA)L ANIMALS AFFECTED-
Company Sanitized. Does not contain TSCACBf
1 1 1 1
| LESIONS
!
1 i_
_ _ _ _____
1 | DIGESTIVE SYSTEM
1 1 | LIVER
1 l NO ABNORMALITY DETECTED l1 | NECROSIS, FOCAL.
1
1 I1 | INFLAMMATION, SUBACUTE/CHRONIC,
1
1
l i i1 | HYPERPLASIA, BILE DUCT. |1 | FIBROSIS, BILE DUCT. |1 | FATTY CHANGE, MEDIAN CLEFT.
1 ii | FATTY CHANGE, CENTRILOBULAR.
1
LESION INCIDENCE (NUMERIC)
Males
| TREATMENT
!
0 10 60 300 mg/kg mg/kg mg/kg mg/kg /day /day /day /day
1 __ _ _ ____
I __
V a VII a IX a
(5) (5) (5) (5)
648297 648310
648279 648240 648272 648292
648219 648253 648268 648234 648226 648254 648279 648240 648228 648265 648285 648272
648283 648296 648287 648314 648292
648254 648279
648314
648219 648298
648234
648285
Figure in parentheses is number of animals microscopically examined for this tissue The absence oJLj l number indicates the lesion specified wa^ not identified a H-24678 ii
317
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 44 (CONTINUED)
MICROSCOPIC OBSERVATINOENOSPILNAMSTAILCEARNADTSNOLINS-TNIENQGPILNADSITVIICDUAL ANIMALS AFFECTED(THREE-MONTH RECOVERY EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 11
Males
TREATMENT
0 10 60 300 j mg/kg mg/kg mg/kg mg/kg 1/day /day /day /day
1 I V a via a| IX a
LIVER
ECTASIA, BILE DUCT.
ENDOCRINE SYSTEM THYROID GLAND
ALTERATION, COLLOID.
(5) (5) (5) (5) 648314
(5) (5) (5) (5) 648219 648253 648,268 648234 648226 648254 640279 648240 648228 648265 648j285 648272 648297 648283 6481296 648287 648298 648310 640314 648292
Figure in parentheses is number of animals microscopically examined for this tissue The absence (jfc a number indicates the lesion specified was nol-f..identified a H-24678 is
i8 P 'X ? s*
318
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats____________________________________________________________________________________________DuPont-6554
TABLE 45 MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESION INCIDENCE (NUMERIC)
Females
LESIONS DIGESTIVE SYSTEM
TREATMENT
0 1 mg/kg 1 /day
1 II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
LIVER
(10)
(11)
NO ABNORMALITY DETECTED
648347 648375 648376 648412
INFLAMMATION, SUBACUTE/CHRONIC.
648353 648370 648372 648393 648395 648421 648423 648430 648436
648363 648388 648392 648400 648407 648435 648438
FATTY CHANGE, MEDIAN CLEFT. Sis Or
648351 648421 648423
648388
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
648375
3 Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified a 60 mg/kq/day Isoaropanol
b H-24678 isl
319
sm a
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED)
MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTEDNEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
o 60 mg/kg| mg/kg /day /day
II IV a
10 mg/kg /day
VI b
60| mg/kg /day
VIIIb
300 mg/kg /day
Xb
PANCREAS NO ABNORMALITY DETECTED
HYPERPLASIA. FOCAL, ACINAR CELL. DEGENERATION/NECROSISi ACINAR CELL. ATROPHY.
(10)
648351 648353 648370 648372 648393 648423 648430
648421
648421
648395 648436
(11)
648363 648375 648376 648388 648392 648407 648412 648435 648438
648347 648400
648400
648347
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/da^_IsopropanoI b H-24678 is|
Sanitized- Does notcontai TSfcAC&t
320
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONN(ES9O0I-NPDLAFAEYSMTEIAXCLPAEONRSUDARTNESOELNVI-SNATELIONUGPALTIANIOSDTNIVI)CIDUAL ANIMALS AFFECTED-
1
-4
1
of
1
I | LESIONS 1 l l
-- ----1 TREATMENT
1 l
1
LESION INCIDENCE (NUMERIC)
Females
o mg/kg /day
II
60 mg/kg /day
IV a
10 60; mg/kgj mgi/kg /day /day
VI b VIIIb
300 mg /kg /day
Xb
i | DIGESTIVE SYSTEM
1 1 | ESOPHAGUS 11 ] NO ABNORMALITY DETECTED
1 1 1 1 1 1 1 1 |
j INFLAMMATION, SUBACUTE/CHRONIC.
! 1
(10),
648351 648353 648370 648372 648393 648395 648421 648423 648430
648436
(11)
648347 648363 648376 648388 648392 648400 648407 648435 648438
648375 648412
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mn/Vn/rUy Tgrrpi-Qpanol
b H-24678 id
321
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
| TREATMENT 1 1 1
LESION INCIDENCE (NUMERIC)
Females
o mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
STOMACH NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 ma/ka/dfy Tsnnropanol b H-24678 is
322
H90--2D>46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOINPLFAESMTIACLAENRDATNSOLNI-SNTEIONGPLIANSDTIVICIDUAL ANIMALS AFFECTED-
(90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
o mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60, mg/kg /day
VIIIb
300 mg/kg /day
Xb
DUODENUM NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/<^gv TsnnrnnanoL
b H-24678 is
Sanitized, Does ** TSCACBS
323
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS DIGESTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 10 mg/kg| mg/kg /day /day
IV a VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
JEJUNUM NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648375
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 6 ^ g / k g / ^ Isopropanol ;
- ---------'
--
ganifwgd, 55"rtormtain TSCACSS
324
>
>
H90-2-D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________________________________________________________ ____________________________ DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS DIGESTIVE SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
0
mg/kg /day
II
60 mg /kg /day
IV a
10 60 mg/kg| mg/kg /day /day
VI b VIIIb
300 mg/kg /day
Xb
ILEUM NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(ID
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
Company Sanitised. 00e *otcrmtafn TSCA CB1
325
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________________________ ________________
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
0 60 1 mg/kg| mg/kg
1 /day /day
1 11
IV a
10 60 300 mg/kgj mg/kgj mg/kg /day /day /day
VI b VIIIb x b
CECUM NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/daji Isopropanol b H-24678 isj
Company SanWzed. Does not contain TSCA CBt
326
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOINPLFAESMTIACLAENRDATNSOLNI-SNTEIONGPLIANSDTIIVCIDUAL ANIMALS AFFECTED-
(90-DAY EXPOSURE EVALUATION)
LESIONS
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
j0 mg/kg
11 II/day
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
DIGESTIVE SYSTEM
COLON NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/c b H-24678 is
Company Sanitized. Does not contain TSCACBI
327
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
RECTUM NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
b H-24678 is
Sanfffzetf. Does m i eonfafn TSCA Cffl
328
H90--2)D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
______
> _________
> DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
11
!Ii | LESIONS
1 1 1
LESION INCIDENCE (NUMERIC) i
Females
1 TREATMENT
1 1 1
0 mg/kg /day
II
60 10 mg/kg| mg/kg /day /day
IV a VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
1 | DIGESTIVE SYSTEM
1
j SALIVARY GLANDS |1 | NO ABNORMALITY DETECTED | j |
1 1 1 1 | |
1 !
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 m a / t o / d a ^ T a n n r n m n o l b H-24678 is#
Company Sanitized. Does not contain TSCA CBS
329
)>} H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats___________________________________________________________________________________________ DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC) ----- |
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 1 60 mg/kg| mg/kg /day 1 /day
VI b 1 VIIIb
300 mg/kg
x/daby
URINARY SYSTEM
KIDNEYS NO ABNORMALITY DETECTED
NEPHROPATHY, CHRONIC PROGRESSIVE. INFARCT. AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648393 648423 648436
648372 648395 648421 648430
648430
(11)
648347 648363 648375 648388 648392 648400 648412 648438
648376 648407 648435
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mcr/kg/dav Isonronanol b H-24678 is
Company Sanitized. Does not contain TSCA CBI
330
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS URINARY SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
0 60 10 mg/kg| mg/kg| mg/kg /day /day /day
ii IV a VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
URINARY BLADDER NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/daY_lsopropanol b H-24678 is
Company Sanitized. Does not contain TSCACBS
331
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONN(E9SO0I-PNDLAFAEYSMTEIAXCLPAEONRSUDARTNESOELNVI-SNATELIONUGPALTIANIOSDTNIIV)CIDUAL ANIMALS AFFECTED-
LESIONS
LESION INCIDENCE (NUMERIC)
Females
TREATMENT 1
0 I 60 1 10
j1 mg/kg| mg/kg| mg/kg
j /day 1 /day /day
1 II 1 IV a 1 VI b
60; mg/kg /day
VIIIb
300 mg/kg /day
Xb
RESPIRATORY SYSTEM LUNGS
NO ABNORMALITY DETECTED
INFLAMMATION, SUBACUTE/CHRONIC.
( 10)
648351 648353 648370 648372 648393 648395 648423 648430 648436
648421
( 11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dgy Isopropano1 b H-24678 il
Company Sanitized. Does not contain TSCACBi
332
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
1
1 | LESIONS
! i
1
1
____
_
i | RESPIRATORY SYSTEM
1
____
___
___
1 TREATMENT
i i 1
LESION INCIDENCE (NUMERIC)
|
Females
o 60 mg/kg| mg/kg /day /day
II IV a
10 mg/kg /day
VI b
60: mg/kg /day
VIIIb
300 mg/kg /day
Xb
| TRACHEA |! j NO ABNORMALITY DETECTED
1 1 1 1 1 | |
1 1 1 1
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/d^.v Ie
b H-24678 i F
Sanitized Doss f.nfa?n TSCACBI
333
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
1 11 1 1
LESIONS
1 1
1 1
i | RESPIRATORY SYSTEM
I I | PHARYNX/LARYNX 11 | NO ABNORMALITY DETECTED l l l l 1 l i 1
1 | INFLAMMATION, SUBACUTE/CHRONIC.
1
TREATMENT
LESION INCIDENCE (NUMERIC)
|
Females
0 1 60 I 10 I 60 mg/kg| mg/kg| mg/kgj mg/kg /day /day /day /day
II IV a 1 VI b VIIIb
300 mg/kg /day
Xb
(10)
648353 648370 648372 648393 648395 648421 648423 648430 648436
648351
GO)
648347 648363 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/c b H-24678 is
Company Sanitized. Does not confata TSCACBI
334
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________
) _
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS RESPIRATORY SYSTEM
| TREATMENT
1 1 i
LESION INCIDENCE (NUMERIC)
Females
0 mg /kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60: mg/kg /day
VIIIb
300 mg/kg /day
Xb
NOSE NO ABNORMALITY DETECTED
REGENERATION, OLFACTORY, EPITHELIUM. AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648392 648400 648407 648412 648435 648438
648388
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kq/dav Isopropano b H-24678 isf
Company Sanitized. D5es not contain TSCA CBl
335
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS
CARDIOVASCULAR SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
o 1 mg/kg 1 /day
1 II
60 mg/kg /day
IV a
10 60: 300 mg/kg1 mg/kg) mg/kg /day /day /day
VI b VIIIb X b
HEART
(10)
(11)
NO ABNORMALITY DETECTED
I
648351 648353 648370 648372 648393 648395 648421 648423 648430
648347 648363 648375 648392 648400 648407 648412 648435 648438
CARDIOMYOPATHY.
648436
648376
I 648388
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/day Isopropanol
b H-24678 is
T8CACBI
336
H90-2-D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS CARDIOVASCULAR SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
o 1 mg/kg 1 /day
1 II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
AORTA NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kq/dav Isopropanol b H-24678 is
Does notcontain TSCAC
337
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats_________________
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
LYMPHATIC AND HEMATOPOIETIC SYSTEM
SPLEEN NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
M Q. Figure in parentheses is nuitiber of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
s a 60 mn/krr/ria^-Tgnnrnriannl___ ______
at 'i
3
(ID
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
l a o v o s i ' W "00
338
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
| TREATMENT
.1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 60 mg/kgj mg/kg /day /day
II IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
THYMUS NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue
Ta he60abisnenn/VcefT o/ff^ y aTngunmnbren rp a rinndicates the lesion specified was not identified
b H-24678 is
Company Sanitized. Does not contain
>
339
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONN(ES9O0I-NPDLAFAEYSMTEAIXCLPAEONRSDUARTNESOELNVI-SNATELIONUGPALTIANIOSDTNIIV)CIDUAL ANIMALS AFFECTED-
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
| TREATMENT i 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 10 mg/kgj mg/kg /day /day
IV a VI b
60: mg/kg /day
VIIIb
300 mg/kg /day
Xb
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mcr/kg/dair Isopropanol b H-24678 i s j ~
Company Sanitized. Does not contain TSCA CBI
340
)) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats_______________________ _______________
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEQPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS LYMPHATIC AND HEMATOPOIETIC SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified yas not identified a 60 mg/kg/d b H-24678 is
Company Sanitized. Does not contain TSCACBI
341
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
o 60 mg/kgj mg/kg /day /day
II IV a
10 mg/kg /day
VI b
60: mg/kg /day
VIIIb
300 mg/kg /day
Xb
LYMPHATIC AND HEMATOPOIETIC SYSTEM
BONE MARROW NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/4aii_Jagpropanol b H-24678 is#
Company Sanitized. Does not contain TSCACBI
342
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats______________________
)
_________________________
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS ENDOCRINE SYSTEM
| TREATMENT
1 1 i
LESION INCIDENCE (NUMERIC)
|
Females
0 mg/kg /day
IX
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg /kg /day
VIIIb
300 mg/kg /day
Xb
PITUITARY GLAND NO ABNORMALITY DETECTED
CYST.
(101
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648347
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dfljf Isopropanol b H-24678 ii
Company Sanitized. Does not contain TSCA CBS
343
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
CompanySanttfeed Does Hofonlafn fSCA C
LESIONS ENDOCRINE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60- 300 mg/kgi mg/kg /day /day
VIIIb X b
THYROID GLAND
(10) (10) (10) (10) (11)
NO ABNORMALITY DETECTED
648353 648364 648345 648348 648347
648370 648369 648366 648(368 648375
648395 648390 648374 648380 648388
648421 648397 648382 648381 648392
648430 648402 648403 648401 648407
648409 648414 648jl32 648412
648410 648441
648435
648424
648438
HYPERTROPHY, FOLLICULAR.
648400
ALTERATION, COLLOID.
648351 648396 648406 648354 648363
648372 648408 648429 648362 648376
648393
648433 648^17 648400
648423
648440
648436
AUTOLYSIS. NECROPSY AND HISTOLOGY PERFORMED.
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 is
648375) I
344
') H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS ENDOCRINE SYSTEM
| TREATMENT 1 1
1
LESION INCIDENCE (NUMERIC)
Females
0 mg /kg /day
II
60 10 mg/kg| mg/kg /day /day
IV a VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
PARATHYROID GLANDS NO ABNORMALITY DETECTED
(8)
648351 648370 648372 648395 648421 648423 648430 648436
(7)
648347 648363 648376 648392 648400 648412 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/ka/da^ Isopronanol b H-24678 isjj
345
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS ENDOCRINE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 10 mg/kg| mg/kg /day /day
IV a VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
ADRENAL GLANDS NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified
C o m p a n y Sanitized. D o e s not eontasr? T S C A CI
346
} H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOIPNLFAESMTIACLAENRDATNSOLNI-SNTEIONGPLIANSDTIIVCIDUAL ANIMALS AFFECTED-
(90-DAY EXPOSURE EVALUATION)
LESIONS NERVOUS SYSTEM
| TREATMENT 1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 60 10 60 mg/kgj mg/kg| mg/kgj mg/kg /day /day /day /day
IV a VI b VIIIb
300 mg/kg /day
xb
BRAIN NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(ID
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dgii IsoorODanol b H-24678 i f
Company Sanitized. Does not contain TSCA CBl
347
> H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOIPNLFAESMTIACLAENRDATNSOLNI-SNTEIONGPLIANSDTIIVCIDUAL ANIMALS AFFECTED-
(90-DAY EXPOSURE EVALUATION)
LESIONS NERVOUS SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg /kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
SPINAL CORD NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kq/djp Isnnrnnannl b H-24678 isl
Company Sanitized. Does not contain TSCACB1
348
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
0 mg /kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
NERVOUS SYSTEM
SCIATIC NERVE NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(ID
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number o animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/c^gy Isooropanol b H-24678
349
H90--2D)46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS MUSCULAR AND SKELETAL SYSTEM
LESION INCIDENCE (NUMERIC) 1I
Females
[ TREATMENT 1 1 1
0 mg/kg /day
II
60 mg/kg /day
IV a
10 60s mg/kg1 mg/kg /day /day
VI b VIIIb
300 mg/kg /day
Xb
SKELETAL MUSCLE NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kq/da^ Isooropanol b H-24678 isf
C o m p a n y Sanitized. Does not ew*tan TSCACB!
350
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
LESIONS MUSCULAR AND SKELETAL SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
o mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg
x b/day
FEMUR/KNEE JOINT
(10)
(11)
NO ABNORMALITY DETECTED
648351
648347
648353
648363
648370
648375
648372
648376
3o
648393 648395
648388 648392
o
648421
648400
5a
648423
648407
648430
648412
asm
648436
648435
3 648438
a.3 Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified
a 60 mg/kg/<jnf T ^ p ^ p anol
m b H-24678 isl
not contain TSCACBI
351
H90--2D)46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS MUSCULAR AND SKELETAL SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC) Females
1 1
0 mg/kg /day
II
60 10 mg/kgj mg/kg /day /day
IV 3 VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
STERNUM NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435
648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mct/to/ijav Isopropanol b H-24678 isi
#*i vy (diuBS
Ifi WylsA
352
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONN(ES9O0I-NPDLAFAEYSMTEIAXCLPAEONRSDUARTNESOELNIV-SNATELIONUGPALTIANIOSDTNIIV)CIDUAL ANIMALS AFFECTED-
' LESIONS
REPRODUCTIVE SYSTEM
TREATMENT
LESION INCIDENCE (NUMERIC)
Females
o mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
OVARIES
J NO ABNORMALITY DETECTED
I
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(ID
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isopropanol b H-24678 isj
I.Oo^rioi'chian TSCM C f
353
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSUDRNEOENV-NAELOUPALTAIOSTNI)C
Company Sanitized* Does net c
LESIONS REPRODUCTIVE SYSTEM
| TREATMENT
1 1 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
60 mg/kg /day
IV a
10 60 300 mg/kgj mg/kg| mg/kg /day /day /day
VI b VIIIb x b
UTERUS NO ABNORMALITY DETECTED
DILATATION, GLAND/LUMEN.
(10)
648351 648353 648395 648421 648430 648436
648370 648372 648393 648423
(11)
648347 648363 648375 648376 648388 648400 648407 648435 648438
648392 648412
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/daiti isopropanol b H-24678 is! ) %
J
354
H90-2-D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
N(E9O0-PDLAAYSTEIXCPAONSDURNEOENV-NAELOUPALTAIOSTNI)C
LESIONS REPRODUCTIVE SYSTEM
LESION INCIDENCE (NUMERIC) 1 1 1 Females
|
1 1
| TREATMENT 1 1 1
0 mg/kg /day
II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 300 mg/kg| mg/kg /day /day
VIIIb x b
MAMMARY GLAND (FEMALE) NO ABNORMALITY DETECTED
(8)
648353 648370 648372 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mq/kg/dgy ,1s b H-24678 ij
Sanitized Does so! contain TSCA CBI
355
H90--2D)46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS CUTANEOUS SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
o 1 mg/kg 1 /day
1 II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 300 mg/kgj mg/kg /day /day
VIIIb X b
SKIN NO ABNORMALITY DETECTED
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
Figure in parentheses is number of animals microscopically examined for this tissue
absence of a number indicates the lesion specified was not identified a 60 mg/kg/day Isoprooanol
b H-24678 is
Company Sanitized. Does not contain TSCA CBI
356
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (90-DAY EXPOSURE EVALUATION)
LESIONS SPECIAL SENSES SYSTEM
LESION INCIDENCE (NUMERIC)
Females
TREATMENT
0 | mg/kg 1 /day
1 II
60 mg/kg /day
IV a
10 mg/kg /day
VI b
60 mg/kg /day
VIIIb
300 mg/kg /day
Xb
EYE(S) WITH OPTIC NERVE NO ABNORMALITY DETECTED
OPTIC NERVE NOT PRESENT. AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(10)
648351 648353 648370 648372 648393 648395 648421 648423 648430 648436
648423
(11)
648347 648363 648375 648376 648388 648392 648400 648407 648412 648435 648438
648375
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion specified was not identified a 60 mg/kg/dair Isopronanol b H-24678 is
Does not contain TSCACB1
357
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATI(OONNNESEO-IMPNLOFAENSMTTHIACLEAEXNPRODASTNUSORLNEI-SNETEVIONAGPLLUIANASDTTIIIVOCIND)UAL ANIMALS AFFECTED-
LESIONS DIGESTIVE SYSTEM
s LESION INCIDENCE (NUMERIC)
|
11 | Females |
TREATMENT
0
| mg/kg | /day
1 II
300 |
mg/kg| /day 1
xa 1 1
LIVER FATTY CHANGE, MEDIAN CLEFT.
(1)
648439
PANCREAS NO ABNORMALITY DETECTED
(1)
648439
ESOPHAGUS NO ABNORMALITY d e t e c t e d
(1)
64S439
STOMACH NO ABNORMALITY DETECTED
(1)
648439
DUODENUM
NO ABNORMALITY DETECTED
Figure in parentheses is number of animals microscopically examined for this tissue The absence of a number indicates the lesion..specified Was nq_identified a H -24678 if
(1)
648439
i i
i i
1i1
i i
1
I ! 1 1
1j1
1 1 1 1
|1
1
358
Sanitized. Does not contain TSCACB1
)
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
____________________________
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOINPLFAESMTIACLAENRDATNSOLNI-SNTEIONGPLIANSDTIIVCIDUAL ANIMALS AFFECTED-
(ONE-MONTH EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
| LESION INCIDENCE (NUMER3 C) |--------------------
Femeles
| TREATMENT 1 1 1
0 mg/kg /day
II
300 mg/kg /day
Xa
JEJUNUM
NO ABNORMALITY DETECTED
o0
3 AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
"0 S 3
ILEUM
NO ABNORMALITY DETECTED
AUTOLYSIS: NECROPSY AND HISTOLOGY PERFORMED.
(1) 648439 648439
(11 648439 648439
CECUM NO ABNORMALITY DETECTED
(1) 648439
COLON
NO ABNORMALITY DETECTED
Figure in parentheses is number of animals microscopically examined for this tissue
The absence oil a number iindicates the lesion specified Was not.identified
a H-24678 i s "
....................
(1) 648439
Sanitized. Does not contain TSCACBl
359
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEQPLASTIC (ONE-MONTH EXPOSURE EVALUATION)
LESIONS DIGESTIVE SYSTEM
[ LESION INCIDENCE (NUMERIC) I1
Females
TREATMENT
0 | mg/kg | /day
1 II
300 mg/kg /day
Xa
RECTUM
NO ABNORMALITY DETECTED
o3o SALIVARY GLANDS
NO ABNORMALITY DETECTED
(1) 648439
(1) 648439
3 Figure in parentheses is number of. animals microscopically examined for this tissue The absence o.L a number :indicates the lesion specified Was not identified a H-24678 is
litized. Does not contain TSC CBS
360
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
(ONNEEO-MPLOANSTTHICEAXNPODSNUORNE-NEEVOAPLLUAASTTIIOCN)
LESIONS URINARY SYSTEM
| LESION INCIDENCE (NUMERIC) |--------------------
Females
| TREATMENT
1 1 1
0 | 300 mg/kg| mg/kg /day | /day
II | X a
KIDNEYS NO ABNORMALITY DETECTED
(1) 648439
URINARY BLADDER NO ABNORMALITY DETECTED
(1) 648439
Figure in parentheses is number of animals microscopically examined for this tissue
seoo *pa*91uB
361
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (ONE-MONTH RECOVERY EVALUATION)
|
1
1 LESIONS 1 1 1
i1 _
| RESPIRATORY SYSTEM
_____
_ __ _____
| LESION INCIDENCE (NUMERIC)
|
1 | Females
TREATMENT
o I mg/kg I /day
1 II
300 mg/kg /day
Xa
| LUNGS 11 | NO ABNORMALITY DETECTED
1
1
3 | TRACHEA 11 0 | NO ABNORMALITY DETECTED m
1
1 | PHARYNX/LARYNX
(1) 648439
(1) 648439
(1)
| NO ABNORMALITY DETECTED
1 1 | NOSE |1 | NO ABNORMALITY DETECTED
1
648439
(1) 648439
Figure in parentheses is number of animals microscopically examined for this tissue The absence ofL-a number Indicates the lesion specified was not^identified a H-24678 is
m 0 V O SI umuc IO000 **M"*8
362
O o
3
a
0 3
m a.
o m 3 O o a
3 a.
<2 el 3?
s
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (ONE-MONTH RECOVERY EVALUATION)
LESIONS
LESION INCIDENCE (NUMERIC)
Females
I TREATMENT j j
I
|0 |300 jmg/kg( mg/kg |/day j/day
III IX a
CARDIOVASCULAR SYSTEM
HEART NO ABNORMALITY DETECTED
(1) 648439
AORTA NO ABNORMALITY DETECTED
(1! 648439
Figure in parentheses is number, of animals microscopically examined for this tissue
The absence of
identified
a H-24678 i
9H0--2)D4a6y78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (ONE-MONTH RECOVERY EVALUATION)
Company Sanitized. P a not
LESIONS
| LESION INCIDENCE (NUMERIC)
Females
| TREATMENT
1 1 i
0 mg/kg /day
II
300 mg/kg /day
Xa
LYMPHATIC AND HEMATOPOIETIC SYSTEM
SPLEEN NO ABNORMALITY DETECTED
(1) 648439
THYMUS NO ABNORMALITY DETECTED
(1) 648439
MANDIBULAR LYMPH NODE NO ABNORMALITY DETECTED
(1) 648439
MESENTERIC LYMPH NODE NO ABNORMALITY DETECTED
(1) 648439
BONE MARROW
(1)
NO ABNORMALITY DETECTED
648439
Hi Figure in parentheses is number of animals microscopically examined for this tissue
in0 0>
The absence a number indicates the lesion specified was not_identified a H-24678 i s T ^
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED)
MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTEDNEOPLASTIC AND NON-NEOPLASTIC
(ONE-MONTH RECOVERY EVALUATION)
| LESION INCIDENCE (NUMERIC) 1
| Females
LESIONS ENDOCRINE SYSTEM
I TREATMENT
1 1 1
o mg/kg /day
II
300 mg/kg /day
Xa
PITUITARY GLAND NO ABNORMALITY DETECTED
(1) 648439
THYROID GLAND
(10)
(9)
NO ABNORMALITY DETECTED
!
648346 648389 648,404 648425 648427 648434 648439 648442
ALTERATION, COLLOID.
648394 648350 648426 648355
648359 648378 648383 648387 648398 648399 648419
Figure in parentheses is number of animals microscopically examined for this tissue The absence aH a n n m W indicates the lesion_specified Was not identified a H-24678 is
|iO-OS4nPIo-tSo a 'T ZSJPeS
365
9H0--2D)46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats_____________________
) ________________________________________________________________
) DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
(ONNEEO-MPLOANSTTHICRAENCODVNEORNY-NEEVOAPLLUAASTTIIOCN)
LESIONS
LESION INCIDENCE (NUMERIC)
TREATMENT
Females ----- i
0 300 j mg/kg mg/kg| /day /day |
II X * j
ENDOCRINE SYSTEM
ADRENAL GLANDS NO ABNORMALITY DETECTED
(1) 648439
NERVOUS SYSTEM
BRAIN NO ABNORMALITY DETECTED
(1) 648439
SPINAL CORD NO ABNORMALITY DETECTED
(1) 648439
SCIATIC NERVE NO ABNORMALITY DETECTED
(1) 648439
Figure in parentheses is number of animals microscopically examined for this tissue The absence of.a number indicates the lesion snenif-iad was not__identified a H-24678 isf
Sanfeed. O f w ta* " TSC ce*
366
)
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONNESOINPLFAESMTAICLEANRDATNSOLNI-SNTEIONGPLIANSDTIVICIDUAL ANIMALS AFFECTED-
(ONE-MONTH RECOVERY EVALUATION)
S
LESIONS MUSCULAR AND SKELETAL SYSTEM
| LESION INCIDENCE (NUMERIC) I1 __ __ _ _
Females
TREATMENT
0 300 | mg/kg| mg/kg
1 /<3ay /day
i ii
Xa
SKELETAL MUSCLE NO ABNORMALITY DETECTED
(1! 648439
FEMUR/KNEE JOINT NO ABNORMALITY DETECTED
(1) 648439
-
STERNUM NO ABNORMALITY DETECTED
(1) 648439
Figure in parentheses is number of animals microscopically examined for this tissue The absence oi, a number Indicates t;he lesion specified was not identified a H-24678 i | ^
1
Sanitized. D&ST>frfefm TSCA-CBl
367
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (ONE-MONTH RECOVERY EVALUATION)
LESIONS REPRODUCTIVE SYSTEM
| LESION INCIDENCE (NUMERIC)
11 .
. ._
| Females
] TREATMENT ] 1 !
0 mg/kg /day
II
300 mg/kg /day
Xa
OVARIES NO ABNORMALITY DETECTED
(1) 648439
UTERUS
! NO ABNORMALITY DETECTED MAMMARY GLAND (FEMALE)
(1) 648439
(1)
NO ABNORMALITY DETECTED
648439
i 1
Figure in parentheses is number of animals microscopically examined for this tissue The absence qa number indicates the lesion specified was not..identified a H-24678
Sanitized. Dos^rtOt'Cftntaln tSClP
368
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATI(OONNNESEO-IMPNLOFANESMTTHIACRLAEENCRODAVTNESORLNYI-SNETEVIONAGPLLUIANASDTTIIIVOCIND)UAL ANIMALS AFFECTED-
LESIONS
| LESION INCIDENCE (NUMERIC) 11 __ __
| Females
TREATMENT
0 mg/kg /day
II
300 mg/kg /day
Xa
CUTANEOUS SYSTEM
SKIN NO ABNORMALITY DETECTED
(1) 548439
SPECIAL SENSES SYSTEM
EYE(S) WITH OPTIC NERVE NO ABNORMALITY DETECTED
(1) 648439
Figure in parentheses is number of animals microscopically examined for this tissue
The absence of_a number indicates the lesion specified was not identified
1
369
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
TABLE 45 (CONTINUED) MICROSCOPIC OBSERVATIONS IN FEMALE RATS LISTING INDIVIDUAL ANIMALS AFFECTED-
NEOPLASTIC AND NON-NEOPLASTIC (THREE-MONTH RECOVERY EVALUATION)
LESIONS
| TREATMENT
1 ! 1
LESION INCIDENCE (NUMERIC)
Females
0 mg/kg /day
II
10 mg/kg /day
VI a
60 | 300 mg/kg| mg/kg /day | /day
VIIIa| X a
ENDOCRINE SYSTEM
THYROID GLAND
(5) (5) (5) (5)
NO ABNORMALITY DETECTED
648379 648358
ALTERATION, COLLOID.
? 1
648356 648352 648349 648367 648357 648365 648360 648373 648405 648384 648386 648391 648422 648385 648415 648411 648431 648413
< REPRODUCTIVE SYSTEM m
3a
MAMMARY GLAND (FEMALE) FIBROADENOMA [B].
(1) 648352
f
< [B] Benign tumour
3 Figure in parentheses is number of animals microscopically examined for this tissue S3J The absence of. a number indicates the lesion specified was not identified
>
a H-24678 is
I
` ~^
J r
370
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats_______________________________________ _______________ DuPont-6554
FIGURES
371
ewugiimsfanttfeuf. nTM* nf
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
FIGURES
Study Design
EXPLANATORY NOTES
Group
Male
inI
Femnale
IV
vYn
VI VIII
IX X
Dosage 06100mmmg/ggk//kkg/ggd//ddayaayy 63000mmg/gk/kg/gd/dayay
Test Substance VIsoephricolpeacnoonltcroonl trol HHH---222444666777888
Critical Dates
Day 90 > Lonaest-mdaoyntohfatensdt 3su-mbsotnatnhcereacdomveirnyisptreartiioodnsf.or male and female rats designated for the Day 91 > Last day of test substance administration for male rats designated for the 90-day
sacrifice. > Recovery period begins for rats designated for the one-month and 3-month recovery
periods. Day 92 > Last day of test substance administration for female rats designated for the 90-day
sacrifice. > Male rats designated for the 90-day sacrifice were sacrificed. Day 93 > Female rats designated for the 90-day sacrifice were sacrificed. Day 122 > Male and female rats designated for the one-month recovery period were sacrificed.
Statistical Methods for Neurobehavioral Figures McvoaneraitarnnoFcl eoatrfeopllil<mow0b.e0ad5n.dbyMDeuannnHetint'dsltiemstb; GthreipreSwtreernegtnhowstearteisatnicaallylyzesdigbnyifoicnaen-twdaiyffaerneanlycseissforofm Mean Total Duration of Movement and Mean Total Number of Movements were analyzed
by Shapiro-Wilk's and Levene's tests; there were no statistically significant differences from control at p < 0.05.
372 Company Sanitized. Does
SC GB
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
FIGURE 1 MEAN BODY WEIGHTS OF MALE RATS
)
DuPont-6554
Company Sanfteed,
Days on Test
i o
373
H90--2D46a)y78O: raSluGbcahvraogneicSTtuodxyiciintyRats____________________ _________________ )
FIGURE 2 MEAN BODY WEIGHTS OF FEMALE RATS
I
DuPont-6554
Sanfffeed, Does noternten
Days on Test
374
)
9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
FIGURE 3 MEAN FORELIMB GRIP STRENGTH FOR MALE RATS
)
DuPont-6554
Companys,n,,te6d
0 mg/kg/day 60 mg/kg/day Isopropanol 10 mg/kg/day 60 mg/kg/day 300 mg/kg/day_________
Errorbars represent standard deviation. Tdihfeferreewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
CO
Baseline
Week 13
s
g
Assessment Period
375
9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
FIGURE 4 MEAN FORELIMB GRIP STRENGTH FOR FEMALE RATS
1.40 1
'P*mue9UBdui0i
o
9 9 Oo 3" m o
1.20
1.00
e
'S
bo
csCo
0.80
a,
'
I
0.60
o 0.40
0.20
0.00
0 mg/kg/day B 60 mg/kg/day Isopropanol 1110 mg/kg/day B 60 mg/kg/day B 300 mg/kg/day_________
Error bars represent standard deviation. Tdihffeerreewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
Baseline
Week 13
Assessment Period
376
DuPont-6554
))
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats_______________________________________
FIGURE 5 MEAN HINDLIMB GRIP STRENGTH FOR MALE RATS 0.70 i
0.60 -
)
DuPont-6554
Company Sanfcw. Bms ,,oi ^
0 mg/kg/day 60 mg/kg/day Isopropanol ^ 10 mg/kg/day 60 mg/kg/day U 300 mg/kg/day_________
Errorbars represent standard deviation. Tdihfeferreewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
Baseline
Week 13
Assessment Period
377
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Hindlimb Grip Strength (kg)
FIGURE 6 MEAN HINDLIMB GRIP STRENGTH FOR FEMALE RATS
0.70 -I
0.60 -
0.50 -
0.40 -
0 mg/kg/day 60 mg/kg/day Isopropanol
10 mg/kg/day
0.30 -
M 60 mg/kg/day B 300 mg/kg/day_________
Error bars represent standard deviation.
0.20 -
Tdihfeferreewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
0.10 -
0.00 Baseline
Week 13
Assessment Period
DuPont-6554
H90--2D46a)7y8O: raSluGbcahvraogneicSTtuodxyicinityRats
)
2500 -,
FIGURE 7 MEAN TOTAL DURATION OF MOVEMENT FOR MALE RATS
)
DuPont-6554
2000 -
0 mg/kg/day 60 mg/kg/day Isopropanol ^ 10 mg/kg/day H 60 mg/kg/day B 300 mg/kg/day_________
Errorbars represent standard deviation. Tdihffeerreewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
Company Sanitized. Does not contain TSCA CB1
Baseline
Week 13
Assessment Period
379
1
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
3000 n
FIGURE 8 MEAN TOTAL DURATION OF MOVEMENT FOR FEMALE RATS
2500 -
)
DuPont-6554
2000 -
0 mg/kg/day 60 mg/kg/day Isopropanol ^ 10 mg/kg/day 60 mg/kg/day B 300 mg/kg/day_________
Error bars represent standard deviation. There were no statistically significant differences by Shapiro-Wilk's and
T tests.
Company Sanitised. Does not contain TSCACBS
Baseline
Week 13
Assessment Period
380
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
-,1000
900 800 -
FIGURE 9 MEAN TOTAL NUMBER OF MOVEMENTS FOR MALE RATS
DuPont-6554
a
0 mg/kg/day
>o 60 mg/kg/day Isopropanol
o<+H
<5
10 mg/kg/day 60 mg/kg/day
M 300 mg/kg/day_________
3
z Errorbars represent standard deviation.
Tdihfefererewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
Company Sanitized. Does not contain TSCA CBI
Baseline
Week 13
Assessment Period
381
i
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
900 i
800 -
700 -
2 600 -
3
g<L> 500 s & 400 -
|-o
3 300 -
t*
s 200a3 -
M
aa, 100 -
5a
0 0-
o
-4 O >
FIGURE 10 MEAN TOTAL NUMBER OF MOVEMENTS FOR FEMALE RATS
Baseline
Week 13
Assessment Period
0 mg/kg/day ED60 mg/kg/day Isopropanol H 10 mg/kg/day M 60 mg/kg/day B 300 mg/kg/day_________
Errorbars represent standard deviation. Tdihfefererewnceerse fnroomstactoisnttircoalllayt spig<n0if.i0c5a.nt
T
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
APPENDICES
383
'jCeapaprSanitized Doe
H-24678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
DuPont-6554
Table L Concentration Verification and Stability of H-24678 in Dosing Solutions
Preparation Day
mg/mLH-24678(A)
Percent
Sample Type
Nominal Measured
Nominal
Test Day 1
Concentration Verification
Control
0.0 n d (Q
--
1.33-1 1.51 1.33-2 1.48 M ean : 1.50 0.02
113.5 111.3
(112.8)
C.V. 1 %
88..0000--12
7.32 7.99
M ean : 7.66 0.47
91.5 99.9
(95.8)
C.V. 6 %
4400..00--12
40.4 36.8
M ean(P): 38.6 2.5
101.0 92.0
(96.5)
C.V. 6 %
5-Hour RSootambiTliteymperature 7-Day Refrigerated
5 Hour Room Temperature
1.33 1.33 1.33
1.41 1.49 1.59
106.0 112.0 119.5
5-Hour Room Temperature 7-Day Refrigerated
5 Hour Room Temperature
88..0000 8.00
7.80 8.71 8.63
97.5 108.9 107.9
5-Hour Room Temperature 7-Day Refrigerated
5 Hour Room Temperature
40.0 38.2 40.0 44.8
95.5 112.0
40.0 43.4 #108.5 _
78/mLbased on 7.5 mLdose volume. H-24678
(B) (Q
(D)
(E)
MDtDooeetnshaionentgearesnssionmuloluatttlfidsooeinrtnesdctihhteeeeddld.sutpfuoldircya7. tedasyasmrpelfersig. eSraatmedpMlfeoselalnonow,tSead.dDbm.yian5nidshteoCru.eVrds. tacotartlohcueolmaantetiemdmtaoplsevrieanrtiutfhryee.usntSuifadomyr.mplietsynooftmaidxmtuinreis. tered
385
Cempasy Sanitized. Does notcontain TSCACSf
H90--2D46ay78O: raSluGbcahvraogmecSTtuodxyiciintyRats
DuPont-6554
Table I:(continued) Concentration Verification and Stability of Isopropyl Alcohol in Dosing
Solutions________________________________________________________________________
Preparation Day _____ mg/mL Isopropyl Alcohol_____
Percent
________ Sample Type____________ Nominal_________Measured___________ Nominal
Concentration Verification(A)
8.0-1 8.0-2
Mean:
4400..00--2l(B )
Mean:
8.71 8.68
8.70 0.02
C.V. 0.2%
7.80 7.97
7.89 0.12
C.V. 2 %
108.9 108.5
(108.8)
97.5 99.6
(98.6)
Stability 5 Hour Room Temperature
7-Day Refrigerated(C) Hour Room Temperature^)
8.0 8.0 8.0
88..6860 9.04
110180..30 113.0
5 Hour Room Temperature
40.0(B)
8.03
100.4
7-Day Refrigerated(C)
40.0
7.99
99.9
Hour Room Temperature^) 40.0
7.83
97.9
((((ADBC>>)) 4MDtSh0aueemmpaslnptgiulcr/edamesytse.hLueslHtaldmf-o2fpro4lt6reh7s7e8wddsaeuayrpmesliarpcenlafeatreliwygszaeaesrmadat.penldaMe,lsy.etzhaeSendna,mSt5o.pDhsloeh.usoarwnnsdoatthCtaar.dVotmoi.tmiccnaoitlsnectmtuearlipaenetdeerdadtot2utot0rhe%ve.earoSnirfaiymm8upamnllseigfsi/omnnrmotLhtieotayfdstimousfodinmypi.rsioxtpeturyerldea.tlocothhoel.animals in
386
Com p a s P*-Ww* *--
' S C A CB f
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
Table H Concentration Verification of H-24678 in Dosing Solutions
Preparation Day
mg/mLH-24678(A)
Sample Type
Nominal
Measured
Test Day 42
Concentration VerificationCB)
Control
0.0 n d (c )
1.33-1 1.22 1.33-2 1.20
Mean:
1.21 0.01
C.V.1%
88..0000--12
Mean:
7.56 7.62 7.59 0.04
C.V. 1 %
40.0-1 41.6 40.0-2 36.3
Mean: 39.0 3.7
C.V. 9 %
Percent Nominal
-- 91.7 90.2
(91.0)
9945..35
(94.9)
104.0 90.8
(97.5)
/ Test Day 91
Concentration VerificationCB)
Control
0.0
ND(C)
--
11..3333--12 11..3339
110040..50
Mean:
1.36 0.04
(102.3)
C.V. 3 %
88..0000--12
8.49 7.96
106.1 99.5
Mean:
8.23 0.37
(102.9)
C.V. 5 %
4400..00--12
Mean:
37.9 38.3 38.1 0.28
94.8 95.8
(95.3)
1ST 678/mLbased on 7.5 mLdoCs.eVv.olu1m%e. H-24678 isj
(B)
(O Denotes not detected.
yzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
387
Company SanFfttfiftdLD
CB1
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Table II. (continued) Concentration Verification of Isopropyl Alcohol in Dosing Solutions
Preparation Day
mg/mL Isopropyl Alcohol
Percent
Sample Type
Nominal
Measured
Nominal
Test Day 42
Concentration Verification(^)
8.0-1 9.20 115.0
8.0-2 9.02 112.8
Mean: 9.11 0.13
(113.9)
C.V. 1 %
4400..00-- 12(B)
7.59 7.41
94.9 92.6
M e a n : 7.50 0.13
(93.8)
C.V. 2 %
Test Day 91 Concentration Verification(^)
8.0-1 8.0-2
Mean:
4400..00-- l2(B)
Mean:
9.31 9.64
9.48 0.23 C.V. 2 %
7.27 7.35
7.31 0.06 C.V. 1 %
116.4 120.5
(118.5)
90.9 91.9
(91.4)
^ Duplicate samples were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture. (B> 40 mg/mL H-24678 sample was analyzed to show that it contained 20% or 8 mg/mL of isopropyl alcohol.
388
Company
*)*** -*4ft-***
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Representative AnaFliygtuicrael1Calibration Curves
DuPont-6554
Figure la: iaCsroaepalirbmorpaeyatilsouanrlcecomuhreovnelt(s(HG(s-Cq2u)4a8shr9eo4sw)) difnoilgructleiandlieboarvraeftriitoan(lcisnoonel)cuettnoiotrnreasptoiloifcnarteanpgeeak of 1.002 to 4.008 mg/mL.
Figure lb: rfcCiaatnlai(gblliiebrnaroeta)fitoi0tnoo.n0sr9oec1lpuu8rlitvcitoeoant(0esL.p3oCe2f/a1MHk3S-am2r4-eg6Ca/7mm68-LeIdP.aislAuu/trmeedmixoeevndetsrb(iass)qcousnhacoreewnsi)tnrfgaotrliionnear 389 Company Sanitized. Doe? not c'V't1''' TSCA CRl
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
RepresentaFtiigvuerAen1a(lcyotinctainl uCeadl)ibration Curve
DuPont-6554
Figure lc: Calibration curve (LC/MS fplH R gpixed bis) showing linear cfiatli(blirnaet)iotno sroelpulticioantespoefaHk-a2r4e6a7m8edaisluutreedmoevnetrs (asqcounacreens)trfaotrion range of 0.0918 to 0.3213 mg/mL.
Figure Id: Calibration curve (LC/MS{ jB |P y n ix e d bis) showing non linear fit (line) to replicate peak area measurements (squares) for rcaanligberaotfio0n.0s9o1lu8ttioon0s.3o2f1H3-2m4g6/7m8Ld.iluted over a concentration
390 Company Sanhteed. nw*
TSCACBI
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
/"'"'N,
RepresentaFtiigvuerAen1a(lcyotinctainl uCeadli)bration Curve
DuPont-6554
Figure le: Calibration curve (L C M sQ (((|j||sh o w m g non-linear fit rc(laainnligbee)ratootfior0ne.0ps9loi1clua8ttietoopn0es.a3ok2f1hH3e-igm2h4gt6/7mm8eLad.siluurteemd eonvtesr(asqcuoanrceesn)tfroartion
rcfFiaatinlgi(gbulierrnaeoet)fiIo0ftno:.0Csr9oea1lpul8ilbticitrooaantt0esi.op3on2efa1cHku3r-a2mvr4eeg6a(/7mLm8CLed/.aMisluuStreedmoevnetrs a(sqcounacrbeeonsw)trfiaontrgiolninear
391 company SanHteed Boas not canta* C A CEI
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
/ '""N, Figure 1 (continued) Representative Analytical Calibration Curve
DuPont-6554
Peak Area, counts*sec
Figure lg: Calibration curve (L C /M S {j|^ J P (^ o w in g linear fit (line) to replicate peak area measurements (squares) for calibration solutions of H-24678 diluted over a concentration range of 0.0918 to 0.3213 mg/mL.
392 Company Sanitized. Does not contain TSCA CBI
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
Representative Gas ChFroigmuarteo2graphy Chromatograms
DuPont-6554
Figure 2a: Representative GC chromatogram of 3.006 mg/mL isopropyl alcohol analytical reference solution.
Figure 2b: rnReoepmpreriensseaenlntcatoatitnvicveeensGotrlCauttiicoohnnrooismf 82a..t54o2gmrmagmg/m/moLfLo8o.f0fisimosopgpr/moropLpyylplaolasclioctiohvhoeol.cl.oTnhtreoml deoassiunrgedsoclounticoenntdrialtuitoendotof tahe
Figure 2c: RrceoepnprcreeessneetnnrtataattitioivvneeosGfol2Cu.4tciohmnrogim/sm8aLt.0oo8gfrmaimsgo/pomrfoL4p0oy.fl0iasmlocpgor/hmooplL.ylHTa-hl2ce4om6h7oe8la.sduorseidngcosnocluetnitornatdioilnutoefdthtoe a nominal
393 Sanzetf- not contidn TSC CBS oaspsMf
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
Representative HPLCFi/gMuSreC2h(rcoomntaintougerda)phy Chromatograms
0.0 mg/mL -1
051501-S10 S m (Mn, 2x1)
1: SIR of 3 Chan nels E S -
DuPont-6554
0.0 mg/mL -1 051501-S10 S m (Mn, 2x5)
100-1
1: SIR of 3 Chan nels E S 43.00
5.42e3
2.00
4.00
0.0 mg/mL -1 051501-310 S m (Mn, 2x8)
6.00
8.00
10.00
12.00
14.00
1: SIR of 3 Ch an nels E S -
0.0 m g/m L-1 051501-S10 S m (Mn, 2x6)
2: SIR of 3 Chan nels E S -
0.0 mg/mL -1 051501-s10 S m (Mn, 2x2)
100-1
2: SIR of 3 Chan nels E S 585.00 '6.11e3
2.00
4.00
6.00
8.00
10.00
12.00
14.00
- Time
0.0 mg/mL -1 051501-S10 S m (Mn, 2x1)
2: SIR of 3 Chan nels E S -
Figure 2d: HR-e2p4r6e7se8n. tative HPLC/MS chromatograms of 0.00 mg/mL dosing solution of
394 Company Sanr.ti-zeda. duw0<vb contain
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
Representative HPLCFi/gMuSreC2h(rcoomntaintougerda)phy Chromatograms
s td 2 051501
10CH
18 S m (Mn, 2x1) 0.62
1073340
8211436
%-
0 U - , . .......... ..
2.00
4.00
6.00
s td 2 051501-s18 S m (Mn, 2x5)
1: SIR of 3 Ch an n els E S 443.00 8.25e6
Area, Height
12.00 14.00
Tim e
1: SIR of 3 C h an n els E S -
DuPont-6554
s td 2
Sd2 Std2
Std2 051501-s i 8 S m (Mn, 2x1)
2: SIR of 3 C h an nels E S -
Figure 2e: sRoeluptrieosnenotfaHtiv-e24H6P7L8.C/MS chromatograms of 0.1836 mg/mL analytical reference
Company Sanitized. Does not contain TSCA CBI
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Representative HPLC/MFSigCurhero2m(caotnogtirnaupehdy) Chromatograms
1.33 m g/m L - 1
DuPont-6554
1.33 mg/mL - 1
1.33 mg/mL - 1 051501-s25 S m (Mn, 2x8)
1: SIR of 3 Channels 6S -
1.33 mg/mL - 1 1.33 mg/mL - 1
2: S IR of 3 Chan nels E S -
133rngrmL-1 051501-625 Sm (Mn, 2x1)
100
9.94;92357;702466
2 : S IR of 3 Channels ES685.00 7.06e5
A rea, Height
0 .................... ..................I I I I I
2 .00 4.00
8.00 10.00 12.00 14.00
Figure 2f: Representative HPLC/MS chromatograms of 1.33 mg/mL dosing
solution diluted to nominal concentration of 0.160 mg/mL of
H-24678. The measured concentration of the representative solution
is 1.51 mg/mL.
396
Company Sanitized. Does not contain TSCA CBI
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
APPENDIX B INDIVIDUAL DOSE VOLUMES
397 company Sanitized, Does not contain TSCACBI
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
INDIVIDUAL DOSE VOLUMES
Study Design
EXPLANATORY NOTES
Group
Male Female____________ Dosage
I mV vIXn
InV
060mmg/gk/kg/gd/dayay
Vehicle control Isopropanol control
VI vXm
10 mg/kg/day 60 mg/kg/day
HH--2244667788
300 mg/kg/day H-24678
Critical Dates
Day 90 > Lonaes-tmdaoyntohfatnesdt3s-umbsotnatnhcereacdomveinryistpreartiioodnsf.or male and female rats designated for the
Day 91 >
Last day of test substance administration for male rats designated for the 90-day exposure period.
> Rpeercioovdes.ry period begins for rats designated for the one-month and 3-month recovery
Day 92 > Last day of test substance administration for female rats designated for the 90-day exposure period.
> Male rats designated for the 90-day exposure period were sacrificed.
> Male rats dosed with isopropanol (Group HI) were sacrificed.
Day 93 > Female rats designated for the 90-day exposure period were sacrificed.
> Female rats dosed with isopropanol (Group IV) were sacrificed.
Day 122 > Male and female rats designated for the one-month recovery period were sacrificed.
Day 183 > Male and female rats designated for the 3-month recovery period were sacrificed.
Note Unless footnoted, absent data indicates animal was not alive at the time of dosing.
Footnotes ba.. AInneimrroarl,manaiymhaalvdeobseeednwmithisd6o0semdg. /kg/day isopropanol dose solution.
398
Company Santthred. Does not contain TSCACB!
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
)
)
DuPont-6554
Individual Dose Volumes
Gavage ml
Day 0
Gavage ml
Day 1
Gavage ml
Day 2
Gavage ml
Day 3
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
Gavage ml
Day 8
Gavage ml
Day 9
Gavage ml
Day 10
Gavage ml
Day 11
Male, I - 0 mg/kg/day
648225 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.4 648247 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.4 648307 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.3 2.3 2.3 2.3 2.3 648294 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.5 2.5 2.5 2.5 2.5 648315 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.6 2.6 2.6 2.6 2.6 648256 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.2 2.2 2.2 2.2 2.2 648255 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.4 648246 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.5 2.5 2.5 2.5 2.5 648238 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.2 2.2 2.2 2.2 2.2 648220 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.5 2.5 2.5 2.5 2.5 648298 1.9 1.9 1.9 1.9 1.9 1.9 1.9 2.2 2.2 2.2 2.2 2.2 648228 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.8 1.8 1.8 1.8 1.8 648297 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.3 2.3 2.3 2.3 2.3 648219 1.7 1.7 1.7 1.7 1.7 1.7 1.7 2.0 2.0 2.0 2.0 2.0 648226 1.9 1.9 1.9 1.9 1.9 1.9 1.9 2.2 2.2 2.2 2.2 2.2 648222 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.2 2.2 2.2 2.2 2.2 648250 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.2 2.2 2.2 2.2 2.2 648271 1.8 1.8 1.8 1.8 1.8 1.8 1.8 2.3 2.3 2.3 2.3 2.3
648260 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.4 648264 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.5 2.5 2.5 2.5 2.5 648233 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.4 648311 1.7 1.7 1.7 1.7 1.7 1.7 1.7 2.2 2.2 2.2 2.2 2.2
1 648257 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.6 2.6 2.6 2.6 2.6 648278 1.9 1.9 1.9 1.9 1.9 1.9 1-9 2.3 2.3 2.3 2.3 2.3 m 648216 1.9 1.9 1.9 1.9 1.9 1.9 1.9 2.2 2.2 2.2 2.2 2.2 3
t. o
S
not contain TSCCB
H90--2D46)ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
> DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Male, I - 0 mg/kg/day
648225 2.4 2.4 648247 2.4 2.4 648307 2.3 2.3 648294 2.5 2.5 648315 2.6 2.6 648256 2.2 2.2 648255 2.4 2.4 648246 2.5 2.5 648238 2.2 2.2 648220 2.5 2.5 648298 2.2 2.2 648228 1.8 1.8 648297 2.3 2.3 648219 2.0 2.0 648226 2.2 2.2 648222 2.2 2.2 648250 2.2 2.2 648271 2.3 2.3 648260 2.4 2.4 648264 2.5 2.5 648233 2.4 2.4 648311 2.2 2.2 648257 2.6 2.6 648278 2.3 2.3 648216 2.2 2.2
Gavage ml
Day 14
2.4 2.4 2.3 2.5 2.6 2.2 2.4 2.5 2.2 2.5 2.2 1.8 2.3 2.0 2.2 2.2 2.2 2.3 2.4 2.5 2.4 2.2 2.6 2.3 2.2
Gavage ml
Day 15
Individuai Dose Volumes
Gavage ml
Day 1-6
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
2.6 2.6 2.6 2.6 2.6
2.7 2.7 2.7 2.7 2.7
2.7 2.7 2.7 2.7 2.7
2.9 2.9 2.9 2.9 2.9
2.9 2.9 2.9 2.9 2.9
2.6 2.6 2.6 2.6 2.6
2.8 2.8 2.8 2.8 2.8
2.9 2.9 2.9 2.9 2.9
2.7 2.7 2.7 2.7 2.7
2.9 2.9 2.9 2.9 2.9
2.5 2.5 2.5 2.5 2.5
2.2 2.2 2.2 2.2 2.2
2.8 2.8 2.8 2.8 2.8
2.3 2.3 2.3 2.3 2.3
2.5 2.5 2.5 2.5 2.5
2.6 2.6 2.6 2.6 2.6
2.6 2.6 2.6 2.6 2.6
2.7 2.7 2.7 2.7 2.7
2.9 2.9 2.9 2.9 2.9
2.9 2.9 2.9 2.9 2.9
2.8 2.8 2.8 2.8 2.8
2.6 2.6 2.6 2.6 2.6
1.2 b
2.9
2.9
2.9
2.9
2.7 2.7 2.7 2.7 2.7
2.5 2.5 2.5 2.5 2.5
Gavage ml
Day 20
2.6 2.7 2.7 2.9 2.9 2.6 2.8 2.9 2.7 2.9 2.5 2.2 2.8 2.3 2.5 2.6 2.6 2.7 2.9 2.9 2.8 2.6 2.9 2.7 2.5
Gavage ml
Day 21
2.9 3.0 2.9 3.1 3.0 2.9 3.1 3.1 2.9 3.2 2.7 2.4 3.0 2.5 2.7 2.9 2.9 3.1 3.2 3.2 3.2 2.9 3.2 2.9 2.8
Gavage ml
Day 22
2.9 3.0 2.9 3.1 3.0 2.9 3.1 3.1 2.9 3.2 2.7 2.4 3.0 2.5 2.7 2.9 2.9 3.1 3.2 3.2 3.2 2.9 3.2 2.9 2.8
Gavage ml
Day 23
2.9 3.0 2.9 3.1 3.0 2.9 3.1 3.1 2.9 3.2 2.7 2.4 3.0 2.5 2.7 2.9 2.9 3.1 3.2 3.2 3.2 2.9 3.2 2.9 2.8
Company Sarete^. oca*
m o > a oe
400
9H0--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Male, I - 0 mg/kg/day
648225 2.9 2.9 648247 3.0 3.0 648307 2.9 2.9 648294 3.1 3.1 648315 3.0 3.0 648256 2.9 2.9 648255 3.1 3.1 648246 3.1 3.1 648238 2.9 2.9 648220 3.2 3.2 648298 2.7 2.7 648228 2.4 2.4 648297 3.0 3.0 648219 2.5 2.5 648226 2.7 2.7 648222 2.9 2.9 648250 2.9 2.9 648271 3.1 3.1 648260 3.2 3.2 648264 3.2 3.2 648233 3.2 3.2 648311 2.9 2.9 648257 3.2 3.2 648278 2.9 2.9
648216 2.8 2.8
Gavage ml
Day 26
2.9 3.0 2.9 3.1 3.0 2.9 3.1 3.1 2.9 3.2 2.7 2.4 3.0 2.5 2.7 2.9 2.9 3.1 3.2 3.2 3.2 2.9 3.2 2.9 2.8
Gavage ml
Day 27
2.9 3.0 2.9 3.1 3.0 2.9 3.1 3.1 2.9 3.2 2.7 2.4 3.0 2.5 2.7 2.9 2.9 3.1 3.2 3.2 3.2 2.9 3.2 2.9 2.8
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.1 3.1 3.1 3.1 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.2 3.2 3.2 3.2 3.5 3.5 3.5 3.5 2.9 2.9 2.9 2.9 2.6 2.6 2.6 2.6 3.2 3.2 3.2 3.2 2.6 2.6 2.6 2.6 3.0 3.0 3.0 3.0 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.0 3.0 3.0 3.0 3.5 3.5 3.5 3.5 3.3 3.3 3.3 3.3 2.9 2.9 2.9 2.9
Gavage ml
Day 32
3.1 3.2 3.2 3.3 3.3 3.1 3.4 3.4 3.2 3.5 2.9 2.6 3.2 2.6 3.0 3.2 3.2 3.3 3.4 3.4 3.5 3.0 3.5 3.3 2.9
Gavage ml
Day 33
3.1 3.2 3.2 3.3 3.3 3.1 3.4 3.4 3.2 3.5 2.9 2.6 3.2 2.6 3.0 3.2 3.2 3.3 3.4 3.4 3.5 3.0 3.5 3.3 2.9
Gavage ml
Day 34
3.1 3.2 3.2 3.3 3.3 3.1 3.4 3.4 3.2 3.5 2.9 2.6 3.2 2.6 3.0 3.2 3.2 3.3 3.4 3.4 3.5 3.0 3.5 3.3 2.9
Gavage ml
Day 35
3.2 3.3 3.4 3.5 3.4 3.3 3.7 3.5 3.5 3.8 3.0 2.7 3.5 2.8 3.2 3.4 3.5 3.6 3.6 3.5 3.7 3.3 3.7 3.5 3.1
Company Sanitized. Does
O
O o
401
H90--2D46a)y78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________________
) _________________
)
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Male, I - 0 mg/kg/day
648225 3.2 3.2 648247 3.3 3.3 648307 3.4 3.4 648294 3.5 3.5 648315 3.4 3.4 648256 3.3 3.3 648255 3.7 3.7 648246 3.5 3.5 648238 3.5 3.5 648220 3.8 3.8 648298 3.0 3.0 648228 2.7 2.7 648297 3.5 3.5 648219 2.8 2.8 648226 3.2 3.2 648222 3.4 3.4 648250 3.5 3.5 648271 3.6 3.6 648260 3.6 3.6 648264 3.5 3.5 648233 3.7 3.7 648311 3.3 3.3 648257 3.7 3.7 648278 3.5 3.5 648216 3.1 3.1
Gavage ml
Day 38
3.2 3.3 3.4
3.4 3.3 3.7 3.5 3.5 3.8 3.0 2.7 3.5 2.8 3.2 3.4 3.5 3.6 3.6 3.5 3.7 3.3 3.7 3.5 3.1
Gavage ml
Day 39
3.2 3.3 3.4
3.4 3.3 3.7 3.5 3.5 3.8 3.0 2.7 3.5 2.8 3.2 3.4 3.5 3.6 3.6 3.5 3.7 3.3 3.7 3.5 3.1
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
3.2 3.2 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.5 3.5
3.4 3.4 3.5 3.5 3.3 3.3 3.5 3.5 3.7 3.7 3.8 3.8 3.5 3.5 3.6 3.6 3.5 3.5 3.6 3.6 3.8 3.8 3.9 3.9 3.0 3.0 3.1 3.1 2.7 2.7 2.9 2.9 3.5 3.5 3.6 3.6 2.8 2.8 2.9 2.9 3.2 3.2 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.7 3.7 3.6 3.6 3.8 3.8 3.6 3.6 3.8 3.8 3.5 3.5 3.8 3.8 3.7 3.7 3.8 3.8 3.3 3.3 3.4 3.4 3.7 3.7 3.9 3.9 3.5 3.5 3.6 3.6 3.1 3.1 3.2 3.2
Gavage ml
Day 44
3.3 3.4 3.5
3.5 3.5 3.8 3.6 3.6 3.9 3.1 2.9 3.6 2.9 3.4 3.5 3.7 3.8 3.8 3.8 3.8 3.4 3.9 3.6 3.2
Gavage ml
Day 45
3.3 3.4 3.5
3.5 3.5 3.8 3.6 3.6 3.9 3.1 2.9 3.6 2.9 3.4 3.5 3.7 3.8 3.8 3.8 3.8 3.4 3.9 3.6 3.2
Gavage ml
Day 46
3.3 3.4 3.5
3.5 3.5 3.8 3.6 3.6 3.9 3.1 2.9 3.6 2.9 3.4 3.5 3.7 3.8 3.8 3.8 3.8 3.4 3.9 3.6 3.2
Gavage ml
Day 47
3.3 3.4 3.5
3.5 3.5 3.8 3.6 3.6 3.9 3.1 2.9 3.6 2.9 3.4 3.5 3.7 3.8 3.8 3.8 3.8 3.4 3.9 3.6 3.2
Sanitized. Doss notconta'n TSCACBI
402
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Individual Dose Volumes
Gavage ml
Day 48
Gavage ml
Day 49
Gavage ml
Day 50
Gavage ml
Day 51
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
Gavage ml
Day 56
Gavage ml
Day 57
Gavage ml
Day 58
Gavage ml
Day 59
Male, I - 0 mg/kg/day
648225 3.3 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.8 3.8 3.8 3.8 648247 3.4 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 648307 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.8 3.8 3.8 3.8
648294 648315 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 648256 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7 3.7 648255 3.8 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 648246 3.6 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 648238 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.9 3.9 3.9 3.9 648220 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.3 4.3 4.3 4.3 648298 3.1 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 648228 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 648297 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 3.8 3.8 648219 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 648226 3.4 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.8 3.8 3.8 3.8 648222 3.5 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 648250 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.8 4.0 4.0 4.0 4.0 648271 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.1 4.1 4.1 4.1 648260 3.8 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1
I 648264 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.1 4.1 4.1 4.1 648233 3.8 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.2 4.2 4.2 4.2 648311 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.8 3.8 3.8 3.8 648257 3.9 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.2 4.2 4.2 4.2 648278 3.6 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.1 4.1 4.1 4.1 648216 3.2 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5
ifeed. Basenotennfafn TC kI
403
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
________________________________________________________ DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Male, I - 0 mg/kg/day
648225 3.8 3.8 648247 3.7 3.7 648307 3.8 3.8 648294 648315 3.7 3.7 648256 3.7 3.7 648255 4.1 4.1
648246 3.9 3.9 648238 3.9 3.9 648220 4.3 4.3 648298 3.3 3.3 648228 3.1 3.1 648297 3.8 3.8 648219 3.1 3.1 648226 3.8 3.8 648222 3.9 3.9 648250 4.0 4.0 648271 4.1 4.1 648260 4.1 4.1 648264 4.1 4.1 648233 4.2 4.2 0 648311 3.8 3.8 O 648257 4.2 4.2
3 648278 4.1 4.1
g 648216 3.5 3.5
Gavage ml
Day 62
3.8 3.7 3.8
3.7 3.7 4.1 3.9 3.9 4.3 3.3 3.1 3.8 3.1 3.8 3.9 4.0 4.1 4.1 4.1 4.2 3.8 4.2 4.1 3.5
Gavage ml
Day 63
3.9 3.8 3.8
3.8 3.9 4.2 4.0 4.1 4.3 3.3 2.4 4.0 3.1 3.8 4.1 4.2 4.2 4.3 4.2 4.2 3.8 4.2 4.3 3.5
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
3.9 3.9 3.9 3.9 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8
3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 4.2 4.2 4.2 4.2 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.3 4.3 4.3 4.3 3.3 3.3 3.3 3.3 2.4 2.4 2.4 2.4 4.0 4.0 4.0 4.0 3.1 3.1 3.1 3.1 3.8 3.8 3.8 3.8 4.1 4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.3 4.3 4.3 4.3 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 3.8 3.8 3.8 3.8 4.2 4.2 4.2 4.2 4.3 4.3 4.3 4.3 3.5 3.5 3.5 3.5
Gavage ml
Day 68
3.9 3.8 3.8
3.8 3.9 4.2 4.0 4.1 4.3 3.3 2.4 4.0 3.1 3.8 4.1 4.2 4.2 4.3 4.2 4.2 3.8 4.2 4.3 3.5
Gavage ml
Day 69
3.9 3.8 3.8
3.8 3.9 4.2 4.0 4.1 4.3 3.3 2.4 4.0 3.1 3.8 4.1 4.2 4.2 4.3 4.2 4.2 3.8 4.2 4.3 3.5
Gavage ml
Day 70
4.0 3.9 4.0
4.0 4.0 4.4 4.1 4.3 4.6 3.4 2.9 4.0 3.2 3.9 4.1 4.3 4.2 4.4 4.2 4.4 3.9 4.4 4.4 3.6
Gavage ml
Day 71
4.0 3.9 4.0
4.0 4.0 4.4 4.1 4.3 4.6 3.4 2.9 4.0 3.2 3.9 4.1 4.3 4.2 4.4 4.2 4.4 3.9 4.4 4.4 3.6
m m
a o 3
404
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Individual Dose Volumes
Gavage ml
Day 72
Gavage ml
Day 73
Gavage ml
Day 74
Gavage ml
Day 75
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
Gavage ml
Day 80
Gavage ml
Day 81
Gavage ml
Day 82
Gavage ml
Day 83
Male, I - 0 mg/kg/day
648225 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
648247 3.9 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0
648307 4.0 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.1 4.1 4.1
648294
648315 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
648256 4.0 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.1 4.1 4.1
648255 4.4 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5 4.5
648246 4.1 4.1 4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.2 4.2 4.2
648238 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3
648220 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6
648298 3.4 3.4 3.4 3.4 3.4 3.6 3.6 3.6 3.6 3.6 3.6 3.6
648228 2.9 2.9 2.9 2.9 2.9 3.2 3.2 3.2 3.2 3.2 3.2 3.2
648297 4.0 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.1 4.1 4.1
648219 3.2 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3
648226 3.9 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0
648222 4.1 4.1 4.1 4.1 4.1 4.3 4.3 4.3 4.3 4.3 4.3 4.3
648250 4.3 4.3 4.3 4.3 4.3 4.5 4.5 4.5 4.5 4.5 4.5 4.5
648271 4.2 4.2 4.2 4.2 4.2 4.4 4.4 4.4 4.4 4.4 4.4 4.4
648260 4.4 4.4 4.4 4.4 4.4 4.6 4.6 4.6 4.6 4.6 4.6 4.6
648264 4.2 4.2 4.2 4.2 4.2 4.3 4.3 4.3 4.3 4.3 4.3 4.3
648233 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.4
648311 3.9 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0
m m
648257 4.4 4.4 4.4 4.4 4.4 4.5 648278 4.4 4.4 4.4 4.4 4.4 4.5
4.5 4.5
4.5 4.5 4.5 4.5 4.5 4.5
4.5 4.5
4.5 4.5
3
648216
3.6
3.6
3.6
3.6
3.6
3.7
3.7
3.7
3.7
3.7
3.7
3.7
H90--2D46>ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
_______________________________
Gavage ml
Day 84
Gavage ml
Day 85
Male, I - 0 mg/kg/day
648225 4.1 4.1 648247 4.1 4.1 648307 4.1 4.1 648294
648315 4.1 4.1 648256 4.2 4.2 648255 4.5 4.5 648246 4.3 4.3 648238 4.4 4.4 648220 4.7 4.7 648298 3.7 3.7 648228 3.3 3.3 648297 4.1 4.1 648219 3.1 3.1 648226 4.0 4.0 648222 4.3 4.3 648250 4.4 4.4 648271 4.4 4.4 648260 4.8 4.8 648264 4.4 4.4 648233 4.5 4.5 648311 4.0 4.0 648257 4.7 4.7 648278 4.5 4.5 648216 3.7 3.7
Gavage ml
Day 86
4.1 4.1 4.1
4.1 4.2 4.5 4.3 4.4 4.7 3.7 3.3 4.1 3.1 4.0 4.3 4.4 4.4 4.8 4.4 4.5 4.0 4.7 4.5 3.7
Gavage ml
Day 87
4.1 4.1 4.1
4.1 4.2 4.5 4.3 4.4 4.7 3.7 3.3 4.1 3.1 4.0 4.3 4.4 4.4 4.8 4.4 4.5 4.0 4.7 4.5 3.7
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
4.1 4.1 4.1 4.2 4.1 4.1 4.1 4.3 4.1 4.1 4.1 4.2
4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.3 4.5 4.5 4.5 4.6 4.3 4.3 4.3 4.4 4.4 4.4 4.4 4.5 4.7 4.7 4.7 4.9 3.7 3.7 3.7 3.3 3.3 3.3 4.1 4.1 4.1 3.1 3.1 3.1 4.0 4.0 4.0 4.3 4.3 4.3 4.4 4.4 4.4 4.4 4.4 4.4 4.8 4.8 4.8 4.4 4.4 4.4 4.5 4.5 4.5 4.0 4.0 4.0 4.7 4.7 4.7 4.5 4.5 4.5 3.7 3.7 3.7
')
DuPont-6554
CoHiparty Sanitized. Does not contain TSCA CSI
406
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Male, III - 60 mg/kg/day Isopropanol
648302
1.9
1.9
1.9
1.9
1.9
1.9
1.9
2.2
2.2
648274
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.4
2.4
648227
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.5
2.5
648299
2.2
2.2
2.2 2.2
2.2
2.2
2.2
2.5
2.5
648303
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.5
2.5
648269
1.9
1.9
1.9
1.9
1.9
1.9
1.9
2.3
2.3
648252
1.9
1.9
1.9
1.9
1.9
1.9
1.9
2.3
2.3
648290
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.5
2.5
648258
1.9
1.9
1.9
1.9
1.9
1.9
1.9
2.3
2.3
648232
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.5
2.5
tasvosi 6ipsp!i^
407
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
> DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
Day 15
Day 16
Day 17
Male, :III - 60 mg/kg/day Isopropanol
648302
2.2
2.2
2.2
2.2
2.2
2.2
2.7
2.7
2.7
648274
2.4
2.4
2.4
2.4
2.4
2.4
2.9
2.9
2.9
648227
2.5
2.5
2.5
2.5
2.5
2.5
2.9
2.9
2.9
648299
2.5
2.5
2.5
2.5
2.5
2.5
2.9
2.9
2.9
648303
2.5
2.5
2.5
2.5
2.5
2.5
2.9
2.9
2.9
648269
2.3
2.3
2.3
2.3
2.3
2.3
2.7
2.7
2.7
648252
2.3
2.3
2.3
2.3
2.3
2.3
2.6
2.6
2.6
648290
2.5
2.5
2.5
2.5
2.5
2.5
3.0
3.0
3.0
648258
2.3
2.3
2.3
2.3
2.3
2.3
2.8
2.8
2.8
648232
2.5
2.5
2.5
2.5
2.5
2.5
3.0
3.0
3.0
1
408
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
Gavage Isopr Gavage Isopr Gavage Iso;
ml ml ml
Day 18
Day 19
Day 20
Male, :III - 60 mg/kg/day Isopropanol
648302
2.7
2.7
2.7
648274
2.9
2.9
2.9
648227
2.9
2.9
2.9
648299
2.9
2.9
2.9
648303
2.9
2.9
2.9
648269
2.7
2.7
2.7
648252
2.6
2.6
2.6
648290
3.0
3.0
3.0
648258
2.8
2.8
2.8
648232
3.0
3.0
3.0
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml
Day 21
Day 22
Day 23
Day 24
Day 25
Day 26
3.0 3.0 3.0 3.0 3.0 3.0
3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 2.9 2.9 2.9 2.9 2.9 2.9 2.8 2.8 2.8 2.8 2.8 2.8 3.3 3.3 3.3 3.3 3.3 3.3 3.1 3.1 3.1 3.1 3.1 3.1 3.3 3.3 3.3 3.3 3.3 3.3
Sanitised. Does notcontainTSCACBI
409
H90--2D46a)y78O: raSluGbcahvraogneicStTuodxyicinityRats
Gavage isopr Gavage Isopr Gavage Iso;
ml ml ml
Day 27
Day 28
Day 29
Male, :III - 60 mg/kg/day Isopropanol
648302
3.0
3.2
3.2
648274
3.2
3.4
3.4
648227
3.2
3.4
3.4
648299
3.2
3.5
3.5
648303
3.2
3.4
3.4
648269
2.9
3.1
3.1
648252
2.8
2.9
2.9
648290
3.3
3.5
3.5
648258
3.1
3.2
3.2
648232
3.3
3.5
3.5
Individual Dose Volumes
Isopr Gavage Isopr Gavage Isopr ml ml
30 Day 31 Day 32
3.2 3.2 3.2 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.4 3.4 3.4 3.1 3.1 3.1 2.9 2.9 2.9 3.5 3.5 3.5 3.2 3.2 3.2 3.5 3.5 3.5
DuPont-6554
Isopr Gavage Isopr Gavage Isopr ml ml
33 Day 34 Day 35
3.2 3.2 3.4 3.4 3.4 3.7 3.4 3.4 3.7 3.5 3.5 3.7 3.4 3.4 3.6 3.1 3.1 3.4 2.9 2.9 3.0 3.5 3.5 3.8 3.2 3.2 3.5 3.5 3.5 3.9
Sanitized. Does not contain TSCACBI
410
) 9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
Gavage Isopr Gavage Isopr Gavage Iso;
ml ml ml
Day 36
Day 37
Day 38
Male, :III - 60 mg/kg/day Isopropanol
648302
3.4
3.4
3.4
648274
3.7
3.7
3.7
648227
3.7
3.7
3.7
648299
3.7
3.7
3.7
648303
3.6
3.6
3.6
648269
3.4
3.4
3.4
648252
3.0
3.0
3.0
648290
3.8
3.8
3.8
648258
3.5
3.5
3.5
648232
3.9
3.9
3.9
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml
Day 39
Day 40
Day 41
Day 42
Day 43
Day 44
3.4 3.4 3.4 3.5 3.5 3.5 3.7 3.7 3.7 3.8 3.8 3.8 3.7 3.7 3.7 3.8 3.8 3.8 3.7 3.7 3.7 3.7 3.7 3.7 3.6 3.6 3.6 3.6 3.6 3.6 3.4 3.4 3.4 3.4 3.4 3.4 3.0 3.0 3.0 3.1 3.1 3.1 3.8 3.8 3.8 3.8 3.8 3.8 3.5 3.5 3.5 3.6 3.6 3.6 3.9 3.9 3.9 3.9 3.9 3.9
Does not contain TSCACBS
411
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Iso;
ml ml ml ml
Day 45
Day 46
Day 47
Day 48
Male, III - 60 mg/kg/day Isopropanol
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml
Day 49
Day 50
Day 51
Day 52
Day 53
648302
3.5
3.5
3.5
3.5
3.7
3.7
3.7
3.7
3.7
648274
3.8
3.8
3.8
3.8
4.1
4.1
4.1
4.1
4.1
648227
3.8
3.8
3.8
3.8
4.0
4.0
4.0
4.0
4.0
648299
3.7
3.7
3.7
3.7
3.9
3.9
3.9
3.9
3.9
648303
3.6
3.6
3.6
3.6
3.8
3.8
3.8
3.8
3.8
648269
3.4
3.4
3.4
3.4
3.6
3.6
3.6
3.6
3.6
648252
3.1
3.1
3.1
3.1
3.2
3.2
3.2
3.2
3.2
648290
3.8
3.8
3.8
3.8
4.0
4.0
4.0
4.0
4.0
648258
3.6
3.6
3.6
3.6
3.8
3.8
3.8
3.8
3.8
648232
3.9
3.9
3.9
3.9
4.1
4.1
4.1
4.1
4.1
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 54
Day 55
Day 56
Male, III - 60 mg/kg/day Isopropanol
Gavage Isopr ml
Day 57
Gavage Isopr ml
Day 58
Gavage Isopr ml
Day 59
Gavage Isopr ml
Day 60
Gavage Isopr ml
Day 61
Gavage Isopr ml
Day 62
648302 648274 648227 648299 648303 648269 648252 648290 648258 648232
3.7 4.1 4.0 3.9 3.8 3.6 3.2 4.0 3.8 4.1
3.7 4.1 4.0 3.9 3.8 3.6 3.2 4.0 3.8 4.1
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
3.9 4.2 4.1 4.0 3.9 3.8 3.3 4.2 4.0 4.2
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
)
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 63
Day 64
Day 65
Day 66
Day 67
Day 68
Day 69
Day 70
Day 71
Male, III - 60 mg/kg/day Isopropanol
648302
4.1
4.1
4.1
4.1
4.1
4.1
4.1
4.2
4.2
648274
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.5
4.5
648227
4.3
4.3
4.3
4.3
4.3
4.3
4.3
4.4
4.4
648299
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.3
4.3
648303
4.0
4.0
4.0
4.0
4.0
4.0
4.0
4.1
4.1
648269
3.9
3.9
3.9
3.9
3.9
3.9
3.9
4.0
4.0
648252
3.4
3.4
3.4
3.4
3.4
3.4
3.4
3.5
3.5
648290
4.3
4.3
4.3
4.3
4.3
4.3
4.3
4.4
4.4
648258
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
648232
4.3
4.3
4.3
4.3
4.3
4.3
4.3
4.5
4.5
414
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
ml Day 72
Male, III
648302 648274 648227 648299 648303 648269 648252 648290 648258 648232
4.2 4.5 4.4 4.3 4.1 4.0 3.5 4.4 4.2 4.5
Individual Dose Volumes
Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Iso] ml ml ml ml ml ml ml
73 Day 74 Day 75 Day 76 Day 77 Day 78 Day 79 Day 80
sropanol
4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.3 4.3 4.3 4.3 4.4 4.4 4.4 4.4 4.1 4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.2 4.2 4.2 4.2 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.6 4.6 4.6 4.6
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 81
Day 82
Day 83
Day 84
Day 85
Day 86
Day 87
Day 88
Day 89
Male, :III - 60 mg/kg/day Isopropanol
648302
4.2
4.2
4.2
4.4
4.4
4.4
4.4
4.4
4.4
648274
4.5
4.5
4.5
4.7
4.7
4.7
4.7
4.7
4.7
648227
4.5
4.5
4.5
4.6
4.6
4.6
4.6
4.6
4.6
648299
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
648303
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
4.2
648269
4.0
4.0
4.0
4.0
4.0
4.0
4.0
4.0
4.0
648252
3.6
3.6
3.6
3.6
3.6
3.6
3.6
3.6
3.6
648290
4.5
4.5
4.5
4.5
4.5
4.5
4.5
4.5
4.5
648258
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
648232
4.6
4.6
4.6
4.7
4.7
4.7
4.7
4.7
4.7
Company Sanitized. Does not contain TSCACBI
416
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
Gavage Isopr Gavage Isopr
ml ml
Day 90
Day 91
Male, ill - 60 mg/kg/day Isopropanol
648302 648274 648227 648299 648303 648269 648252 648290 648258 648232
4.4 4.7 4.6 4.4 4.2 4.0 3.6 4.5 4.4 4.7
4.4 4.5 4.5 4.4 4.2 4.2 3.6 4.7 4.6 4.8
Company Sanitized, Does notcontain TSC CM
Individual Dose Volumes
DuPont-6554
417
9H0--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Male, V - 10 mg/kg/day
648288 1.9 1.9 648286 2.0 2.0
648309 2.0 2.0 648312 2.2 2.2 648221 1.9 1.9 648273 1.8 1.8 648245 1.9 1.9 648301 1.9 1.9 648224 1.9 1.9 648283 1.9 1.9 648254 1.6 1.6 648310 2.0 2.0 648265 1.7 1.7 648253 1.9 1.9 648313 2.2 2.2
Gavage ml
Day 2
1.9 2.0 2.0 2.2 1.9 1.8 1.9 1.9 1.9 1.9 1.6 2.0 1.7 1.9 2.2
Gavage ml
Day 3
1.9 2.0 2.0 2.2 1.9 1.8 1.9 1.9 1.9 1.9 1.6 2.0 1.7 1.9 2.2
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.9 1.9 1.9 2.3 2.0 2.0 2.0 2.5 2.0 2.0 2.0 2.4 2.2 2.2 2.2 2.6 1.9 1.9 1.9 2.4 1.8 1.8 1.8 2.3 1.9 1.9 1.9 2.4 1.9 1.9 1.9 2.2 1.9 1.9 1.9 2.3 1.9 1.9 1.9 2.3 1.6 1.6 1.6 1.9 2.0 2.0 2.0 2.3 1.7 1.7 1.7 2.1 1.9 1.9 1.9 2.3 2.2 2.2 2.2 2.7
Gavage ml
Day 8
2.3 2.5 2.4 2.6 2.4 2.3 2.4 2.2 2.3 2.3 1.9 2.3 2.1 2.3 2.7
Gavage ml
Day 9
2.3 2.5 2.4 2.6 2.4 2.3 2.4 2.2 2.3 2.3 1.9 2.3 2.1 2.3 2.7
Gavage ml
Day 10
2.3 2.5 2.4 2.6 2.4 2.3 2.4 2.2 2.3 2.3 1.9 2.3 2.1 2.3 2.7
Gavage ml
Day 11
2.3 2.5 2.4 2.6 2.4 2.3 2.4 2.2 2.3 2.3 1.9 2.3 2.1 2.3 2.7
Company Sanitized. Does net contain TSCACB1
418
H90--2D46a)y78O: raSluGbcahvraogneicStTuodxyiciintyRats______
)
)
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Male, V - 10 mg/kg/day
648288 2.3 2.3 648286 2.5 2.5 648309 2.4 2.4 648312 2.6 2.6 648221 2.4 2.4 648273 2.3 2.3 648245 2.4 2.4 648301 2.2 2.2 648224 2.3 2.3 648283 2.3 2.3 648254 1.9 1.9 648310 2.3 2.3 648265 2.1 2.1 648253 2.3 2.3 648313 2.7 2.7
Gavage ml
Day 14
2.3 2.5 2.4 2.6 2.4 2.3 2.4 2.2 2.3 2.3 1.9 2.3 2.1 2.3 2.7
Gavage ml
Day 15
2.6 2.9 2.8 3.1 2.8 2.7 2.7 2.6 2.7 2.6 2.3 2.7 2.5 2.6 3.2
Individual Dose Volumes
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
2.6 2.6 2.6 2.6 2.9 2.9 2.9 2.9 2.8 2.8 2.8 2.8 3.1 3.1 3.1 3.1 2.8 2.8 2.8 2.8 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.7 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.3 2.3 2.3 2.3 2.7 2.7 2.7 2.7 2.5 2.5 2.5 2.5 2.6 2.6 2.6 2.6 3.2 3.2 3.2 3.2
Gavage ml
Day 20
2.6 2.9 2.8 3.1 2.8 2.7 2.7 2.6 2.7 2.6 2.3 2.7 2.5 2.6 3.2
Gavage ml
Day 21
2.8 3.3 3.1 3.4 3.3 2.9 3.0 2.8 3.0 2.9 2.5 3.0 2.8 2.9 3.4
Gavage ml
Day 22
2.8 3.3 3.1 3.4 3.3 2.9 3.0 2.8 3.0 2.9 2.5 3.0 2.8 2.9 3.4
Gavage ml
Day 23
2.8 3.3 3.1 3.4 3.3 2.9 3.0 2.8 3.0 2.9 2.5 3.0 2.8 2.9 3.4
TSCA CBI
419
H90--2D46a) y78O: raSluGbcahvraogneicStTuodxyiciintyRats________
)
)
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Male, V - 10 mg/kg/day
Gavage ml
Day 26
Gavage ml
Day 27
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
Gavage ml
Day 32
Gavage ml
Day 33
Gavage ml
Day 34
Gavage ml
Day 35
648288 2.8 2.8 2.8 2.8 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.2 a
648286 3.3 3.3 3.3 3.3 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.9 a
648309 3.1 3.1 3.1 3.1 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.5 a
648312 3.4 3.4 3.4 3.4 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.9 a
648221 3.3 3.3 3.3 3.3 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.9 a 648273 2.9 2.9 2.9 2.9 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.4 648245 3.0 3.0 3.0 3.0 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.4 648301 2.8 2.8 2.8 2.8 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.3 648224 3.0 3.0 3.0 3.0 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.5
648283 2.9 2.9 2.9 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.2 a
648254 2.5 2.5 2.5 2.5 2.8 2.8 2.8 2.8 2.8 2.8 2.8 3.0 a 648310 3.0 3.0 3.0 3.0 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.5 648265 2.8 2.8 2.8 2.8 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.2 648253 2.9 2.9 2.9 2.9 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.4 648313 3.4 3.4 3.4 3.4 3.8 3.8 3.8 3.8 3.8 3.8 3.8 4.0
Sanitized. Dess not contain TSCACBi
420
H-24678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Male, V - 1 0 mg/kg/day
648288 3.2 3.2 648286 3.9 3.9 648309 3.5 3.5 648312 3.9 3.9 648221 3.9 3.9 648273 3.4 3.4 648245 3.4 3.4 648301 3.3 3.3 648224 3.5 3.5 648283 3.2 3.2 648254 3.0 3.0 648310 3.5 3.5 648265 3.2 3.2 648253 3.4 3.4 648313 4.0 4.0
Gavage ml
Day 38
3.2 3.9 3.5 3.9 3.9 3.4 3.4 3.3 3.5 3.2 3.0 3.5 3.2 3.4 4.0
Gavage ml
Day 39
3.2 3.9 3.5 3.9 3.9 3.4 3.4 3.3 3.5 3.2 3.0 3.5 3.2 3.4 4.0
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
3.2 3.2 3.3 3.3 3.9 3.9 4.0 4.0 3.5 3.5 3.7 3.7 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.4 3.4 3.5 3.5 3.4 3.4 3.5 3.5 3.3 3.3 3.5 3.5 3.5 3.5 3.5 3.5 3.2 3.2 3.4 3.4 3.0 3.0 3.2 3.2 3.5 3.5 3.7 3.7 3.2 3.2 3.4 3.4 3.4 3.4 3.4 3.4 4.0 4.0 4.1 4.1
Gavage ml
Day 44
3.3 4.0 3.7 3.9 3.9 3.5 3.5 3.5 3.5 3.4 3.2 3.7 3.4 3.4 4.1
Gavage ml
Day 45
3.3 4.0 3.7 3.9 3.9 3.5 3.5 3.5 3.5 3.4 3.2 3.7 3.4 3.4 4.1
Gavage ml
Day 46
3.3 4.0 3.7 3.9 3.9 3.5 3.5 3.5 3.5 3.4 3.2 3.7 3.4 3.4 4.1
Gavage ml
Day 47
3.3 4.0 3.7 3.9 3.9 3.5 3.5 3.5 3.5 3.4 3.2 3.7 3.4 3.4 4.1
Company Sanitized. Doesnot contain TSCACB
421
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
) DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Male, V - 10 mg/kg/day
648288 3.3 3.4 648286 4.0 4.2 648309 3.7 3.8 648312 3.9 4.0 648221 3.9 4.1 648273 3.5 3.6 648245 3.5 3.6 648301 3.5 3.6 648224 3.5 3.6
648283 3.4 3.5
648254 3.2 3.4 648310 3.7 3.8 648265 3.4 3.6 648253 3.4 3.6 648313 4.1 4.2
Gavage ml
Day 50
3.4 4.2 3.8 4.0 4.1 3.6 3.6 3.6 3.6 3.5 3.4 3.8 3.6 3.6 4.2
Gavage ml
Day 51
3.4 4.2 3.8 4.0 4.1 3.6 3.6 3.6 3.6 3.5 3.4 3.8 3.6 3.6 4.2
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
3.4 3.4 3.4 3.4 4.2 4.2 4.2 4.2 3.8 3.8 3.8 3.8 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6
3.5 3.5 3.5 3.5
3.4 3.4 3.4 3.4 3.8 3.8 3.8 3.8 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 4.2 4.2 4.2 4.2
Gavage ml
Day 56
Gavage ml
Day 57
3.5 4.4 4.0 4.2 4.4 3.8 3.7 3.8 3.8
3.7 b
3.5 b 3.9 3.7 3.8 4.4
3.5 4.4 4.0 4.2 4.4 3.8 3.7 3.8 3.8
3.7
3.5 3.9 3.7 3.8 4.4
Gavage ml
Day 58
3.5 4.4 4.0 4.2 4.4 3.8 3.7 3.8 3.8 3.7 3.5 3.9 3.7 3.8 4.4
Gavage ml
Day 59
3.5 4.4 4.0 4.2 4.4 3.8 3.7 3.8 3.8 3.7 3.5 3.9 3.7 3.8 4.4
d. Doss not contain TSCft CBI
422
H90-2-D4>6a7y8"O. raSluGbcahvraogneicSTtuodxyiciintyRats
)
') DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Male, V - 10 mg/kg/day
648288 3.5 3.5 648286 4.4 4.4 648309 4.0 4.0 648312 4.2 4.2 648221 4.4 4.4 648273 3.8 3.8 648245 3.7 3.7 648301 3.8 3.8 648224 3.8 3.8 648283 3.7 3.7 648254 3.5 3.5 648310 3.9 3.9 648265 3.7 3.7 648253 3.8 3.8 648313 4.4 4.4
Gavage ml
Day 62
3.5 4.4 4.0 4.2 4.4 3.8 3.7 3.8 3.8 3.7 3.5 3.9 3.7 3.8 4.4
Gavage ml
Day 63
3.5 4.6 4.1 4.4 4.5 3.9 4.0 3.9 3.9 3.7 3.6 3.9 3.8 3.9 4.6
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
3.5 3.5 3.5 3.5 4.6 4.6 4.6 4.6 4.1 4.1 4.1 4.1 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.7 3.7 3.7 3.7 3-6 3.6 3.6 3.6 3.9 3.9 3.9 3.9 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 4.6 4.6 4.6 4.6
Gavage ml
Day 68
3.5 4.6 4.1 4.4 4.5 3.9 4.0 3.9 3.9 3.7 3.6 3.9 3.8 3.9 4.6
Gavage ml
Day 69
3.5 4.6 4.1 4.4 4.5 3.9 4.0 3.9 3.9 3.7 3.6 3.9 3.8 3.9 4.6
Gavage ml
Day 70
3.6 4.7 4.2 4.5 4.6 4.0 4.0 4.0 4.0 3.8 3.7 4.0 3.9 4.0 4.7
Gavage ml
Day 71
3.6 4.7 4.2 4.5 4.6 4.0 4.0 4.0 4.0 3.8 3.7 4.0 3.9 4.0 4.7
Company Sanitized. Does not contain TSCACBf
423
9H0--2D4>a6y78O: raSluGbcahvraogneicStTuodxyicinityRats
)
DuPont-6554
Gavage ml
Day 72
Gavage ml
Day 73
Male, V - 10 mg/kg/day
648288 3.6 3.6 648286 4.7 4.7 648309 4.2 4.2 648312 4.5 4.5 648221 4.6 4.6 648273 4.0 4.0 648245 4.0 4.0 648301 4.0 4.0 648224 4.0 4.0 648283 3.8 3.8 648254 3.7 3.7 648310 4.0 4.0 648265 3.9 3.9 648253 4.0 4.0 648313 4.7 4.7
Gavage ml
Day 74
3.6 4.7 4.2 4.5 4.6 4.0 4.0 4.0 4.0 3.8 3.7 4.0 3.9 4.0 4.7
Gavage ml
Day 75
3.6 4.7 4.2 4.5 4.6 4.0 4.0 4.0 4.0 3.8 3.7 4.0 3.9 4.0 4.7
Individual Dose Volumes
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
3.6 3.7 3.7 3.7 4.7 4.8 4.8 4.8 4.2 4.3 4.3 4.3 4.5 4.6 4.6 4.6 4.6 4.7 4.7 4.7 4.0 4.2 4.2 4.2 4.0 4.2 4.2 4.2 4.0 4.1 4.1 4.1 4.0 4.1 4.1 4.1 3.8 3.8 3.8 3.8 3.7 3.7 3.7 3.7 4.0 4.1 4.1 4.1 3.9 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.7 4.8 4.8 4.8
Gavage ml
Day 80
3.7 4.8 4.3 4.6 4.7 4.2 4.2 4.1 4.1 3.8 3.7 4.1 4.0 4.1 4.8
Gavage ml
Day 81
3.7 4.8 4.3 4.6 4.7 4.2 4.2 4.1 4.1 3.8 3.7 4.1 4.0 4.1 4.8
Gavage ml
Day 82
3.7 4.8 4.3 4.6 4.7 4.2 4.2 4.1 4.1 3.8 3.7 4.1 4.0 4.1 4.8
Gavage ml
Day 83
3.7 4.8 4.3 4.6 4.7 4.2 4.2 4.1 4.1 3.8 3.7 4.1 4.0 4.1 4.8
t g o IfO S I Iau
424
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
Gavage ml
Day 84
Gavage ml
Day 85
Male, V - 10 mg/kg/day
648288 3.7 3.7 648286 4.8 4.8 648309 4.4 4.4 648312 4.7 4.7 648221 4.8 4.8 648273 4.2 4.2 648245 4.3 4.3 648301 4.2 4.2 648224 4.2 4.2 648283 3.4 3.4 648254 3.7 3.7 648310 4.2 4.2 648265 4.1 4.1 648253 4.2 4.2 648313 5.0 5.0
Gavage ml
Day 86
3.7 4.8 4.4 4.7 4.8 4.2 4.3 4.2 4.2 3.4 3.7 4.2 4.1 4.2 5.0
Gavage ml
Day 87
3.7 4.8 4.4 4.7 4.8 4.2 4.3 4.2 4.2 3.4 3.7 4.2 4.1 4.2 5.0
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
3.7 3.7 3.7 3.8 4.8 4.8 4.8 4.9 4.4 4.4 4.4 4.4 4.7 4.7 4.7 4.7 4.8 4.8 4.8 4.8 4.2 4.2 4.2 4.3 4.3 4.3 4.3 4.4 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.3 3.4 3.4 3.4 3.7 3.7 3.7 4.2 4.2 4.2 4.1 4.1 4.1 4.2 4.2 4.2 5.0 5.0 5.0 5.0
DuPont-6554
Samtfeed. Does not contain TSCACBI
425
H-24)678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
)
)
DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Male, VII: - 60 mg/kg/day
648300 1.8 1.8 648305 2.1 2.1 648280 1.9 1.9 648259 2.2 2.2 648223 2.1 2.1
648270 1.8 1.8 648237 2.0 2.0 648266 2.0 2.0 648243 1.9 1.9 648244 1.9 1.9 648279 2.0 2.0 648296 1.7 1.7 648314 1.9 1.9 648285 1.6 1.6 648268 1.9 1.9
Gavage ml
Day 2
1.8 2.1 1.9 2.2 2.1 1.8 2.0 2.0 1.9 1.9 2.0 1.7 1.9 1.6 1.9
Gavage ml
Day 3
1.8 2.1 1.9 2.2 2.1 1.8 2.0 2.0 1.9 1.9 2.0 1.7 1.9 1.6 1.9
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.8 1.8 1.8 2.1 2.1 2.1 2.1 2.5 1.9 1.9 1.9 2.4 2.2 2.2 2.2 2.6 2.1 2.1 2.1 2.6 1.8 1.8 1.8 2.2 2.0 2.0 2.0 2.5 2.0 2.0 2.0 2.5 1.9 1.9 1.9 2.3 1.9 1.9 1.9 2.3 2.0 2.0 2.0 2.3 1.7 1.7 1.7 2.0 1.9 1.9 1.9 2.3 1.6 1.6 1.6 2.0 1.9 1.9 1.9 2.4
Gavage ml
Day 8
2.1 2.5 2.4 2.6 2.6 2.2 2.5 2.5 2.3 2.3 2.3 2.0 2.3 2.0 2.4
Gavage ml
Day 9
2.1 2.5 2.4 2.6 2.6 2.2 2.5 2.5 2.3 2.3 2.3 2.0 2.3 2.0 2.4
Gavage ml
Day 10
2.1 2.5 2.4 2.6 2.6 2.2 2.5 2.5 2.3 2.3 2.3 2.0 2.3 2.0 2.4
Gavage ml
Day 11
2.1 2.5
22.. 64 22.. 26
2.5 2.5 2.3 2.3 2.3 2.0 2.3 2.0 2.4
Company Sanitized D oes not contain TSCACBf
426
H-24678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Male, VII' - 60 mg/kg/day
648300 2.1 2.1 648305 2.5 2.5 648280 2.4 2.4 648259 2.6 2.6 648223 2.6 2.6 648270 2.2 2.2 648237 2.5 2.5 648266 2.5 2.5 648243 2.3 2.3 648244 2.3 2.3 648279 2.3 2.3 648296 2.0 2.0 648314 2.3 2.3 648285 2.0 2.0 648268 2.4 2.4
Gavage ml
Day 14
2.1 2.5 2.4 2.6 2.6 2.2 2.5 2.5 2.3 2.3 2.3 2.0 2.3 2.0 2.4
Gavage ml
Day 15
2.4 2.9 2.9 3.0 3.0 2.7 3.0 2.9 2.6 2.6 2.6 2.3 2.6 2.3 2.8
Individual Dose Volumes
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
2.4 2.4 2.4 2.4 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 2.7 2.7 2.7 2.7 3.0 3.0 3.0 3.0 2.9 2.9 2.9 2.9 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.3 2.3 2.3 2.3 2.6 2.6 2.6 2.6 2.3 2.3 2.3 2.3 2.8 2.8 2.8 2.8
Gavage ml
Day 20
2.4 2.9 2.9 3.0 3.0 2.7 3.0 2.9 2.6 2.6 2.6 2.3 2.6 2.3 2.8
Gavage ml
Day 21
2.6 3.2 3.2 3.2 3.4 2.8 3.2 3.1 2.9 2.8 2.8 2.6 2.8 2.6 3.0
Gavage ml
Day 22
2.6 3.2 3.2 3.2 3.4 2.8 3.2 3.1 2.9 2.8 2.8 2.6 2.8 2.6 3.0
Gavage ml
Day 23
2.6 3.2 3.2 3.2 3.4 2.8 3.2 3.1 2.9 2.8 2.8 2.6 2.8 2.6 3.0
Sanitized B&m notcontain TSCACBI
427
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Male, VII: - 60 mg/kg/day
648300 2.6 2.6 648305 3.2 3.2 648280 3.2 3.2 648259 3.2 3.2 648223 3.4 3.4
648270 2.8 2.8 648237 3.2 3.2 648266 3.1 3.1 648243 2.9 2.9 648244 2.8 2.8 648279 2.8 2.8 648296 2.6 2.6 648314 2.8 2.8 648285 2.6 2.6 648268 3.0 3.0
Gavage ml
Day 26
2.6 3.2 3.2 3.2 3.4 2.8 3.2 3.1 2.9 2.8 2.8 2.6 2.8 2.6 3.0
Gavage ml
Day 27
2.6 3.2 3.2 3.2 3.4 2.8 3.2 3.1 2.9 2.8 2.8 2.6 2.8 2.6 3.0
Individual Cose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
2.7 2.7 2.7 2.7 3.5 3.5 3.5 3.5 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.7 3.7 3.7 3.7 3.1 3.1 3.1 3.1 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.1 3.1 3.1 3.1 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 2.7 2.7 2.7 2.7 3.0 3.0 3.0 3.0 2.7 2.7 2.7 2.7 3.3 3.3 3.3 3.3
Gavage ml
Day 32
2.7 3.5 3.4 3.5 3.7 3.1 3.5 3.5 3.1 3.0 3.1 2.7 3.0 2.7 3.3
Gavage ml
Day 33
2.7 3.5 3.4 3.5 3.7 3.1 3.5 3.5 3.1 3.0 3.1 2.7 3.0 2.7 3.3
Gavage ml
Day 34
2.7 3.5 3.4 3.5 3.7 3.1 3.5 3.5 3.1 3.0 3.1 2.7 3.0 2.7 3.3
Gavage ml
Day 35
2.9 3.8 3.6 3.7 3.9 3.3 3.9 3.7 3.3 3.2 3.2 2.8 3.2 2.9 3.6
leovosi ujetiiosiosma v*m m &mmm
428
) H90--2D46a7y8O: raSluGbcahvraogneicStTuodxyiciintyRats
)
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Male, VII - 60 mg/kg/day
648300 2.9 2.9 648305 3.8 3.8 648280 3.6 3.6 648259 3.7 3.7 648223 3.9 3.9 648270 3.3 3.3 648237 3.9 3.9 648266 3.7 3.7 648243 3.3 3.3 648244 3.2 3.2 648279 3.2 3.2 648296 2.8 2.8 648314 3.2 3.2 648285 2.9 2.9 648268 3.6 3.6
Gavage ml
Day 38
2.9 3.8 3.6 3.7 3.9 3.3 3.9 3.7 3.3 3.2 3.2 2.8 3.2 2.9 3.6
Gavage ml
Day 39
2.9 3.8 3.6 3.7 3.9 3.3 3.9 3.7 3.3 3.2 3.2 2.8 3.2 2.9 3.6
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
2.9 2.9 2.9 2.9 3.8 3.8 3.7 3.7 3.6 3.6 3.7 3.7 3.7 3.7 3.8 3.8 3.9 3.9 4.0 4.0 3.3 3.3 3.4 3.4 3.9 3.9 3.9 3.9 3.7 3.7 3.7 3.7 3.3 3.3 3.5 3.5 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 2.8 2.8 3.0 3.0 3.2 3.2 3.2 3.2 2.9 2.9 2.9 2.9 3.6 3.6 3.7 3.7
Gavage ml
Day 44
2.9 3.7 3.7 3.8 4.0 3.4 3.9 3.7 3.5 3.2 3.3 3.0 3.2 2.9 3.7
Gavage ml
Day 45
2.9 3.7 3.7 3.8 4.0 3.4 3.9 3.7 3.5 3.2 3.3 3.0 3.2 2.9 3.7
Gavage ml
Day 46
2.9 3.7 3.7 3.8 4.0 3.4 3.9 3.7 3.5 3.2 3.3 3.0 3.2 2.9 3.7
Gavage ml
Day 47
2.9 3.7 3.7 3.8 4.0 3.4 3.9 3.7 3.5 3.2 3.3 3.0 3.2 2.9 3.7
Company Sanitized Does not contain TSCA CBf
429
H90--2D46)ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
')
DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Male, VII: - 60 mg/kg/day
648300 2.9 3.0 648305 3.7 3.8 648280 3.7 3.8 648259 3.8 3.9 648223 4.0 4.2 648270 3.4 3.5 648237 3.9 4.2 648266 3.7 4.0 648243 3.5 3.7 648244 3.2 3.5 648279 3.3 3.4 648296 3.0 3.2 648314 3.2 3.2 648285 2.9 3.1 648268 3.7 3.8
Gavage ml
Day 50
3.0 3.8 3.8 3.9 4.2 3.5 4.2 4.0 3.7 3.5 3.4 3.2 3.2 3.1 3.8
Gavage ml
Day 51
3.0 3.8 3.8 3.9 4.2 3.5 4.2 4.0 3.7 3.5 3.4 3.2 3.2 3.1 3.8
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
3.0 3.0 3.0 3.0 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 4.2 4.2 4.2 4.2 3.5 3.5 3.5 3.5 4.2 4.2 4.2 4.2 4.0 4.0 4.0 4.0 3.7 3.7 3.7 3.7 3.5 3.5 3.5 3.5 3.4 3.4 3.4 3.4 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.1 3.1 3.1 3.1 3.8 3.8 3.8 3.8
Gavage ml
Day 56
3.1 4.0 3.9 4.0 4.5 3.7 4.3 4.2 3.9 3.6 3.5 3.4 3.4 3.3 3.9
Gavage ml
Day 57
3.1 4.0 3.9 4.0 4.5 3.7 4.3 4.2 3.9 3.6 3.5 3.4 3.4 3.3 3.9
Gavage ml
Day 58
3.1 4.0 3.9 4.0 4.5 3.7 4.3 4.2 3.9 3.6 3.5 3.4 3.4 3.3 3.9
Gavage ml
Day 59
3.1 4.0 3.9 4.0 4.5 3.7 4.3 4.2 3.9 3.6 3.5 3.4 3.4 3.3 3.9
Sanitized. 6oe a notconifn TSCA CBI
430
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
.)
)
DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Male, VII: - 60 mg/kg/day
648300 3.1 3.1 648305 4.0 4.0 648280 3.9 3.9 648259 4.0 4.0 648223 4.5 4.5 648270 3.7 3.7 648237 4.3 4.3 648266 4.2 4.2 648243 3.9 3.9 648244 3.6 3.6 648279 3.5 3.5 648296 3.4 3.4 648314 3.4 3.4 648285 3.3 3.3 648268 3.9 3.9
Gavage ml
Day 62
3.1 4.0 3.9 4.0 4.5 3.7 4.3 4.2 3.9 3.6 3.5 3.4 3.4 3.3 3.9
Gavage ml
Day 63
3.2 4.2 4.0 4.1 4.7 3.8 4.5 4.4 4.0 3.8 3.5 3.4 3.5 3.2 4.1
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
3.2 3.2 3.2 3.2 4.2 4.2 4.2 4.2 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.7 4.7 4.7 4.7 3.8 3.8 3.8 3.8 4.5 4.5 4.5 4.5 4.4 4.4 4.4 4.4 4.0 4.0 4.0 4.0 3.8 3.8 3.8 3.8 3.5 3.5 3.5 3.5 3.4 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.2 3.2 3.2 3.2 4.1 4.1 4.1 4.1
Gavage ml
Day 68
3.2 4.2 4.0 4.1 4.7 3.8 4.5 4.4 4.0 3.8 3.5 3.4 3.5 3.2 4.1
Gavage ml
Day 69
3.2 4.2 4.0 4.1 4.7 3.8 4.5 4.4 4.0 3.8 3.5 3.4 3.5 3.2 4.1
Gavage ml
Day 70
3.3 4.3 4.2 4.2 4.8 3.8 4.6 4.5 4.1 3.9 3.7 3.6 3.4 3.3 4.2
Gavage ml
Day 71
3.3 4.3 4.2 4.2 4.8 3.8 4.6 4.5 4.1 3.9 3.7 3.6 3.4 3.3 4.2
Swlfesdl tfoesnafconfln TSC CBI
431
9H0--2D46a)y78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 72
Gavage ml
Day 73
Male, VII: - 60 mg/kg/day
648300 3.3 3.3 648305 4.3 4.3 648280 4.2 4.2 648259 4.2 4.2 648223 4.8 4.8 648270 3.8 3.8 648237 4.6 4.6 648266 4.5 4.5 648243 4.1 4.1 648244 3.9 3.9 648279 3.7 3.7 648296 3.6 3.6 648314 3.4 3.4 648285 3.3 3.3 648268 4.2 4.2
Gavage ml
Day 74
3.3 4.3 4.2 4.2 4.8 3.8 4.6 4.5 4.1 3.9 3.7 3.6 3.4 3.3 4.2
Gavage ml
Day 75
3.3 4.3 4.2 4.2 4.8 3.8 4.6 4.5 4.1 3.9 3.7 3.6 3.4 3.3 4.2
Individual Dose Volumes
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
3.3 3.3 3.3 3.3 4.3 4.4 4.4 4.4 4.2 4.2 4.2 4.2 4.2 4.3 4.3 4.3 4.8 4.9 4.9 4.9 3.8 3.9 3.9 3.9 4.6 4.7 4.7 4.7 4.5 4.6 4.6 4.6 4.1 4.3 4.3 4.3 3.9 3.9 3.9 3.9 3.7 3.8 3.8 3.8 3.6 3.7 3.7 3.7 3.4 3.5 3.5 3.5 3.3 3.4 3.4 3.4 4.2 4.3 4.3 4.3
Gavage ml
Day 80
3.3 4.4 4.2 4.3 4.9 3.9 4.7 4.6 4.3 3.9 3.8 3.7 3.5 3.4 4.3
Gavage ml
Day 81
3.3 4.4 4.2 4.3 4.9 3.9 4.7 4.6 4.3 3.9 3.8 3.7 3.5 3.4 4.3
Gavage ml
Day 82
3.3 4.4 4.2 4.3 4.9 3.9 4.7 4.6 4.3 3.9 3.8 3.7 3.5 3.4 4.3
Gavage ml
Day 83
3.3 4.4 4.2 4.3 4.9 3.9 4.7 4.6 4.3 3.9 3.8 3.7 3.5 3.4 4.3
Sanitized. Does not contain TSCACBS
432
H90--2D46a)y78O: raSluGbcahvraogneicStTuodxyicinityRats_________
)
Gavage ml
Day 84
Gavage ml
Day 85
Male, VII: - 60 mg/kg/day
648300 3.4 3.4 648305 4.5 4.5 648280 4.3 4.3 648259 4.3 4.3 648223 5.0 5.0 648270 4.0 4.0 648237 4.8 4.8 648266 4.7 4.7 648243 4.3 4.3 648244 3.9 3.9
648279 3.8 3.8
648296 3.6 3.6 648314 3.4 3.4 648285 3.4 3.4 648268 4.3 4.3
Gavage ml
Day 86
3.4 4.5 4.3 4.3 5.0 4.0 4.8 4.7 4.3 3.9 3.8 3.6 3.4 3.4 4.3
Gavage ml
Day 87
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
3.4 3.4 3.4 3.4 3.4 4.5 4.5 4.5 4.5 4.5 4.3 4.3 4.3 4.3 4.2 4.3 4.3 4.3 4.3 4.3 5.0 5.0 5.0 5.0 5.0 4.0 4.0 4.0 4.0 4.0 4.8 4.8 4.8 4.8 4.9 4.7 4.7 4.7 4.7 4.8 4.3 4.3 4.3 4.3 4.4 3.9 3.9 3.9 3.9 4.0
5.0 b
3.8
3.8
3.8
3.6 3.6 3.6 3.6 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 4.3 4.3 4.3 4.3
>
DuPont-6554
fflp'any SA Dms notcontain TSCA CB!
433
H90-Da^y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Male, IX - 300 mg/kg/day
648236 1.9 1.9 648217 2.2 2.2 648248 1.9 1.9 648218 2.1 2.1 648239 2.1 2.1 648293 1.8 1.8 648275 1.9 1.9 648308 2.1 2.1 648235 1.9 1.9 648289 2.0 2.0 648292 1.8 1.8 648272 1.6 1.6 648234 2.0 2.0 648240 1.7 1.7 648287 1.8 1.8 648277 1.9 1.9 648261 1.9 1.9 648306 1.9 1.9 648241 2.0 2.0 648284 1.7 1.7 648282 1.8 1.8 648231 2.0 2.0 648262 1.9 1.9 648230 1.9 1.9 648249 2.0 2.0
Gavage ml
Day 2
1.9 2.2 1.9 2.1 2.1 1.8 1.9 2.1 1.9 2.0 1.8 1.6 2.0 1.7 1.8 1.9 1.9 1.9 2.0 1.7 1.8 2.0 1.9 1.9 2.0
Gavage ml
Day 3
1.9 2.2 1.9 2.1 2.1 1.8 1.9 2.1 1.9 2.0 1.8 1.6 2.0 1.7 1.8 1.9 1.9 1.9 2.0 1.7 1.8 2.0 1.9 1.9 2.0
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.9 1.9 1.9 2.3 2.2 2.2 2.2 2.7 1.9 1.9 1.9 2.2 2.1 2.1 2.1 2.5 2.1 2.1 2.1 2.6 1.8 1.8 1.8 2.1 1.9 1.9 1.9 2.3 2.1 2.1 2.1 2.5 1.9 1.9 1.9 2.3 2.0 2.0 2.0 2.5 1.8 1.8 1.8 2.1 1.6 1.6 1.6 2.1 2.0 2.0 2.0 2.3 1.7 1.7 1.7 2.0 1.8 1.8 1.8 2.3 1.9 1.9 1.9 2.1 1.9 1.9 1.9 2.3 1.9 1.9 1.9 2.4 2.0 2.0 2.0 2.4 1.7 1.7 1.7 2.1 1.8 1.8 1.8 2.2 2.0 2.0 2.0 2.3 1.9 1.9 1.9 2.3 1.9 1.9 1.9 2.2 2.0 2.0 2.0 2.3
Gavage ml
Day 8
2.3 2.7 2.2 2.5 2.6 2.1 2.3 2.5 2.3 2.5 2.1 2.1 2.3 2.0 2.3 2.1 2.3 2-4 2.4 2.1 2.2 2.3 2.3 2.2 2.3
Gavage ml
Day 9
2.3 2.7 2.2 2.5 2.6 2.1 2.3 2.5 2.3 2.5 2.1 2.1 2.3 2.0 2.3 2.1 2.3 2.4 2.4 2.1 2.2 2.3 2.3 2.2 2.3
Gavage ml
Day 10
2.3 2.7 2.2 2.5 2.6 2.1 2.3 2.5 2.3 2.5 2.1 2.1 2.3 2.0 2.3 2.1 2.3 2.4 2.4 2.1 2.2 2.3 2.3 2.2 2.3
Gavage ml
Day 11
2.3 2.7 2.2 2.5 2.6 2.1 2.3 2.5 2.3 2.5 2.1 2.1 2.3 2.0 2.3 2.1 2.3 2.4 2.4 2.1 2.2 2.3 2.3 2.2 2.3
Company8nl!l2ed. Does not contain TSCACBI
434
H90--2D4)6ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Gavage ml
Day 12
Gavage ml
Day 13
Male, IX - 300 mg/kg/day
648236 2.3 2.3 648217 2.7 2.7 648248 2.2 2.2 648218 2.5 2.5 648239 2.6 2.6 648293 2.1 2.1 648275 2.3 2.3 648308 2.5 2.5 648235 2.3 2.3 648289 2.5 2.5 648292 2.1 2.1 648272 2.1 2.1 648234 2.3 2.3 648240 2.0 2.0 648287 2.3 2.3 648277 2.1 2.1
648261 2.3 2.3 648306 2.4 2.4 648241 2.4 2.4 648284 2.1 2.1 648282 2.2 2.2 648231 2.3 2.3 648262 2.3 2.3 648230 2.2 2.2 648249 2.3 2.3
Gavage ml
Day 14
2.3 2.7 2.2 2.5 2.6 2.1 2.3 2.5 2.3 2.5 2.1 2.1 2.3 2.0 2.3 2.1 2.3 2.4 2.4 2.1 2.2 2.3 2.3 2.2 2.3
Gavage ml
Day 15
2.6 2.9 2.6 2.8 3.0 2.5 2.6 2.9 2.6 3.0 2.5 2.4 2.6 2.3 2.6 2.5 2.7 2.8 2.9 2.5 2.5 2.5 2.7 2.5 2.6
Inc
Gavage ml
Day 16
2.6 2.9 2.6 2.8 3.0 2.5 2.6 2.9 2.6 3.0 2.5 2.4 2.6 2.3 2.6 2.5 2.7 2.8 2.9 2.5 2.5 2.5 2.7 2.5 2.6
Company Sanitized. Does not contain TSCA CBI
DuPont-6554
lividual Dose Volumes
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
Gavage ml
Day 20
Gavage ml
Day 21
Gavage ml
Day 22
Gavage ml
Day 23
2.6 2 . 6 2 . 6 2 . 6 2.9 2.9 2.9
22.. 69
2.9 2.6
2.9 2.6
2.9 2.6
3.4 2.8
3.4 2.8
3.4 2.8
2.8 2.8 2.8 2.8 3.1 3.1 3.1
3.0 3.0 3.0 3.0 3.3 3.3 3.3
2.5 2.5 2.5 2.5 2.7 2.7 2.7
2.6 2. 6 2.6 2.6 2.8 2.8 2.8
2.9 2.6
22.. 69
22.. 69
2.9 2.6
3.1 2.9
3.1 2.9
3.1 2.9
3.0 3.0 3.0 3.0 3.3 3.3 3.3
2.5 2.5 2.5 2.5 2.8 2.8 2.8
2.4 2.4 2.4 2.4 2.6 2.6 2.6
2.6 2.6 2.6 2.6 2.9 2.9 2.9
2.3 2.3 2.3 2.3 2.4 2.4 2.4
2.6 2.6 2.6 2.6 2.8 2.8 2.8
2.5 2.5 2.5 2.5 2.7 2.7 2.7
2.7 2.8
2.7 2.8
22.. 87
2.7 2.8
3.0 3.1
3.0 3.1
3.0 3.1
2.9 2.9 2.9 2.9 3.1 3.1 3.1
2.5 2.5 2.5 2.5 2.6 2.6 2.6
2.5 2.5 2.5 2.5 2.7 2.7 2.7
2.5 2.5 2.5 2.5 2.7 2.7 2.7
2.7 2.7 2.7 2.7 2.8 2.8 2.8
2.5 2.6
2.5 2.6
22.. 65
2.5 2.6
2.8 2.8
2.8 2.8
2.8 2.8
435
H90--2D46a) y78O: raSluGbcahvraogneicStTuodxyiciintyRats____
)
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Male, IX - 300 mg/kg/day
648236 2.9 2.9 648217 3.4 3.4 648248 2.8 2.8 648218 3.1 3.1 648239 3.3 3.3 648293 2.7 2.7 648275 2.8 2.8 648308 3.1 3.1 648235 2.9 2.9 648289 3.3 3.3 648292 2.8 2.8 648272 2.6 2.6 648234 2.9 2.9 648240 2.4 2.4 648287 2.8 2.8 648277 2.7 2.7
648261 3.0 3.0 648306 3.1 3.1 648241 3.1 3.1 648284 2.6 2.6 648282 2.7 2.7 648231 2.7 2.7 648262 2.8 2.8 648230 2.8 2.8
648249 2.8 2.8
Gavage ml
Day 26
2.9 3.4 2.8 3.1 3.3 2.7 2.8 3.1 2.9 3.3 2.8 2.6 2.9 2.4 2.8 2.7 3.0 3.1 3.1 2.6 2.7 2.7 2.8 2.8 2.8
Gavage ml
Day 27
2.9 3.4 2.8 3.1 3.3 2.7 2.8 3.1 2.9 3.3 2.8 2.6 2.9 2.4 2.8 2.7 3.0 3.1 3.1 2.6 2.7 2.7 2.8 2.8 2.8
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
3.1 3.1 3.1 3.1 3.7 3.7 3.7 3.7 2.9 2.9 2.9 2.9 3.3 3.3 3.3 3.3 3.6 3.6 3.6 3.6 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 3.4 3.4 3.4 3.4 3.2 3.2 3.2 3.2 3.6 3.6 3.6 3.6 3.1 3.1 3.1 3.1 2.8 2.8 2.8 2.8 3.2 3.2 3.2 3.2 2.7 2.7 2.7 2.7 3.1 3.1 3.1 3.1 3.0 3.0 3.0 3.0 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.4 3.4 3.4 3.4 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 2.9 2.9 2.9 2.9
Gavage ml
Day 32
3.1 3.7 2.9 3.3 3.6 2.9 2.9 3.4 3.2 3.6 3.1 2.8 3.2 2.7 3.1 3.0 3.2 3.3 3.4 2.9 2.9 2.9 3.0 3.1 2.9
Gavage ml
Day 33
3.1 3.7 2.9 3.3 3.6 2.9 2.9 3.4 3.2 3.6 3.1 2.8 3.2 2.7 3.1 3.0 3.2 3.3 3.4 2.9 2.9 2.9 3.0 3.1 2.9
Gavage ml
Day 34
3.1 3.7 2.9 3.3 3.6 2.9 2.9 3.4 3.2 3.6 3.1 2.8 3.2 2.7 3.1 3.0 3.2 3.3 3.4 2.9 2.9 2.9 3.0 3.1 2.9
Gavage ml
Day 35
3.2 3.8 3.1 3.5 3.8 3.0 3.0 3.7 3.4 3.9 3.3 2.9 3.4 2.9 3.2 3.2 3.5 3.6 3.6 3.0 3.1 3.1 3.3 3.3 3.1
Company Sanitized. Does not contain TSCJ
436
H90--2D46a7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Male, IX - 300 mg/kg/day
648236 3.2 3.2 648217 3.8 3.8 648248 3.1 3.1 648218 3.5 3.5 648239 3.8 3.8 648293 3.0 3.0 648275 3.0 3.0 648308 3.7 3.7 648235 3.4 3.4 648289 3.9 3.9 648292 3.3 3.3 648272 2.9 2.9 648234 3.4 3.4 648240 2.9 2.9 648287 3.2 3.2 648277 3.2 3.2 648261 3.5 3.5 648306 3.6 3.6 648241 3.6 3.6 648284 3.0 3.0 648282 3.1 3.1 648231 3.1 3.1 648262 3.3 3.3 648230 3.3 3.3 648249 3.1 3.1
Gavage ml
Day 38
3.2 3.8 3.1 3.5 3.8 3.0 3.0 3.7 3.4 3.9 3.3 2.9 3.4 2.9 3.2 3.2 3.5 3.6 3.6 3.0 3.1 3.1 3.3 3.3 3.1
Gavage ml
Day 39
3.2 3.8 3.1 3.5 3.8 3.0 3.0 3.7 3.4 3.9 3.3 2.9 3.4 2.9 3.2 3.2 3.5 3.6 3.6 3.0 3.1 3.1 3.3 3.3 3.1
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
3.2 3.2 3.3 3.3 3.8 3.8 3.8 3.8 3.1 3.1 3.2 3.2 3.5 3.5 3.5 3.5 3.8 3.8 3.9 3.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.7 3.7 3.6 3.6 3.4 3.4 3.4 3.4 3.9 3.9 4.0 4.0 3.3 3.3 3.4 3.4 2.9 2.9 3.0 3.0 3.4 3.4 3.4 3.4 2.9 2.9 3.0 3.0 3.2 3.2 3.3 3.3 3.2 3.2 3.4 3.4 3.5 3.5 3.5 3.5 3.6 3.6 3.7 3.7 3.6 3.6 3.7 3.7 3.0 3.0 3.1 3.1 3.1 3.1 3.2 3.2 3.1 3.1 3.1 3.1 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 3.1 3.1 3.2 3.2
Gavage ml
Day 44
3.3 3.8 3.2 3.5 3.9 3.0 3.0 3.6 3.4 4.0 3.4 3.0 3.4 3.0 3.3 3.4 3.5 3.7 3.7 3.1 3.2 3.1 3.3 3.4 3.2
Gavage ml
Day 45
3.3 3.8 3.2 3.5 3.9 3.0 3.0 3.6 3.4 4.0 3.4 3.0 3.4 3.0 3.3 3.4 3.5 3.7 3.7 3.1 3.2 3.1 3.3 3.4 3.2
Gavage ml
Day 46
3.3 3.8 3.2 3.5 3.9 3.0 3.0 3.6 3.4 4.0 3.4 3.0 3.4 3.0 3.3 3.4 3.5 3.7 3.7 3.1 3.2 3.1 3.3 3.4 3.2
Gavage ml
Day 47
3.3 3.8 3.2 3.5 3.9 3.0 3.0 3.6 3.4 4.0 3.4 3.0 3.4 3.0 3.3 3.4 3.5 3.7 3.7 3.1 3.2 3.1 3.3 3.4 3.2
9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats______
____ DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Male, IX - 300 mg/kg/day
648236 3.3 3.4 648217 3.8 3.7 648248 3.2 3.3 648218 3.5 3.7 648239 3.9 4.0 648293 3.0 3.1 648275 3.0 3.1 648308 3.6 3.8 648235 3.4 3.5 648289 4.0 4.2 648292 3.4 3.5 648272 3.0 3.1 648234 3.4 3.6 648240 3.0 3.1 648287 3.3 3.5 648277 3.4 3.5
648261 3.5 3.6 648306 3.7 3.8 648241 3.7 3.9 648284 3.1 3.2 648282 3.2 3.3 648231 3.1 3.3 648262 3.3 3.5
648230 3.4 3.5 648249 3.2 3.3
Gavage ml
Day 50
3.4 3.7 3.3 3.7 4.0 3.1 3.1 3.8 3.5 4.2 3.5 3.1 3.6 3.1 3.5 3.5 3.6 3.8 3.9 3.2 3.3 3.3 3.5 3.5 3.3
Gavage ml
Day 51
3.4 3.7 3.3 3.7 4.0 3.1 3.1 3.8 3.5 4.2 3.5 3.1 3.6 3.1 3.5 3.5 3.6 3.8 3.9 3.2 3.3 3.3 3.5 3.5 3.3
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
3.4 3.4 3.4 3.4 3.7 3.7 3.7 3.7 3.3 3.3 3.3 3.3 3.7 3.7 3.7 3.7 4.0 4.0 4.0 4.0 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.8 3.8 3.8 3.8 3.5 3.5 3.5 3.5 4.2 4.2 4.2 4.2 3.5 3.5 3.5 3.5 3.1 3.1 3.1 3.1 3.6 3.6 3.6 3.6 3.1 3.1 3.1 3.1 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.8 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.2 3.2 3.2 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.3 3.3 3.3 3.3
Gavage ml
Day 56
3.5 3.9 3.4 3.8 4.3 3.1 3.2 3.9 3.7 4.4 3.7 3.3 3.8 3.3 3.6 3.6 3.8 3.9 4.1 3.3 3.4 3.5 3.6 3.7 3.4
Gavage ml
Day 57
3.5 3.9 3.4 3.8 4.3 3.1 3.2 3.9 3.7 4.4 3.7 3.3 3.8 3.3 3.6 3.6 3.8 3.9 4.1 3.3 3.4 3.5 3.6 3.7 3.4
Gavage ml
Day 58
3.5 3.9 3.4 3.8 4.3 3.1 3.2 3.9 3.7 4.4 3.7 3.3 3.8 3.3 3.6 3.6 3.8 3.9 4.1 3.3 3.4
3.6 3.7 3.4
Gavage ml
Day 59
3.5 3.9 3.4 3.8 4.3 3.1 3.2 3.9 3.7 4.4 3.7 3.3 3.8 3.3 3.6 3.6 3.8 3.9 4.1 3.3 3.4
3.6 3.7 3.4
Sanitized, Doesnotcontain TSCAGBt
438
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats______________
)
)
_____________ DuPont-6554
Individual Dose Volumes
Gavage ml
Day 60
Gavage ml
Day 61
Gavage ml
Day 62
Gavage ml
Day 63
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
Gavage ml
Day 68
Gavage ml
Day 69
Gavage ml
Day 70
Gavage ml
Day 71
Male, IX - 300 mg/kg/day
648236 3.5 3.5 3.5 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.7 3.7 648217 3.9 3.9 3.9 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.8 3.8 648248 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 648218 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.1 4.1 648233 4.3 4.3 4.3 4.4 4.4 4.4 4.4 4.4 4.4 4.4 4.6 4.6 648293 3.1 3.1 3.1 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 648275 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.3 3.3 648308 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.2 4.2 648235 3.7 3.7 3.7 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 648289 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.7 4.7 648292 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7 648272 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.4 3.4 648234 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.0 4.0 648240 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 3.5 648287 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 648277 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.8 3.8 648261 3.8 3.8 3.8 3.9 3.9 3.9 3.9 3.9 3.9 3.9 4.0 4.0 648306 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.1 4.1 648241 4.1 4.1 4.1 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.4 4.4 648284 3.3 3.3 3.3 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.6 3.6 648282 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6
2 648231
3n 648262 3.6 3.6 3.6 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.9 3.9 3m 648230 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.9 m<< 648249 3.4 3.4 3.4 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 3.6
3
I mmoa
not contain TSCACB
439
H90--2D46a>7y8O: raSluGbcahvraogneicSTtuodxyicinityRats_____________________________
)
) DuPont-6554
Gavage ml
Day 72
Gavage ml
Day 73
Male, IX - 300 mg/kg/day
648236 3,7 3.7 648217 3.8 3.8 648248 3.5 3.5 648218 4.1 4.1 648239 4.6 4.6 648293 3.4 3.4 648275 3.3 3.3 648308 4.2 4.2 648235 3.9 3.9 648289 4.7 4.7 648292 3.7 3.7 648272 3.4 3.4 648234 4.0 4.0 648240 3.5 3.5 648287 3.8 3.8 648277 3.8 3.8 648261 4.0 4.0 648306 4.1 4.1 648241 4.4 4.4 648284 3.6 3.6 648282 3.6 3.6 648231
648262 3.9 3.9 648230 3.9 3.9 648249 3.6 3.6
Gavage ml
Day 74
3.7 3.8 3.5 4.1 4.6 3.4 3.3 4.2 3.9 4.7 3.7 3.4 4.0 3.5 3.8 3.8 4.0 4.1 4.4 3.6 3.6
3.9 3.9 3.6
Gavage ml
Day 75
3.7 3.8 3.5 4.1 4.6 3.4 3.3 4.2 3.9 4.7 3.7 3.4 4.0 3.5 3.8 3.8 4.0 4.1 4.4 3.6 3.6
3.9 3.9 3.6
Individual Dose Volumes
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
3.7 3.8 3.8 3.8 3.8 4.0 4.0 4.0 3.5 3.5 3.5 3.5 4.1 4.1 4.1 4.1 4.6 4.7 4.7 4.7 3.4 3.5 3.5 3.5 3.3 3.4 3.4 3.4 4.2 4.3 4.3 4.3 3.9 4.0 4.0 4.0 4.7 4.7 4.7 4.7 3.7 3.8 3.8 3.8 3.4 3.4 3.4 3.4 4.0 4.1 4.1 4.1 3.5 3.6 3.6 3.6 3.8 3.9 3.9 3.9 3.8 3.8 3.8 3.8 4.0 4.0 4.0 4.0 4.1 4.1 4.1 4.1 4.4 4.4 4.4 4.4 3.6 3.6 3.6 3.6 3.6 3.7 3.7 3.7
3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.6 3.7 3.7 3.7
Gavage ml
Day 80
3.8 4.0 3.5 4.1 4.7 3.5 3.4 4.3 4.0 4.7 3.8 3.4 4.1 3.6 3.9 3.8 4.0 4.1 4.4 3.6 3.7
3.9 3.9 3.7
Gavage ml
Day 81
3.8 4.0 3.5 4.1 4.7 3.5 3.4 4.3 4.0 4.7 3.8 3.4 4.1 3.6 3.9 3.8 4.0 4.1 4.4 3.6 3.7
3.9 3.9 3.7
Gavage ml
Day 82
3.8 4.0 3.5 4.1 4.7 3.5 3.4 4.3 4.0 4.7 3.8 3.4 4.1 3.6 3.9 3.8 4.0 4.1 4.4 3.6 3.7
3.9 3.9 3.7
Gavage ml
Day 83
3.8 4.0 3.5 4.1 4.7 3.5 3.4 4.3 4.0 4.7 3.8 3.4 4.1 3.6 3.9 3.8 4.0 4.1 4.4 3.6 3.7
3.9 3.9 3.7
Company Sanitized. Does notcontain tsca CBS
440
))
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats___________________________________________________________________________
Individual Dose Volumes
Gavage ml
Day 84
Gavage ml
Day 85
Gavage ml
Day 86
Gavage ml
Day 87
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
Male, IX - 300 mg/kg/day
648236 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 648217 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.3 648248 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.7 648218 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 648239 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.9 648293 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.6 648275 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 648308 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.4 648235 4.1 4.1 4.1 4.1 4.1 4.1 4.1 4.1 648289 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 648292 3.9 3.9 3.9 3.9 3.9 3.9 3.9 648272 3.5 3.5 3.5 3.5 3.5 3.5 3.5 648234 4.1 4.1 4.1 4.1 4.1 4.1 4.1 648240 3.5 3.5 3.5 3.5 3.5 3.5 3.5 648287 3.8 3.8 3.8 3.8 3.8 3.8 3.8 648277 3.9 3.9 3.9 3.9 3.9 3.9 3.9 648261 4.1 4.1 4.1 4.1 4.1 4.1 4.1 648306 4.3 4.3 4.3 4.3 4.3 4.3 4.3 648241 4.5 4.5 4.5 4.5 4.5 4.5 4.5 648284 3.6 3.6 3.6 3.6 3.6 3.6 3.6 648282 3.8 3.8 3.8 3.8 3.8 3.8 3.8 648231
648262 3.9 3.9 3.9 3.9 3.9 3.9 3.9 648230 4.0 4.0 4.0 4.0 4.0 4.0 4.0 648249 3.8 3.8 3.8 3.8 3.8 3.8 3.8
)
DuPont-6554
S a n itiz e d . D o e s n o t contain TSCA CBI
441
)) ) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________________________________ __________ _____________________'______________ DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Female, II - 0 mg/kg/day
648421 1.5 1.5 648393 1.5 1.5 648436 1.5 1.5 648430 1.5 1.5 648351 1.5 1.5 648423 1.5 1.5 648353 1.5 1.5 648395 1.4 1.4 648372 1.4 1.4 648370 1.3 1.3 648356 1.3 1.3 648431 1.3 1.3 648422 1.4 1.4 648357 1.5 1.5 648405 1.3 1.3 648439 1.5 1.5 648389 1.2 1.2 648434 1.4 1.4 648425 1.6 1.6 648404 1.5 1.5 648394 1.4 1.4 648426 1.7 1.7 648346 1.4 1.4 648442 1.6 1.6 648427 1.5 1.5
Gavage ml
Day 2
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4 1.3 1.3 1.3 1.4 1.5 1.3 1.5 1.2 1.4 1.6 1.5 1.4 1.7 1.4 1.6 1.5
Gavage ml
Day 3
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4 1.3 1.3 1.3 1.4 1.5 1.3 1.5 1.2 1.4 1.6 1.5 1.4 1.7 1.4 1.6 1.5
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.8 1.5 1.5 1.5 1.6 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.6 1.5 1.5 1.5 1.6 1.4 1.4 1.4 1.6 1.4 1.4 1.4 1.5 1.3 1.3 1.3 1.5 1.3 1.3 1.3 1.5 1.3 1.3 1.3 1.5 1.4 1.4 1.4 1.6 1.5 1.5 1.5 1.6 1.3 1.3 1.3 1.4 1.5 1.5 1.5 1.8 1.2 1.2 1.2 1.4 1.4 1.4 1.4 1.5 1.6 1.6 1.6 1.9 1.5 1.5 1.5 1.6 1.4 1.4 1.4 1.6 1.7 1.7 1.7 2.0
1.4 1.4 1.4 1.5 1.6 1.6 . 1.6 1.9 1.5 1.5 1.5 1.7
Gavage ml
Day 8
1.7 1.7 1.8 1.6 1.7 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.6 1.6 1.4 1.8 1.4 1.5 1.9 1.6 1.6 2.0 1.5 1.9 1.7
Gavage ml
Day 9
1.7 1.7 1.8 1.6 1.7 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.6 1.6 1.4 1.8 1.4 1.5 1.9 1.6 1.6 2.0 1.5 1.9 1.7
Gavage ml
Day 10
1.7 1.7 1.8 1.6 1.7 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.6 1.6 1.4 1.8 1.4 1.5 1.9 1.6 1.6 2.0 1.5 1.9 1.7
Gavage ml
Day 11
1.7 1.7 1.8 1.6 1.7 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.6 1.6 1.4 1.8 1.4 1.5 1.9 1.6 1.6 2.0 1.5 1.9 1.7
Company Sanitized. Does not contain TSCACBI
442
9H0--2D4a6y78O: raSluGbcahvraogneicStTuodxyicinityRats____________________________________________________
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Female, II - 0 mg/kg/day
648421 1.7 1.7 648393 1.7 1.7 648436 1.8 1.8 648430 1.6 1.6 648351 1.7 1.7 648423 1.6 1.6 648353 1.6 1.6 648395 1.6 1.6 648372 1.5 1.5 648370 1.5 1.5 648356 1.5 1.5 648431 1.5 1.5 648422 1.6 1.6 648357 1.6 1.6 648405 1.4 1.4 648439 1.8 1.8 648389 1.4 1.4 648434 1.5 1.5 648425 1.9 1.9 648404 1.6 1.6 648394 1.6 1.6 648426 2.0 2.0 648346 1.5 1.5 648442 1.9 1.9 648427 1.7 1.7
Gavage ml
Day 14
1.7 1.7 1.8 1.6 1.7 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.6 1.6 1.4 1.8 1.4 1.5 1.9 1.6 1.6 2.0 1.5 1.9 1.7
Gavage ml
Day 15
1.9 1.8 2.0 1.8 1.8 1.9 1.8 1.7 1.7 1.7 1.6 1.6 1.6 1.8 1.5 1.9 1.5 1.6 2.1 1.7 1.7 2.1 1.7 2.2 2.0
Individual Dose Volumes
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
1.9 1.9 1.9 1.9
1.8 1.8 1.8 1.8
2.0 2.0 2.0 2.0
1.8 1.8 1.8 1.8
1.8 1.8 1.8 1.8
1.9 1.9 1.9 1.9
1.8 1.8 1.8 1.8
1.7 1.7 1.7 1.7
1.7 1.7 1.7 1.7
1.7 1.7 1.7 1.7
1.6 1.6 1.6 1.6
1.6 1.6 1.6 1.6
1.6 1.6 1.6 1.6
1.8 1.8 1.8 1.8
1.5 1.5 1.5 1.5
1.9
1.9
1.9'
1.9
1.5 1.5 1.5 1.5
1.6 1.6 1.6 1.6
2.1 2.1 2.1 2.1
1.7 1.7 1.7 1.7
1.7 1.7 1.7 1.7
2.1 2.1 2.1 2.1
1.7 1.7 1.7 1.7
2.2 2.2 2.2 2.2
2.0 2.0 2.0 2.0
Gavage ml
Day 20
1.9 1.8 2.0 1.8 1.8 1.9 1.8 1.7 1.7 1.7 1.6 1.6 1.6 1.8 1.5 1.9 1.5 1.6 2.1 1.7 1.7 2.1 1.7 2.2 2.0
Gavage ml
Day 21
2.0 2.0 2.1 1.9 1.9 1.9 1.8 1.8 1.9 1.7 1.7 1.7 1.8 1.9 1.6 2.2 1.6 1.8 2.2 1.9 1.8 2.2 1.8 2.2 2.1
Gavage ml
Day 22
2.0 2.0 2.1 1.9 1.9 1.9 1.8 1.8 1.9 1.7 1.7 1.7 1.8 1.9 1.6 2.2 1.6 1.8 2.2 1.9 1.8 2.2 1.8 2.2 2.1
Gavage ml
Day 23
2.0 2.0 2.1 1.9 1.9 1.9 1.8 1.8 1.9 1.7 1.7 1.7 1.8 1.9 1.6 2.2 1.6 1.8 2.2 1.9 1.8 2.2 1.8 2.2 2.1
Sanitized Doss m exmMn TSC CBI
443
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats__________
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Female, II - 0 mg/kg/day
648421 2.0 2.0 648393 2.0 2.0 648436 2.1 2.1 648430 1.9 1.9 648351 1.9 1.9 648423 1.9 1.9 648353 1.8 1.8 648395 1.8 1.8 648372 1.9 1.9 648370 1.7 1.7 648356 1.7 1.7 648431 1.7 1.7 648422 1.8 1.8 648357 1.9 1.9 648405 1.6 1.6 648439 2.2 2.2 648389 1.6 1.6 648434 1.8 1.8 648425 2.2 2.2 648404 1.9 1.9 648394 1.8 1.8 648426 2.2 2.2 648346 1.8 1.8 648442 2.2 2.2 648427 2.1 2.1
Gavage ml
Day 26
2.0 2.0 2.1 1.9 1.9 1.9 1.8 1.8 1.9 1.7 1.7 1.7 1.8 1.9 1.6 2.2 1.6 1.8 2.2 1.9 1.8 2.2 1.8 2.2 2.1
Gavage ml
Day 27
2.0 2.0 2.1 1.9 1.9 1.9 1.8 1.8 1.9 1.7 1.7 1.7 1.8 1.9 1.6 2.2 1.6 1.8 2.2 1.9 1.8 2.2 1.8 2.2 2.1
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 1.7 1.7 1.7 1.7 2.3 2.3 2.3 2.3 1.6 1.6 1.6 1.6 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 1.9 1.9 1.9 1.9 2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2
Gavage ml
Day 32
2.2 2.0 2.1 2.0 1.9 2.0 2.0 1.9 1.9 1.8 1.8 1.7 .8 2.0 1.7 2.3 1.6 2.0 2.4 2.0 2.0 2.4 1.9 2.5 2.2
Gavage ml
Day 33
2.2 2.0 2.1 2.0 1.9 2.0 2.0 1.9 1.9 1.8 1.8 1.7 1.8 2.0 1.7 2.3 1.6 2.0 2.4 2.0 2.0 2.4 1.9 2.5 2.2
Gavage ml
Day 34
2.2 2.0 2.1 2.0 1.9 2.0 2.0 1.9 1.9 1.8 1.8 1.7 1.8 2.0 1.7 2.3 1.6 2.0 2.4 2.0 2.0 2.4 1.9 2.5 2.2
Gavage ml
Day 35
2.3 2.1 2.1 2.0 2.0 2.1 2.1 1.9 2.1 1.9 1.9 1.9 2.0 2.1 1.8 2.2 1.7 2.1 2.5 2.0 2.0 2.6 2.0 2.6 2.2
Company Sanitized. Does notcontain TSCACEI
444
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats___________
)
)
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Female, II - 0 mg/kg/day
648421 2.3 2.3 648393 2.1 2.1 648436 2.1 2.1 648430 2.0 2.0 648351 2.0 2.0 648423 2.1 2.1 648353 2.1 2.1 648395 1.9 1.9 648372 2.1 2.1 648370 1.9 1.9 648356 1.9 1.9 648431 1.9 1.9 648422 2.0 2.0 648357 2.1 2.1 648405 1.8 1.8 648439 2.2 2.2 648389 1.7 1.7 648434 2.1 2.1 648425 2.5 2.5 648404 2.0 2.0 648394 2.0 2.0 648426 2.6 2.6 648346 2.0 2.0 648442 2.6 2.6 648427 2.2 2.2
Gavage ml
Day 38
2.3 2.1 2.1 2.0 2.0 2.1 2.1 1.9 2.1 1.9 1.9 1.9 2.0 2.1 1.8 2.2 1.7 2.1 2.5 2.0 2.0 2.6 2.0 2.6 2.2
Gavage ml
Day 39
2.3 2.1 2.1 2.0 2.0 2.1 2.1 1.9 2.1 1.9 1.9 1.9 2.0 2.1 1.8 2.2 1.7 2.1 2.5 2.0 2.0 2.6 2.0 2.6 2.2
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.0 2.0 2.1 2.1 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.1 2.1 2.1 2.1 1.9 1.9 2.0 2.0 2.1 2.1 2.0 2.0 1.9 1.9 2.0 2.0 1.9 1.9 2.0 2.0 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 1.8 1.8 1.8 1.8 2.2 2.2 2.3 2.3 1.7 1.7 1.8 1.8 2.1 2.1 2.1 2.1 2.5 2.5 2.6 2.6 2.0 2.0 2.1 2.1 2.0 2.0 2.1 2.1 2.6 2.6 2.8 2.8 2.0 2.0 2.1 2.1 2.6 2.6 2.7 2.7 2.2 2.2 2.3 2.3
Gavage ml
Day 44
2.3 2.1 2.2 2.1 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.1 1.8 2.3 1.8 2.1 2.6 2.1 2.1 2.8 2.1 2.7 2.3
Gavage ml
Day 45
2.3 2.1 2.2 2.1 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.1 1.8 2.3 1.8 2.1 2.6 2.1 2.1 2.8 2.1 2.7 2.3
Gavage ml
Day 46
2.3 2.1 2.2 2.1 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.1 1.8 2.3 1.8 2.1 2.6 2.1 2.1 2.8 2.1 2.7 2.3
Gavage ml
Day 47
2.3 2.1 2.2 2.1 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.1 1.8 2.3 1.8 2.1 2.6 2.1 2.1 2.8 2.1 2.7 2.3
CompanySanitized. Does noi
0 2,
SS'
m
445
g
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Female, II - 0 mg/kg/day
648421 2.3 2.4 648393 2.1 2.1 648436 2.2 2.3 648430 2.1 2.1 648351 2.1 2.2 648423 2.2 2.3 648353 2.1 2.1
648395 2.0 2.0 648372 2.0 2.2 648370 2.0 2.1 648356 2.0 1.9 648431 2.0 2.0 648422 2.0 2.2 648357 2.1 2.2 648405 1.8 1.9 648439 2.3 2.4 648389 1.8 1.9 648434 2.1 2.2 648425 2.6 2.7 648404 2.1 2.2 648394 2.1 2.2 648426 2.8 2.8 648346 2.1 2.1 648442 2.7 2.8 648427 2.3 2.4
Gavage ml
Day 50
2.4 2.1 2.3 2.1 2.2 2.3 2.1 2.0 2.2 2.1 1.9 2.0 2.2 2.2 1.9 2.4 1.9 2.2 2.7 2.2 2.2 2.8 2.1 2.8 2.4
Gavage ml
Day 51
2.4 2.1 2.3 2.1 2.2 2.3 2.1 2.0 2.2 2.1 1.9 2.0 2.2 2.2 1.9 2.4 1.9 2.2 2.7 2.2 2.2 2.8 2.1 2.8 2.4
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 1.9 1.9 1.9 1.9 2.4 2.4 2.4 2.4 1.9 1.9 1.9 1.9 2.2 2.2 2.2 2.2 2.7 2.7 2.7 2.7 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.8 2.8 2.8 2.8 2.1 2.1 2.1 2.1 2.8 2.8 2.8 2.8 2.4 2.4 2.4 2.4
Gavage ml
Day 56
2.5 2.2 2.4 2.2 2.1 2.3 2.2 2.1 2.3 2.1 2.0 2.1 2.2 2.3 2.0 2.6 1.9 2.2 2.7 2.3 2.2 3.0 2.2 2.9 2.4
Gavage ml
Day 57
2.5 2.2 2.4 2.2 2.1 2.3 2.2 2.1 2.3 2.1 2.0 2.1 2.2 2.3 2.0 2.6 1.9 2.2 2.7 2.3 2.2 3.0 2.2 2.9 2.4
Gavage ml
Day 58
2.5 2.2 2.4 2.2 2.1 2.3 2.2 2.1 2.3 2.1 2.0 2.1 2.2 2.3 2.0 2.6 1.9 2.2 2.7 2.3 2.2 3.0 2.2 2.9 2.4
Gavage ml
Day 59
2.5 2.2 2.4 2.2 2.1 2.3 2.2 2.1 2.3 2.1 2.0 2.1 2.2 2.3 2.0 2.6 1.9 2.2 2.7 2.3 2.2 3.0 2.2 2.9 2.4
impany Sanitised. Ds noi
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Gavage ml
Day 62
Female, II - 0 mg/kg/day
648421 2.5 2.5 2.5 648393 2.2 2.2 2.2 648436 2.4 2.4 2.4 648430 2.2 2.2 2.2 648351 2.1 2.1 2.1 648423 2.3 2.3 2.3 648353 2.2 2.2 2.2 648395 2.1 2.1 2.1
648372
2.3
2.3 b
2.3
648370 2.1 2.1 2.1
648356 2.0 2.0 2.0
648431 2.1 2.1 2.1
648422 2.2 2.2 2.2
648357 2.3 2.3 2.3 648405 2.0 2.0 2.0
648439 2.6 2.6 2.6 648389 1.9 1.9 1.9 648434 2.2 2.2 2.2 648425 2.7 2.7 2.7
648404 2.3 2.3 2.3 648394 2.2 2.2 2.2 648426 3.0 3.0 3.0 648346 2.2 2.2 2.2 648442 2.9 2.9 2.9 648427 2.4 2.4 2.4
Gavage ml
Day 63
2.5 2.2 2.3 2.3 2.3 2.4 2.3 2.0 2.3 2.1 2.0 2.1 2.2 2.3 1.9 2.5 1.9 2.3 2.8 2.2 2.2 3.1 2.2 3.0 2.5
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3 2.0 2.0 2.0 2.0
2.3 2.3 2.3 2.3
2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 1.9 1.9 1.9 1.9 2.5 2.5 2.5 2.5 1.9 1.9 1.9 1.9 2.3 2.3 2.3 2.3 2.8 2.8 2.8 2.8 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 3.1 3.1 3.1 3-1 2.2 2.2 2.2 2.2 3.0 3.0 3.0 3.0 2.5 2.5 2.5 2.5
Gavage ml
Day 68
2.5 2.2 2.3 2.3 2.3 2.4 2.3 2.0 2.3 2.1 2.0 2.1 2.2 2.3 1.9 2.5 1.9 2.3 2.8 2.2 2.2 3.1 2.2 3.0 2.5
Gavage ml
Day 69
2.5 2.2 2.3 2.3 2.3 2.4 2.3 2.0 2.3 2.1 2.0 2.1 2.2 2.3 1.9 2.5 1.9 2.3 2.8 2.2 2.2 3.1 2.2 3.0 2.5
Gavage ml
Day 70
2.6 2.3 2.4 2.3 2.2 2.4 2.3 2.2 2.4 2.1 2.1 2.2 2.2 2.3 1.9 2.6 2.0 2.3 2.9 2.3 2.3 3.1 2.3 3.0 2.5
Gavage ml
Day 71
2.6 2.3 2.4 2.3 2.2 2.4 2.3 2.2 2.4 2.1 2.1 2.2 2.2 2.3 1.9 2.6 2.0 2.3 2.9 2.3 2.3 3.1 2.3 3.0 2.5
447
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
DuPont-6554
Gavage ml
Day 72
Gavage ml
Day 73
Female, II - 0 mg/kg/day
648421 2.6 2.6 648393 2.3 2.3 648436 2.4 2.4 648430 2.3 2.3 648351 2.2 2.2 648423 2.4 2.4 648353 2.3 2.3 648395 2.2 2.2 648372 2.4 2.4 648370 2.1 2.1 648356 2.1 2.1 648431 2.2 2.2 648422 2.2 2.2 648357 2.3 2.3 648405 1.9 1.9 648439 2.6 2.6 648389 2.0 2.0 648434 2.3 2.3 648425 2.9 2.9 648404 2.3 2.3 648394 2.3 2.3 648426 3.1 3.1 648346 2.3 2.3 648442 3.0 3.0 648427 2.5 2.5
Gavage ml
Day 74
2.6 2.3 2.4 2.3 2.2 2.4 2.3 2.2 2.4 2.1 2.1 2.2 2.2 2.3 1.9 2.6 2.0 2.3 2.9 2.3 2.3 3.1 2.3 3.0 2.5
Gavage ml
Day 75
2.6 2.3 2.4 2.3 2.2 2.4 2.3 2.2 2.4 2.1 2.1 2.2 2.2 2.3 1.9 2.6 2.0 2.3 2.9 2.3 2.3 3.1 2.3 3.0 2.5
Individual Dose Volumes
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
2.6 2.7 2.7 2.7 2.3 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.3 2.3 2.3 2.3 2.2 2.3 2.3 2.3 2.4 2.5 2.5 2.5 2.3 2.4 2.4 2.4 2.2 2.2 2.2 2.2 2.4 2.5 2.5 2.5 2.1 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.4 2.4 2.4 1.9 2.0 2.0 2.0 2.6 2.5 2.5 2.5 2.0 2.0 2.0 2.0 2.3 2.4 2.4 2.4 2.9 2.9 2.9 2.9 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 3.1 3.1 3.1 3.1 2.3 2.2 2.2 2.2 3.0 3.1 3.1 3.1 2.5 2.6 2.6 2.6
Gavage ml
Day 80
2.7 2.4 2.5 2.3 2.3 2.5 2.4 2.2 2.5 2.2 2.1 2.2 2.3 2.4 2.0 2.5 2.0 2.4 2.9 2.3 2.3 3.1 2.2 3.1 2.6
Gavage ml
Day 81
2.7 2.4 2.5 2.3 2.3 2.5 2.4 2.2 2.5 2.2 2.1 2.2 2.3 2.4 2.0 2.5 2.0 2.4 2.9 2.3 2.3 3.1 2.2 3.1 2.6
Gavage ml
Day 82
2.7 2.4 2.5 2.3 2.3 2.5 2.4 2.2 2.5 2.2 2.1 2.2 2.3 2.4 2.0 2.5 2.0 2.4 2.9 2.3 2.3 3.1 2.2 3.1 2.6
Gavage ml
Day 83
2.7 2.4 2.5 2.3 2.3 2.5 2.4 2.2 2.5 2.2 2.1 2.2 2.3 2.4 2.0 2.5 2.0 2.4 2.9 2.3 2.3 3.1 2.2 3.1 2.6
448
TSCA CBi
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats____________
Gavage ml
Day 84
Gavage ml
Day 85
Female, II - 0 mg/kg/day
648421 2.7 2.7 648393 2.5 2.5 648436 2.6 2.6 648430 2.4 2.4 648351 2.4 2.4 648423 2.5 2.5 648353 2.4 2.4 648395 2.2 2.2 648372 2.6 2.6 648370 2.3 2.3 648356 2.1 2.1 648431 2.2 2.2 648422 2.3 2.3 648357 2.4 2.4 648405 2.1 2.1 648439 2.7 2.7 648389 1.9 1.9 648434 2.5 2.5 648425 2.9 2.9 648404 2.3 2.3 648394 2.4 2.4 648426 3.2 3.2 648346 2.3 2.3 648442 3.2 3.2 648427 2.6 2.6
Gavage ml
Day 86
2.7 2.5 2.6 2.4 2.4 2.5 2.4 2.2 2.6 2.3 2.1 2.2 2.3 2.4 2.1 2.7 1.9 2.5 2.9 2.3 2.4 3.2 2.3 3.2 2.6
Gavage ml
Day 87
2.7 2.5 2.6 2.4 2.4 2.5 2.4 2.2 2.6 2.3 2.1 2.2 2.3 2.4 2.1 2.7 1.9 2.5 2.9 2.3 2.4 3.2 2.3 3.2 2.6
Individual Doss Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
2.7 2.7 2.7 2.7 2.5 2.5 2.5 2.4 2.6 2.6 2.6 2.5 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.4 2.4 2.4 2.5 2.2 2.2 2.2 2.1 2.6 2.6 2.6 2.7 2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.2 2.2 2.2 2.3 2.3 2.3 2.4 2.4 2.4 2.1 2.1 2.1 2.7 2.7 2.7 1.9 1.9 1.9 2.5 2.5 2.5 2.9 2.9 2.9 2.3 2.3 2.3 2.4 2.4 2.4 3.2 3.2 3.2 2.3 2.3 2.3 3.2 3.2 3.2 2.6 2.6 2.6
Gavage ml
Day 92
2.7 2.4 2.5 2.4 2.4 2.5 2.5 2.1 2.7 2.3
i
a, % 4* J
sf
449
DuPont-6554
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats_________
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Iso;
ml ml ml ml ml ml ml ml ml
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Female, IV - 60 mg/kg/day Isopropanol
648396
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.6
1.6
648409
1.7
1.7
1.7
1.7
1.7
1.7
1.7
1.8
1.8
648410
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.7
1.7
648369
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.7
1.7
648397
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.5
1.5
648364
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.6
1.6
648408
1.3
1.3
1.3
1.3
1.3
1.3
1.3
1.5
1.5
648402
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.5
1.5
648424
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.4
1.4
648390
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.7
1.7
Sanitized. Does not contain TSCACBI
450
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 9
Day 10
Day 11
Female, IV - 60 mg/kg/day Isopropanol
648396
1.6
1.6
1.6
648409
1.8
1.8
1.8
648410
1.7
1.7
1.7
648369
1.7
1.7
1.7
648397
1.5
1.5
1.5
648364
1.6
1.6
1.6
648408
1.5
1.5
1.5
648402
1.5
1.5
1.5
648424
1.4
1.4
1.4
648390
1.7
1.7
1.7
DuPont-6554
Individual Dose Volumes
Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr ml ml ml ml ml
12 Day 13 Day 14 Day 15 Day 16 Day 17
1.6 1.6 1.6 1.7 1.7 1.7 1.8 1.8 1.8 2.0 2.0 2.0 1.7 1.7 1.7 1.9 1.9 1.9 1.7 1.7 1.7 1.8 1.8 1.8 1.5 1.5 1.5 1.7 1.7 1.7 1.6 1.6 1.6 1.7 1.7 1.7 1.5 1.5 1.5 1.6 1.6 1.6 1.5 1.5 1.5 1.7 1.7 1.7 1.4 1.4 1.4 1.6 1.6 1.6 1.7 1.7 1.7 1.9 1.9 1.9
Company Sanitized. Does not contain
> O a
451
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 18
Day 19
Day 20
Day 21
Day 22
Day 23
Day 24
Day 25
Day 26
Female, IV - 60 mg/kg/day Isopropanol
648396
1.7
1.7
1.7
1.9
1.9
1.9
1.9
1.9
1.9
648409
2.0
2.0
2.0
2.1
2.1
2.1
2.1
2.1
2.1
648410
1.9
1.9
1.9
2.1
2.1
2.1
2.1
2.1
2.1
648369
1.8
1.8
1.8
1.9
1.9
1.9
1.9
1.9
1.9
648397
1.7
1.7
1.7
1.8
1.8
1.8
1.8
1.8
1.8
648364
1.7
1.7
1.7
1.9
1.9
1.9
1.9
1.9
1.9
648408
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
648402
1.7
1.7
1.7
1.8
1.8
1.8
1.8
1.8
1.8
648424
1.6
1.6
1.6
1.7
1.7
1.7
1.7
1.7
1.7
648390
1.9
1.9
1.9
1.9
1.9
1.9
1.9
1.9
1.9
d&Q'yQSi, u lBJ^0!ioyi:;seoo p s z m m s
452
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 27
Day 28
Day 29
Female, IV - 60 mg/kg/day Isopropanol
648396
1.9
2.1
2.1
64,8409
2.1
2.2
2.2
648410
2.1
2.2
2.2
648369
1.9
2.0
2.0
648397
1.8
1.9
1.9
648364
1.9
2.0
2.0
648408
1.6
1.8
1.8
648402
1.8
1.9
1.9
648424
1.7
1.9
1.9
648390
1.9
2.0
2.0
> DuPont-6554
Individuai Dose Volumes
Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr ml ml ml ml ml
30 Day 31 Day 32 Day 33 Day 34 Day 35
2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.0 2.1 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 1.8 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 1.9 1.9 2.0 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.1
J Q V O ^ A use,}u<*ajoMJ8eo<| pjwj j pg ^
453
H90--2D46a)y78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 36
Day 37
Day 38
Day 39
Day 40
Day 41
Day 42
Day 43
Day 44
Female, IV - 60 mg/kg/day Isopropanol
648396
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
648409
2.3
2.3
2.3
2.3
2.3
2.3
2.2
2.2
2.2
648410
2.2
2.2
2.2
2.2
2.2
2.2
2.3
2.3
2.3
648369
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
648397
1.9
1.9
1.9
1.9
1.9
1.9
2.1
2.1
2.1
648364
2.0
2.0
2.0
2.0
2.0
2.0
2.1
2.1
2.1
648408
1.9
1.9
1.9
1.9
1.9
1.9
2.0
2.0
2.0
648402
2.0
2.0
2.0
2.0
2.0
2.0
2.0 2.0
2.0
648424
1.9
1.9
1.9
1.9
1.9
1.9
2.0
2.0
2.0
648390
2.1
2.1
2.1
2.1
2.1
2.1
2.2
2.2
2.2
Company Sanitized. Does not contain TSCACB
454
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Individual Dosa Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 45
Day 46
Day 47
Day 48
Day 49
Day 50
Day 51
Day 52
Day 53
Female, IV - 60 mg/kg/day Isopropanol
648396
2.1
2.1
2.1
2.1
2.2
2.2
2.2
2.2
2.2
648409
2.2
2.2
2.2
2.2
2.3
2.3
2.3
2.3
2.3
648410
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648369
2.1
2.1
2.1
2-1
2.2 2.2
2.2
2.2
2.2
648397
2.1
2.1
2.1
2.1
2.1 2.1
2.1
2.1
2.1
648364
2.1
2.1
2.1
2.1
2.1 2.1
2.1
2.1
2.1
648408
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
648402
2.0
2.0
2.0
2.0
2.2
2.2
2.2
2.2
2.2
648424
2.0
2.0
2.0
2-0
2.1
2.1
2.1
2.1
2.1
648390
2.2
2.2
2.2
2.2
2.3
2.3
2.3
2.3
2.3
Sanitized. Does nt contain TSCACBI
455
)
9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 54
Day 55
Day 56
Day 57
Day 58
Day 59
Day 60
Day 61
Day 62
Female, IV - 60 mg/kg/day Isopropanol
648396
2.2
2.2
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648409
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648410
2.3
2.3
2.4
2.4
2.4
2.4
2.4
2.4
2.4
648369
2.2
2.2
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648397
2.1
2.1
2.2
2.2
2.2
2.2
2.2
2.2
2.2
648364
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
648408
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
648402
2.2
2.2
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648424
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
648390
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
ompany Sanitized. Does not e rta lo TSCA CB
456
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 63
Day 64
Day 65
Female, IV - 60 mg/kg/day Isopropanol
648396
2.2
2.2
2.2
648409
2.4
2.4
2.4
648410
2.3
2.3
2.3
648369
2.2
2.2
2.2
648397
2.1
2.1
2.1
648364
2.2
2.2
2.2
648408
2.0
2.0
2.0
648402
2.3
2.3
2.3
648424
2.2
2.2
2.2
648390
2.3
2.3
2.3
)} DuPont-6554
Individual Dose Volumes
Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr ml ml ml ml ml
66 Day 67 Day 68 Day 69 Day 70 Day 71
2.2 2.2 2.2 2.2 2.3 2.3 2.4 2.4 2.4 2.4 2.5 2.5 2.3 2.3 2.3 2.3 2.4 2.4 2.2 2.2 2.2 2.2 2.3 2.3 2.1 2.1 2.1 2.1 2.3 2.3 2.2 2.2 2.2 2.2 2.3 2.3 2.0 2.0 2.0 2.0 2.2 2.2 2.3 2.3 2.3 2.3 2.4 2.4 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.4 2.4
49p-VP.$A ujpjuAP*iii*aPGi p a z m u s s
457
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
DuPont-6554
Individual Dose Volumes
Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml ml ml ml ml ml ml
Day 72
Day 73
Day 74
Day 75
Day 76
Day 77
Day 78
Day 79
Day 80
Female, IV - 60 mg/kg/day Isopropanol
648396
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648409
2.5
2.5
2.5
2.5
2.5
2.4
2.4
2.4
2.4
648410
2.4
2.4
2.4
2.4
2.4
2.5
2.5
2.5
2.5
648369
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648397
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
648364
2.3
2.3
2.3
2.3
2.3
2.4
2.4
2.4
2.4
648408
2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.2
2.2
648402
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.4
648424
2.2
2.2
2.2
2.2
2.2
2.3
2.3
2.3
2.3
648390
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.4
SmMzed. Does-m'emtm TSCACBf
458
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 81
Day 82
Day 83
Female, IV - 60 mg/kg/day Isopropanol
648396
2.3
2.3
2.3
648409
2.4
2.4
2.4
648410
2.5
2.5
2.5
648369
2.3
2.3
2.3
648397
2.3
2.3
2.3
648364
2.4
2.4
2.4
648408
2.2
2.2
2.2
648402
2.4
2.4
2.4
648424
2.3
2.3
2.3
648390
2.4
2.4
2.4
DuPont-6554
Individual Dose Volumes
Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr Gavage Isopr ml ml ml ml ml
84 Day 85 Day 86 Day 87 Day 88 Day 89
2.4 2.4 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.4 2.4 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3 2.3 2.3 2.5 2.5 2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3 2.3 2.3 2.5 2.5 2.5 2.5 2.5 2.5
Company Samffled, Dw
459
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
Gavage Isopr Gavage Isopr Gavage Isopr
ml ml ml
Day 90
Day 91
Day 92
Female, IV - 60 mg/kg/day Isopropanol
648396
2.4
2.4
2.4
648409
2.5
2.5
2.5
648410
2.5
2.5
2.5
648369
2.4
2.4
2.4
648397
2.3
2.2
2.2
648364
2.5
2.5
2.5
648408
2.2
2.3
2.3
648402
2.4
2.5
2.5
648424
2.3
2.3
2.3
648390
2.5
2.5
2.5
'#*****
USA
3* O
Individual Dose Volumes
DuPont-6554
460
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
> DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Female, VI - 10 mg/kg/day
648433 1.4 1.4 648406 1.5 1.5 648441 1.5 1.5 648414 1.4 1.4 648366 1.5 1.5 648382 1.5 1.5 648345 1.3 1.3 648374 1.4 1.4 648403 1.4 1.4 648429 1.4 1.4 648384 1.5 1.5 648352 1.4 1.4 648365 1.5 1.5 648413 1.6 1.6 648385 1.3 1.3
Gavage ml
Day 2
1.4 1.5 1.5 1.4 1.5 1.5 1.3 1.4 1.4 1.4 1.5 1.4 1.5 1.6 1.3
Gavage ml
Day 3
1.4 1.5 1.5 1.4 1.5 1.5 1.3 1.4 1.4 1.4 1.5 1.4 1.5 1.6 1.3
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.7 1.4 1.4 1.4 1.6 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.5 1.3 1.3 1.3 1.4 1.4 1.4 1.4 1.6 1.4 1.4 1.4 1.6 1.4 1.4 1.4 1.6 1.5 1.5 1.5 1.6 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.6 1.7 1.3 1.3 1.3 1.5
Gavage ml
Day 8
1.5 1.7 1.7 1.6 1.7 1.5 1.4 1.6 1.6 1.6 1.6 1.5 1.6 1.7 1.5
Gavage ml
Day 9
1.5 1.7 1.7 1.6 1.7 1.5 1.4 1.6 1.6 1.6 1.6 1.5 1.6 1.7 1.5
Gavage ml
Day 10
1.5 1.7 1.7 1.6 1.7 1.5 1.4 1.6 1.6 1.6 1.6 1.5 1.6 1.7 1.5
Gavage ml
Day 11
1.5 1.7 1.7 1.6 1.7 1.5 1.4 1.6 1.6 1.6 1.6 1.5 1.6 1.7 1.5
y Sanitized. Does not contain TSCACBi
461
H90--2D4)6ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Female, VI - 10 mg/kg/day
648433 1.5 1.5 648406 1.7 1.7 648441 1.7 1.7 648414 1.6 1.6 648366 1.7 1.7 648382 1.5 1.5 648345 1.4 1.4 648374 1.6 1.6 648403 1.6 1.6 648429 1.6 1.6 648384 1.6 1.6 648352 1.5 1.5 648365 1.6 1.6 648413 1.7 1.7 648385 1.5 1.5
Gavage ml
Day 14
1.5 1.7 1.7 1.6 1.7 1.5 1.4 1.6 1.6 1.6 1.6 1.5 1.6 1.7 1.5
Gavage ml
Day 15
1.7 1.8 1.8 1.7 2.0 1.7 1.5 1.7 1.7 1.8 1.6 1.7 1.8 1.9 1.6
Individual Dose Volumes
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7 2.0 2.0 2.0 2.0 1.7 1.7 1.7 1.7 1.5 1.5 1.5 1.5 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 1.6 1.6 1.6 1.6
Gavage ml
Day 20
1.7 1.8 1.8 1.7 2.0 1.7 1.5 1.7 1.7 1.8 1.6 1.7 1.8 1.9 1.6
Gavage ml
Day 21
1.7 1.8 1.9 1.9 2.1 1.9 1.6 1.8 1.7 1.9 1.8 1.7 1.9 2.0 1.7
Gavage ml
Day 22
1.7 1.8 1.9 1.9 2.1 1.9 1.6 1.8 1.7 1.9 1.8 1.7 1.9 2.0 1.7
Gavage ml
Day 23
1.7 1.8 1.9 1.9 2.1 1.9 1.6 1.8 1.7 1.9 1.8 1.7 1.9 2.0 1.7
Sanitized. Does not contain TSCACB|
462
H-24)678: Subchronic Toxicity 90-Day Oral Gavage Study in Rats
)
")
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Female, VI - 10 mg/kg/day
648433 1.7 1.7 648406 1.8 1.8 648441 1.9 1.9 648414 1.9 1.9 648366 2.1 2.1 648382 1.9 1.9 648345 1.6 1.6 648374 1.8 1.8 648403 1.7 1.7 648429 1.9 1.9 648384 1.8 1.8 648352 1.7 1.7 648365 1.9 1.9 648413 2.0 2.0 648385 1.7 1.7
Gavage ml
Day 26
1.7 1.8 1.9 1.9 2.1 1.9 1.6 1.8 1.7 1.9 1.8 1.7 1.9 2.0 1.7
Gavage ml
Day 27
1.7 1.8 1.9 1.9 2.1 1.9 1.6 1.8 1.7 1.9 1.8 1.7 1.9 2.0 1.7
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 2.1 2.1 2.1 2.1 1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 1.8 1.8 1.8 1.8
Gavage ml
Day 32
1.8 2.0 2.0 1.9 2.1 1.8 1.7 1.9 1.9 2.0 1.9 1.8 2.0 2.1 1.8
Gavage ml
Day 33
1.8 2.0 2.0 1.9 2.1 1.8 1.7 1.9 1.9 2.0 1.9 1.8 2.0 2.1 1.8
Gavage ml
Day 34
1.8 2.0 2.0 1.9 2.1 1.8 1.7 1.9 1.9 2.0 1.9 1.8 2.0 2.1 1.8
Gavage ml
Day 35
1.9 2.1 2.1 2.1 2.2 2.0 1.8 2.1 2.0 2.1 1.9 1.9 2.0 2.2 1.9
Company Sanitized, Does not contain TSC CB
463
H90--2D46a)y78O: raSluGbcahvraogneicSTtuodxyiciintyRats_________
)
)
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Female, VI - 10 mg/kg/day
648433 1.9 1.9 648406 2.1 2.1 648441 2.1 2.1 648414 2.1 2.1 648366 2.2 2.2 648382 2.0 2.0 648345 1.8 1.8 648374 2.1 2.1 648403 2.0 2.0 648429 2.1 2.1 648384 1.9 1.9 648352 1.9 1.9 648365 2.0 2.0 648413 2.2 2.2 648385 1.9 1.9
Gavage ml
Day 38
1.9 2.1 2.1 2.1 2.2 2.0 1.8 2.1 2.0 2.1 1.9 1.9 2.0 2.2 1.9
Gavage ml
Day 39
1.9 2.1 2.1 2.1 2.2 2.0 1.8 2.1 2.0 2.1 1.9 1.9 2.0 2.2 1.9
Individuai Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
1.9 1.9 1.9 1.9 2.1 2.1 2.0 2.0 2.1 2.1 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.2 2.3 2.3 2.0 2.0 2.1 2.1 1.8 1.8 1.8 1.8 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.2 2.2 1.9 1.9 2.0 2.0 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.2 2.2 2.3 2.3 1.9 1.9 1.9 1.9
Gavage ml
Day 44
1.9 2.0 2.2 2.1 2.3 2.1 1.8 2.1 2.0 2.2 2.0 1.9 2.0 2.3 1.9
Gavage ml
Day 45
1.9 2.0 2.2 2.1 2.3 2.1 1.8 2.1 2.0 2.2 2.0 1.9 2.0 2.3 1.9
Gavage ml
Day 46
1.9 2.0 2.2 2.1 2.3 2.1 1.8 2.1 2.0 2.2 2.0 1.9 2.0 2.3 1.9
Gavage ml
Day 47
1.9 2.0 2.2 2.1 2.3 2.1 1.8 2.1 2.0 2.2 2.0 1.9 2.0 2.3 1.9
pszipsg AugduioQ
SO
a
g
4 >
l
464
H90--2D4)6ay78O: raSluGbcahvraogneicStTuodxyiciintyRats
*
)
DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Female, VI - 10 mg/kg/day
648433 1.9 2.0 648406 2.0 2.1 648441 2.2 2.2 648414 2.1 2.0 648366 2.3 2.4 648382 2.1 2.1 648345 1.8 1.8 648374 2.1 2.1 648403 2.0 2.0 648429 2.2 2.1 648384 2.0 2.0 648352 1.9 2.0 648365 2.0 2.1 648413 2.3 2.4 648385 1.9 2.0
Gavage ml
Day 50
2.0 2.1 2.2 2.0 2.4 2.1 1.8 2.1 2.0 2.1 2.0 2.0 2.1 2.4 2.0
Gavage ml
Day 51
2.0 2.1 2.2 2.0 2.4 2.1 1.8 2.1 2.0 2.1 2.0 2.0 2.1 2.4 2.0
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1 1.8 1.8 1.8 1.8 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.4 2.4 2.4 2.4 2.0 2.0 2.0 2.0
Gavage ml
Day 56
2.1 2.2 2.4 2.1 2.5 2.1 1.8 2.2 2.1 2.3 2.1 2.1 2.1 2.5 2.0
Gavage ml
Day 57
2.1 2.2 2.4 2.1 2.5 2.1 1.8 2.2 2.1 2.3 2.1 2.1 2.1 2.5 2.0
Gavage ml
Day 58
2.1 2.2 2.4 2.1 2.5 2.1 1.8 2.2 2.1 2.3 2.1 2.1 2.1 2.5 2.0
Gavage ml
Day 59
2.1 2.2 2.4 2.1 2.5 2.1 1.8 2.2 2.1 2.3 2.1 2.1 2.1 2.5 2.0
o m3
;s>
*5 &
1
not contain TSCACB
465
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Female, VI - 10 mg/kg/day
648433 2.1 2.1 648406 2.2 2.2 648441 2.4 2.4 648414 2.1 2.1 648366 2.5 2.5 648382 2.1 2.1 648345 1.8 1.8 648374 2.2 2.2 648403 2.1 2.1 648429 2.3 2.3 648384 2.1 2.1 648352 2.1 2.1 648365 2.1 2.1 648413 2.5 2.5 648385 2.0 2.0
Gavage ml
Day 62
2.1 2.2 2.4 2.1 2.5 2.1 1.8 2.2 2.1 2.3 2.1 2.1 2.1 2.5 2.0
Gavage ml
Day 63
2.1 2.2 2.4 2.2 2.5 2.2 1.9 2.1 2.1 2.2 2.1 2.2 2.2 2.4 2.0
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.2 2.2 2.2 2.2 2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2 1.9 1.9 1.9 1.9 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.0 2.0 2.0 2.0
Gavage ml
Day 68
2.1 2.2 2.4 2.2 2.5 2.2 1.9 2.1 2.1 2.2 2.1 2.2 2.2 2.4 2.0
Gavage ml
Day 69
2.1 2.2 2.4 2.2 2.5 2.2 1.9 2.1 2.1 2.2 2.1 2.2 2.2 2.4 2.0
Gavage ml
Day 70
2.1 2.3 2.5 2.2 2.5 2.2 1.9 2.2 2.1 2.3 2.1 2.2 2.2 2.5 2.0
Gavage ml
Day 71
2.1 2.3 2.5 2.2 2.5 2.2 1.9 2.2 2.1 2.3 2.1 2.2 2.2 2.5 2.0
m
f3it, O53.
J
0
4 o> o >
%
466
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
Gavage ml
Day 72
Gavage ml
Day 73
Female, VI - 10 mg/kg/day
648433 2.1 2.1 648406 2.3 2.3 648441 2.5 2.5 648414 2.2 2.2 648366 2.5 2.5 648382 2.2 2.2 648345 1.9 1.9 648374 2.2 2.2 648403 2.1 2.1 648429 2.3 2.3 648384 2.1 2.1 648352 2.2 2.2 648365 2.2 2.2 648413 2.5 2.5 648385 2.0 2.0
Gavage ml
Day 74
2.1 2.3 2.5 2.2 2.5 2.2 1.9 2.2 2.1 2.3 2.1 2.2 2.2 2.5 2.0
Gavage ml
Day 75
2.1 2.3 2.5 2.2 2.5 2.2 1.9 2.2 2.1 2.3 2.1 2.2 2.2 2.5 2.0
Gavage ml
Day 76
2.1 2.3 2.5 2.2 2.5 2.2 1.9 2.2 2.1 2.3 2.1 2.2 2.2 2.5 2.0
DuPont-6554
adividual Dose Volumes
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
Gavage ml
Day 80
Gavage ml
Day 81
Gavage ml
Day 82
Gavage ml
Day 83
2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.5 2.5 2.5 2.5 2.5 2.5 2.5
2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.0 2.0 2.0
2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.3 2.3 2.3
2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.1 2.1 2.1 2.1 2.1 2.1 2.1
467
H90-2-D4'6a)7y8O: raSluGbcahvraogneicSTtuodxyiciintyRats____________
)
Gavage ml
Day 84
Gavage ml
Day 85
Female, VI - 10 mg/kg/day
648433 2.2 2.2 648406 2.3 2.3 648441 2.6 2.6 648414 2.2 2.2 648366 2.6 2.6 648382 2.2 2.2 648345 2.0 2.0 648374 2.3 2.3 648403 2.2 2.2
648429 2.4 2.4 648384 2.3 2.3 648352 2.4 2.4 648365 2.3 2.3 648413 2.6 2.6 648385 2.1 2.1
Gavage ml
Day 86
2.2 2.3 2.6 2.2 2.6 2.2 2.0 2.3 2.2 2.4 2.3 2.4 2.3 2.6 2.1
Gavage ml
Day 87
2.2 2.3 2.6 2.2 2.6 2.2 2.0 2.3 2.2 2.4 2.3 2.4 2.3 2.6 2.1
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.4 2.6 2.6 2.6 2.5 2.2 2.2 2.2 2.3 2.6 2.6 2.6 2.6 2.2 2.2 2.2 2.3 2.0 2.0 2.0 2.0 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.4 2.4 2.4 2.3 2.3 2.3 2.6 2.6 2.6 2.1 2.1 2.1
Gavage ml
Day 92
2.2 2.4 2.5 2.3 2.6 2.3 2.0 2.3 2.2 2.4
)
DuPont-6554
Company Sanitized. Does net confai TSCA CB1
468
H90--2D4>6ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Gavage ml
Day 2
Female, VIII - 60 mg/kg/day
648380 1.5 1.5 1.5 648381 1.5 1.5 1.5 648432 1.6 1.6 1.6 648440 1.5 1.5 1.5 648348 1.5 1.5 1.5 648417 1.5 1.5 1.5 648368 1.5 1.5 1.5 648401 1.4 1.4 1.4 648362 1.4 1.4 1.4 648354 1.4 1.4 1.4 648349 1.5 1.5 1.5
648415 1.4 1.4 1.4 648379 1.6 1.6 1.6 648386 1.5 1.5 1.5 648360 1.3 1.3 1.3
Gavage ml
Day 3
1.5 1.5 1.6 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.5 1.4 1.6 1.5 1.3
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.6 1.6 1.6 1.6 1.8 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.6 1.5 1.5 1.5 1.6 1.4 1.4 1.4 1.5 1.4 1.4 1.4 1.5 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.4 1.4 1.4 1.6 1.6 1.6 1.6 1.7 1.5 1.5 1.5 1.6 1.3 1.3 1.3 1.4
Gavage ml
Day 8
1.7 1.6 1.8 1.7 1.7 1.6 1.6 1.5 1.5 1.5 1.6 1.6 1.7 1.6 1.4
Gavage ml
Day 9
1.7 1.6 1.8 1.7 1.7 1.6 1.6 1.5 1.5 1.5 1.6 1.6 1.7 1.6 1.4
Gavage ml
Day 10
1.7 1.6 1.8 1.7 1.7 1.6 1.6 1.5 1.5 1.5 1.6 1.6 1.7 1.6 1.4
Gavage ml
Day 11
1.7 1.6 1.8 1.7 1.7 1.6 1.6 1.5 1.5 1.5 1.6 1.6 1.7 1.6 1.4
Company Sanitized. Does not contain TSCACBS
469
H90--2D46)ay78O: raSluGbcahvraogneicSTtuodxyicinityRats______
>
)
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Gavage ml
Day 14
Female, VIII - 60 mg/kg/day
648380 1.7 1.7 1.7
64.8381 1.6 1.6 1.6 648432 1.8 1.8 1.8
648440 1.7 1.7 1.7 648348 1.7 1.7 1.7 648417 1.6 1.6 1.6 648368 1.6 1.6 1.6 648401 1.5 1.5 1.5 648362 1.5 1.5 1.5 648354 1.5 1.5 1.5 648349 1.6 1.6 1.6 648415 1.6 1.6 1.6 648379 1.7 1.7 1.7 648386 1.6 1.6 1.6 648360 1.4 1.4 1.4
Gavage ml
Day 15
1.9 1.7 2.0 1.9 1.9 1.7 2.0 1.7 1.7 1.7 1.7 1.7 1.9 1.7 1.5
Individual Dose Volumes
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
1.9 1.9 1.9 1.9 1.7 1.7 1.7 1.7 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.7 1.7 1.7 1.7 2.0 2.0 2.0 2.0 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.9 1.9 1.9 1.9 1.7 1.7 1.7 1.7 1.5 1.5 1.5 1.5
Gavage ml
Day 20
1.9 1.7 2.0 1.9 1.9 1.7 2.0 1.7 1.7 1.7 1.7 1.7 1.9 1.7 1.5
Gavage ml
Day 21
2.1 1.9 2.1 2.0 2.0 1.8 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.7
Gavage ml
Day 22
2.1 1.9 2.1 2.0 2.0 1.8 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.7
Gavage ml
Day 23
2.1 1.9 2.1 2.0 2.0 1.8 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.7
Sanfisrecf. Does v>t<sonta*nTSCA CBI
470
) H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
)
>
DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Gavage ml
Day 26
Female, VIII - 60 mg/kg/day
648380 2.1 2.1 2.1 648381 1.9 1.9 1.9 648432 2.1 2.1 2.1 648440 2.0 2.0 2.0 648348 2.0 2.0 2.0 648417 1.8 1.8 1.8 648368 1.9 1.9 1.9 648401 1.8 1.8 1.8 648362 1.8 1.8 1.8 648354 1.8 1.8 1.8 648349 1.8 1.8 1.8 648415 1.9 1.9 1.9 648379 1.9 1.9 1.9 648386 1.9 1.9 1.9 648360 1.7 1.7 1.7
Gavage ml
Day 27
2.1 1.9 2.1 2.0 2.0 1.8 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.7
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
2.1 2.1 2.1 2.1 1.9 1.9 1.9 1.9 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 1.8 1.8 1.8 1.8
Gavage ml
Day 32
2.1 1.9 2.3 2.2 2.2 1.9 2.0 1.9 1.9 1.8 1.9 2.0 2.1 2.0 1.8
Gavage ml
Day 33
2.1 1.9 2.3 2.2 2.2 1.9 2.0 1.9 1.9 1.8 1.9 2.0 2.1 2.0 1.8
Gavage ml
Day 34
2.1 1.9 2.3 2.2 2.2 1.9 2.0 1.9 1.9 1.8 1.9 2.0 2.1 2.0 1.8
Gavage ml
Day 35
2.3 2.0 2.4 2.4 2.3 2.0 2.1 2.0 1.9 1.9 2.0 2.1 2.2 2.1 1.8
Sanfflteed. D am not conf^n TSCACBS
471
H90--2D4)6ay78O: raSluGbcahvraogneicStTuodxyicinityRats
)
) DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Gavage ml
Day 38
Female, VIII - 60 mg/kg/day
648380 2.3 2.3 2.3 648381 2.0 2.0 2.0 648432 2.4 2.4 2.4
648440 2.4 2.4 2.4 648348 2.3 2.3 2.3 648417 2.0 2.0 2.0 648368 2.1 2.1 2.1 648401 2.0 2.0 2.0 648362 1.9 1.9 1.9 648354 1.9 1.9 1.9 648349 2.0 2.0 2.0 648415 2.1 2.1 2.1 648379 2.2 2.2 2.2 648386 2.1 2.1 2.1 648360 1.8 1.8 1.8
Gavage ml
Day 39
2.3 2.0 2.4 2.4 2.3 2.0 2.1 2.0 1.9 1.9 2.0 2.1 2.2 2.1 1.8
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
2.3 2.3 2.3 2.3 2.0 2.0 2.0 2.0 2.4 2.4 2.5 2.5 2.4 2.4 2.5 2.5 2.3 2.3 2.4 2.4 2.0 2.0 2.0 2.0 2.1 2.1 2.2 2.2 2.0 2.0 1.9 1.9 1.9 1.9 2.0 2.0 1.9 1.9 1.9 1.9 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.1 2.1 2.2 2.2 1.8 1.8 1.9 1.9
Gavage ml
Day 44
2.3 2.0 2.5 2.5 2.4 2.0 2.2 1.9 2.0 1.9 2.1 2.2 2.2 2.2 1.9
Gavage ml
Day 45
2.3 2.0 2.5 2.5 2.4 2.0 2.2 1.9 2.0 1.9 2.1 2.2 2.2 2.2 1.9
Gavage ml
Day 46
2.3 2.0 2.5 2.5 2.4 2.0 2.2 1.9 2.0 1.9 2.1 2.2 2.2 2.2 1.9
Gavage ml
Day 47
2.3 2.0 2.5 2.5 2.4 2.0 2.2 1.9 2.0 1.9 2.1 2.2 2.2 2.2 1.9
01
o
5a
Sanitized. Does not contain TSC CBI
472
H90--2D4)6ay78O: raSluGbcahvraogneicStTuodxyicinityRats___________
)
DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Gavage ml
Day 50
Female, VIII - 60 mg/kg/day
648380 2.3 2.4 2.4 648381 2.0 2.1 2.1 648432 2.5 2.6 2.6 648440 2.5 2.5 2.5 648348 2.4 2.5 2.5 648417 2.0 2.1 2.1 648368 2.2 2.2 2.2 648401 1.9 2.1 2.1 648362 2.0 2.0 2.0 648354 1.9 2.0 2.0 648349 2.1 2.1 2.1 648415 2.2 2.3 2.3 648379 2.2 2.3 2.3 648386 2.2 2.2 2.2 648360 1.9 2.0 2.0
Gavage ml
Day 51
2.4 2.1 2.6 2.5 2.5 2.1 2.2 2.1 2.0 2.0 2.1 2.3 2.3 2.2 2.0
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1 2.6 2.6 2.6 2.6 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0
Gavage ml
Day 56
2.5 2.2 2.6 2.7 2.5 2.2 2.4 2.2 2.1 2.0 2.2 2.4 2.4 2.4 2.1
Gavage ml
Day 57
2.5 2.2 2.6 2.7 2.5 2.2 2.4 2.2 2.1 2.0 2.2 2.4 2.4 2.4 2.1
Gavage ml
Day 58
2.5 2.2 2.6 2.7 2.5 2.2 2.4 2.2 2.1 2.0 2.2 2.4 2.4 2.4 2.1
Gavage ml
Day 59
2.5 2.2 2.6 2.7 2.5 2.2 2.4 2.2 2.1 2.0 2.2 2.4 2.4 2.4 2.1
Company Sanitized. Does not confab TSCA CBS
473
)
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyiciintyRats_________
)
)
DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Gavage ml
Day 62
Female, VIII - 60 mg/kg/day
648380 2.5 2.5 2.5 648381 2.2 2.2 2.2 648432 2.6 2.6 2.6 648440 2.7 2.7 2.7 648348 2.5 2.5 2.5 648417 2.2 2.2 2.2 648368 2.4 2.4 2.4 648401 2.2 2.2 2.2 648362 2.1 2.1 2.1 648354 2.0 2.0 2.0 648349 2.2 2.2 2.2 648415 2.4 2.4 2.4 648379 2.4 2.4 2.4 648386 2.4 2.4 2.4 648360 2.1 2.1 2.1
Gavage ml
Day 63
2.6 2.2 2.7 2.6 2.6 2.2 2.5 2.2 2.0 2.0 2.2 2.4 2.4 2.4 2.0
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
2.6 2.6 2.6 2.6 2.2 2.2 2.2 2.2 2.7 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.2 2.2 2.2 2.2 2.5 2.5 2.5 2.5 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.0 2.0 2.0 2.0
Gavage ml
Day 68
2.6 2.2 2.7 2.6 2.6 2.2 2.5 2.2 2.0 2.0 2.2 2.4 2.4 2.4 2.0
Gavage ml
Day 69
2.6 2.2 2.7 2.6 2.6 2.2 2.5 2.2 2.0 2.0 2.2 2.4 2.4 2.4 2.0
Gavage ml
Day 70
2.6 2.2 2.8 2.7 2.6 2.2 2.3 2.1 2.1 2.0 2.2 2.4 2.3 2.4 2.1
Gavage ml
Day 71
2.6 2.2 2.8 2.7 2.6 2.2 2.3 2.1 2.1 2.0 2.2 2.4 2.3 2.4 2.1
Sanded. Pons not contain TSCA CBI
474
9H0--2D4>6ay78O: raSluGbcahvraogneicSTtuodxyicinityRats_____________________________________)_
)
DuPont-6554
Gavage ml
Day 72
Gavage ml
Day 73
Gavage ml
Day 74
Female, VIII - 60 mg/kg/day
648380 2.6 2.6 2.6 648381 2.2 2.2 2.2 648432 2.8 2.8 2.8 648440 2.7 2.7 2.7 648348 2.6 2.6 2.6 648417 2.2 2.2 2.2 648368 2.3 2.3 2.3 648401 2.1 2.1 2.1 648362 2.1 2.1 2.1 648354 2.0 2.0 2.0 648349 2.2 2.2 2.2 648415 2.4 2.4 2.4 648379 2.3 2.3 2.3 648386 2.4 2.4 2.4 648360 2.1 2.1 2.1
Gavage ml
Day 75
2.6 2.2 2.8 2.7 2.6 2.2 2.3 2.1 2.1 2.0 2.2 2.4 2.3 2.4 2.1
Individual Dose Volumes
Gavage ml
Day 76
Gavage ml
Day 77
Gavage ml
Day 78
Gavage ml
Day 79
2.6 2.7 2.7 2.7 2.2 2.2 2.2 2.2 2.8 2.8 2.8 2.8 2.7 2.8 2.8 2.8 2.6 2.6 2.6 2.6 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.1 2.2 2.2 2.2 2.1 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.2 2.4 2.4 2.4 2.4 2.3 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.1 2.2 2.2 2.2
Gavage ml
Day 80
2.7 2.2 2.8 2.8 2.6 2.3 2.3 2.2 2.2 2.0 2.2 2.4 2.4 2.5 2.2
Gavage ml
Day 81
2.7 2.2 2.8 2.8 2.6 2.3 2.3 2.2 2.2 2.0 2.2 2.4 2.4 2.5 2.2
Gavage ml
Day 82
2.7 2.2 2.8 2.8 2.6 2.3 2.3 2.2 2.2 2.0 2.2 2.4 2.4 2.5 2.2
Gavage ml
Day 83
2.7 2.2 2.8 2.8 2.6 2.3 2.3 2.2 2.2 2.0 2.2 2.4 2.4 2.5 2.2
Sanitized. Does not contain TSCA CBI
475
9H0--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Gavage ml
Day 84
Gavage ml
Day 85
Gavage ml
Day 86
Female, VIII - 60 mg/kg/day
648380 2.7 2.7 2.7 648381 2.3 2.3 2.3 648432 3.0 3.0 3.0 648440 2.8 2.8 2.8 648348 2.6 2.6 2.6 648417 2.4 2.4 2.4 648368 2.4 2.4 2.4 648401 2.3 2.3 2.3 648362 2.2 2.2 2.2 648354 2.1 2.1 2.1 648349 2.3 2.3 2.3 648415 2.4 2.4 2.4 648379 2.5 2.5 2.5 648386 2.5 2.5 2.5 648360 2.2 2.2 2.2
Gavage ml
Day 87
2.7 2.3 3.0 2.8 2.6 2.4 2.4 2.3 2.2 2.1 2.3 2.4 2.5 2.5 2.2
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
2.7 2.7 2.7 2.7 2.3 2.3 2.3 2.3 3.0 3.0 3.0 3.1 2.8 2.8 2.8 3.0 2.6 2.6 2.6 2.7 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.0 2.3 2.3 2.3 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.5 2.5 2.2 2.2 2.2
Gavage ml
Day 92
2.' 2.: 3.: 3.1 2.' 2.. 2.: 2.: 2.: 2.1
)
DuPont-6554
476
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 0
Gavage ml
Day 1
Female, X - 300 mg/kg/day
648407 1.5 1.5 64.8392 1.5 1.5 648435 1.6 1.6 648376 1.6 1.6 648347 1.5 1.5 648412 1.4 1.4 648438 1.4 1.4 648400 1.7 1.7 648388 1.6 1.6 648373 1.5 1.5 648358 1.4 1.4 648367 1.5 1.5 648391 1.6 1.6 648411 1.4 1.4 648355 1.5 1.5 648387 1.3 1.3 648419 1.4 1.4 648378 1.4 1.4 648398 1.5 1.5 648350 1.5 1.5 648383 1.3 1.3 648359 1.5 1.5 648375 1.5 1.5 648399 1.5 1.5 648363 1.6 1.6
Gavage ml
Day 2
1.5 1.5 1.6 1.6 1.5 1.4 1.4 1.7 1.6 1.5 1.4 1.5 1.6 1.4 1.5 1.3 1.4 1.4 1.5 1.5 1.3 1.5 1.5 1.5 1.6
Gavage ml
Day 3
1.5 1.5 1.6 1.6 1.5 1.4 1.4 1.7 1.6 1.5 1.4 1.5 1.6 1.4 1.5 1.3 1.4 1.4 1.5 1.5 1.3 1.5 1.5 1.5 1.6
Individual Dose Volumes
Gavage ml
Day 4
Gavage ml
Day 5
Gavage ml
Day 6
Gavage ml
Day 7
1.5 1.5 1.5 1.6 1.5 1.5 1.5 1.6 1.6 1.6 1.6 1.7
1.6 1.6 1.6 1.8 1.5 1.5 1.5 1.7 1.4 1.4 1.4 1.5 1.4 1.4 1.4 1.5 1.7 1.7 1.7 1.7 1.6 1.6 1.6 1.7 1.5 1.5 1.5 1.7 1.4 1.4 1.4 1.4 1.5 1.5 1.5 1.7 1.6 1.6 1.6 1.7 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.3 1.3 1.3 1.5 1.4 1.4 1.4 1.5 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.5 1.5 1.5 1.7 1.3 1.3 1.3 1.4 1.5 1.5 1.5 1.7 1.5 1.5 1.5 1.5 1.7 1.6 1.6 1.6 1.8
Gavage ml
Day 8
1.6 1.6 1.7 1.8 1.7 1.5 1.5 1.7 1.7 1.7 1.4 1.7 1.7 1.5 1.6 1.5 1.5 1.5 1.6 1.7 1.4 1.7
1.7 1.8
Gavage ml
Day 9
1.6 1.6 1.7 1.8 1.7 1.5 1.5 1.7 1.7 1.7 1.4 1.7 1.7 1.5 1.6 1.5 < 1.5 1.5 1.6 1.7 1.4 1.7
1.7 1.8
Gavage ml
Day 10
1.6 1.6 1.7 1.8 1.7 1.5 1.5 1.7 1.7 1.7 1.4 1.7 1.7 1.5 1.6 1.5 1.5 1.5 1.6 1.7 1.4 1.7
1.7 1.8
Gavage ml
Day 11
1.6 1.6 1.7 1.8 1.7 1.5 1.5 1.7 1.7 1.7 1.4 1.7 1.7 1.5 1.6 1.5 1.5 1.5 1.6 1.7 1.4 1.7
1.7 1.8
I
I
TSCACBI
477
H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
DuPont-6554
Gavage ml
Day 12
Gavage ml
Day 13
Female, X - 300 mg/kg/day
648407 1.6 1.6 648392 1.6 1.6 648435 1.7 1.7
648376 1.8 1.8 648347 1.7 1.7 648412 1.5 1.5 648438 1.5 1.5 648400 1.7 1.7 648388 1.7 1.7 648373 1.7 1.7 648358 1.4 1.4 648367 1.7 1.7 648391 1.7 1.7 648411 1.5 1.5 648355 1.6 1.6 648387 1.5 1.5 648419 1.5 1.5 648378 1.5 1.5 648398 1.6 1.6 648350 1.7 1.7 648383 1.4 1.4 648359 1.7 1.7 648375 648399 1.7 1.7 648363 1.8 1.8
Gavage ml
Day 14
1.6 1.6 1.7 1.8 1.7 1.5 1.5 1.7 1.7 1.7 1.4 1.7 1.7 1.5 1.6 1.5 1.5 1.5 1.6 1.7 1.4 1.7
1.7 1.8
Gavage ml
Day 15
1.8 1.7 1.9 2.0 1.8 1.6 1.7 1.9 1.8 1.9 1.6 1.9 1.8 1.7 1.6 1.6 1.7 1.7 1.8 1.9 1.5 1.8
1.9 2.0
Individual Dose Volinr.es
Gavage ml
Day 16
Gavage ml
Day 17
Gavage ml
Day 18
Gavage ml
Day 19
1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7
1.9 1.9 1.9 1.9
2.0
2.0
2.0 b
2.0
1.8 1.8 1.8 1.8 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 1.6 1.6 1.6 1.6
1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 1.5 1.5 1.5 1.5 1.8 1.8 1.8 1.8
1.9 1.9 , 1.9 1.9 2.0 2.0 2.0 2.0
Gavage ml
Day 20
1.8 1.7 1.9 2.0 1.8 1.6 1.7 1.9 1.8 1.9 1.6 1.9 1.8 1.7 1.6 1.6 1.7 1.7 1.8 1.9 1.5 1.8
1.9 2.0
Gavage ml
Day 21
1.8 1.9 2.0 2.0 1.9 1.8 1.8 2.0 1.9 1.9 1.7 2.0 1.9 1.8 1.7 1.7 1.9 1.8 1.8 1.9 1.6 1.9
2.1 2.3
Gavage ml
Day 22
1.8 1.9 2.0 2.0 1.9 1.8 1.8 2.0 1.9 1.9 1.7 2.0 1.9 1.8 1.7 1.7 1.9 1.8 1.8 1.9 1.6 1.9
2.1 2.3
Gavage ml
Day 23
1.8 1.9 2.0 2.0 1.9 1.8 1.8 2.0 1.9 1.9 1.7 2.0 1.9 1.8 1.7 1.7 1.9 1.8 1.3 1.9 1.6 1.9
2.1 2.3
478
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats__________________
))
______________________________________________ DuPont-6554
Gavage ml
Day 24
Gavage ml
Day 25
Female, X - 300 mg/kg/day
648407 1.8 1.8 648392 1.9 1.9 648435 2.0 2.0 648376 2.0 2.0 648347 1.9 1.9 648412 1.8 1.8 648438 1.8 1.8 648400 2.0 2.0 648388 1.9 1.9 648373 1.9 1.9 648358 1.7 1.7 648367 2.0 2.0 648391 1.9 1.9 648411 1.8 1.8 648355 1.7 1.7 648387 1.7 1.7 648419 1.9 1.9 648378 1.8 1.8 648398 1.8 1.8 648350 1.9 1.9 648383 1.6 1.6 648359 1.9 1.9 648375 648399 2.1 2.1 648363 2.3 2.3
Gavage ml
Day 26
1.8 1.9 2.0 2.0 1.9 1.8 1.8 2.0 1.9 1.9 1.7 2.0 1.9 1.8 1.7 1.7 1.9 1.8 1.8 1.9 1.6 1.9
2.1 2.3
Gavage ml
Day 27
1.8 1.9 2.0 2.0 1.9 1.8 1.8 2.0 1.9 1.9 1.7 2.0 1.9 1.8 1.7 1.7 1.9 1.8 1.8 1.9 1.6 1.9
2.1 2.3
Individual Dose Volumes
Gavage ml
Day 28
Gavage ml
Day 29
Gavage ml
Day 30
Gavage ml
Day 31
2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.8 1.8 1.8 1.8 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 1.9 1.9 1.9 1.9 2.1 2.1 2.1 2.1 1.7 1.7 1.7 1.7 2.1 2.1 2.1 2.1
2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2
Gavage ml
Day 32
2.0 2.0 2.1 2.1 2.0 1.8 2.0 2.1 2.1 2.1 1.8 2.0 1.9 1.9 1.9 1.8 1.9 2.0 1.9 2.1 1.7 2.1
2.2 2.2
Gavage ml
Day 33
2.0 2.0 2.1 2.1 2.0 1.8 2.0 2.1 2.1 2.1 1.8 2.0 1.9 1.9 1.9 1.8 1.9 2.0 1.9 2.1 1.7 2.1
2.2 2.2
Gavage ml
Day 34
2.0 2.0 2.1 2.1 2.0 1.8 2.0 2.1 2.1 2.1 1.8 2.0 1.9 1.9 1.9 1.8 1.9 2.0 1.9 2.1 1.7 2.1
2.2 2.2
Gavage ml
Day 35
2.1 2.0 2.2 2.2 2.1 1.9 2.1 2.2 2.2 2.1 1.9 2.1 2.1 2.0 1.9 2.0 2.0 2.0 2.0 2.2 1.8 2.2
2.3 2.4
Company Sanitized. Does not contain TSCACBI
479
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats
)
)
DuPont-6554
Gavage ml
Day 36
Gavage ml
Day 37
Female, X - 300 mg/kg/day
648407 2.1 2.1 648392 2.0 2.0 648435 2.2 2.2 648376 2.2 2.2 648347 2.1 2.1 648412 1.9 1.9 648438 2.1 2.1 648400 2.2 2.2 648388 2.2 2.2 648373 2.1 2.1 648358 1.9 1.9 648367 2.1 2.1 648391 2.1 2.1 648411 2.0 2.0 648355 1.9 1.9 648387 2.0 2.0 648419 2.0 2.0 648378 2.0 2.0 648398 2.0 2.0 648350 2.2 2.2 648383 1.8 1.8 648359 2.2 2.2 648375
648399 2.3 2.3 648363 2.4 2.4
Gavage ml
Day 38
2.1 2.0 2.2 2.2 2.1 1.9 2.1 2.2 2.2 2.1 1.9 2.1 2.1 2.0 1.9 2.0 2.0 2.0 2.0 2.2 1.8 2.2
2.3 2.4
Gavage ml
Day 39
2.1 2.0 2.2 2.2 2.1 1.9 2.1 2.2 2.2 2.1 1.9 2.1 2.1 2.0 1.9 2.0 2.0 2.0 2.0 2.2 1.8 2.2
2.3 2.4
Individual Dose Volumes
Gavage ml
Day 40
Gavage ml
Day 41
Gavage ml
Day 42
Gavage ml
Day 43
2.1 2.1 2.1 2.1 2.0 2.0 2.1 2.1 2.2 2.2 2.3 2.3 2.2 2.2 2.3 2.3 2.1 2.1 2.1 2.1 1.9 1.9 2.0 2.0 2.1 2.1 2.1 2.1 2.2 2.2 2.3 2.3 2.2 2.2 2.2 2.2 2.1 2.1 2.3 2.3 1.9 1.9 1.9 1.9 2.1 2.1 2.2 2.2 2.1 2.1 2.0 2.0 2.0 2.0 2.1 2.1 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.2 2.2 2.3 2.3 1.8 1.8 1.8 1.8 2.2 2.2 2.3 2.3
2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4
Gavage ml
Day 44
2.1 2.1 2.3 2.3 2.1 2.0 2.1 2.3 2.2 2.3 1.9 2.2 2.0 2.1 2.0 2.0 2.1 2.0 2.1 2.3 1.8 2.3
2.3 2.4
Gavage ml
Day 45
2.1 2.1 2.3 2.3 2.1 2.0 2.1 2.3 2.2 2.3 1.9 2.2 2.0 2.1 2.0 2.0 2.1 2.0 2.1 2.3 1.8 2.3
2.3 2.4
Gavage ml
Day 46
2.1 2.1 2.3 2.3 2.1 2.0 2.1 2.3 2.2 2.3 1.9 2.2 2.0 2.1 2.0 2.0 2.1 2.0 2.1 2.3 1.8 2.3
2.3 2.4
Gavage ml
Day 47
2.1 2.1 2.3 2.3 2.1 2.0 2.1 2.3 2.2 2.3 1.9 2.2 2.0 2.1 2.0 2.0 2.1 2.0 2.1 2.3 1.8 2.3
2.3 2.4
Company Sanitized. Does not contain TSCACBS
480
)
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats____________________________
)
)
_____________ DuPont-6554
Gavage ml
Day 48
Gavage ml
Day 49
Female, X - 300 mg/kg/day
648407 2.1 2.1 648392 2.1 2.2 648435 2.3 2.3 648376 2.3 2.4 648347 2.1 2.2 648412 2.0 2.0 648438 2.1 2.2 648400 2.3 2.3 648388 2.2 2.2 648373 2.3 2.3 648358 1.9 2.0 648367 2.2 2.3 648391 2.0 2.2 648411 2.1 2.1 648355 2.0 2.0 648387 2.0 2.1 648419 2.1 2.1 648378 2.0 2.2
648398 2.1 2.1 648350 2.3 2.4 648383 1.8 1.8 648359 2.3 2.3
648375
648399 2.3 2.3 648363 2.4 2.5
Gavage ml
Day 50
2.1 2.2 2.3 2.4 2.2 2.0 2.2 2.3 2.2 2.3 2.0 2.3 2.2 2.1 2.0 2.1 2.1 2.2 2.1 2.4 1.8 2.3
2.3 2.5
Gavage ml
Day 51
2.1 2.2 2.3 2.4 2.2 2.0 2.2 2.3 2.2 2.3 2.0 2.3 2.2 2.1 2.0 2.1 2.1 2.2 2.1 2.4 1.8 2.3
2.3 2.5
Individual Dose Volumes
Gavage ml
Day 52
Gavage ml
Day 53
Gavage ml
Day 54
Gavage ml
Day 55
2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4 2.2 2.2 2.2 2.2 2.0 2.0 2.0 2.0 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.0 2.0 2.0 2.0 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.4 2.4 2.4 2.4 1.8 1.8 1.8 1.8 2.3 2.3 2.3 2.3
2.3 2.3 2.3 2.3 2.5 2.5 2.5 2.5
Gavage ml
Day 56
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
Gavage ml
Day 57
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
Gavage ml
Day 58
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
Gavage ml
Day 59
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
-Do wo*contain TSCA CBI
481
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyicinityRats__________
DuPont-6554
Gavage ml
Day 60
Gavage ml
Day 61
Female, X - 300 mg/kg/day
648407 648392 648435 648376 648347 648412 648438 648400 648388 648373 648358 648367 648391 648411 648355 648387 648419 648378 648398 648350 648383 648359 648375
648399 648363
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 b 2.6
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
Gavage ml
Day 62
2.2 2.2 2.6 2.3 2.3 2.0 2.3 2.4 2.3 2.4 2.8 2.4 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.5 1.9 2.4
2.5 2.6
Gavage ml
Day 63
2.3 2.3 2.6 2.5 2.4 2.1 2.4 2.3 2.4 2.5 2.0 2.4 2.2 2.2 2.1 2.2 2.2 2.3 2.3 2.5 2.0 2.5
2.5 2.5
Individual Dose Volumes
Gavage ml
Day 64
Gavage ml
Day 65
Gavage ml
Day 66
Gavage ml
Day 67
2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.6 2.6 2.6 2.6 2.5 2.5 2.5 2.5 2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1 2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.0 2.0 2.0 2.0 2.4 2.4 2.4 2.4 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.5 2.5 2.5 2.5 2.0 2.0 2.0 2.0 2.5 2.5 2.5 2.5
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Gavage ml
Day 68
2.3 2.3 2.6 2.5 2.4 2.1 2.4 2.3 2.4 2.5 2.0 2.4 2.2 2.2 2.1 2.2 2.2 2.3 2.3 2.5 2.0 2.5
2.5 2.5
Gavage ml
Day 69
2.3 2.3 2.6 2.5 2.4 2.1 2.4 2.3 2.4 2.5 2.0 2.4 2.2 2.2 2.1 2.2 2.2 2.3 2.3 2.5 2.0 2.5
2.5 2.5
Gavage ml
Day 70
2.3 2.3 2.7 2.6 2.4 2.1 2.4 2.5 2.4 2.5 2.1 2.4 2.2 2.2 2.1 2.3 2.3 2.3 2.4 2.7 2.0 2.6
2.6 2.7
Gavage ml
Day 71
2.3 2.3 2.7 2.6 2.4 2.1 2.4 2.5 2.4 2.5 2.1 2.4 2.2 2.2 2.1 2.3 2.3 2.3 2.4 2.7 2.0 2.6
2.6 2.7
Company Sanitized. Does rt contain TSCACBI
482
) H90--2D46ay78O: raSluGbcahvraogneicStTuodxyicinityRats
Ir
Gavage ml
Day 72
Gavage ml
Day 73
Gavage ml
Day 74
Gavage ml
Day 75
Gavage ml
Day 76
Female, X - 300 mg/kg/day
648407 2.3 2.3 2.3 2.3 2.3 648392 2.3 2.3 2.3 2.3 2.3 648435 2.7 2.7 2.7 2.7 2.7
648376 2.6 2.6 2.6 2.6 2.6 648347 2.4 2.4 2.4 2.4 2.4
648412 2.1 2.1 2.1 2.1 2.1 648438 2.4 2.4 2.4 2.4 2.4 648400 2.5 2.5 2.5 2.5 2.5 648388 2.4 2.4 2.4 2.4 2.4 648373 2.5 2.5 2.5 2.5 2.5 648358 2.1 2.1 2.1 2.1 2.1 648367 2.4 2.4 2.4 2.4 2.4 648391 2.2 2.2 2.2 2.2 2.2 648411 2.2 2.2 2.2 2.2 2.2 648355 2.1 2.1 2.1 2.1 2.1 648387 2.3 2.3 2.3 2.3 2.3
2 648419 2.3 2.3 2.3 2.3 2.3 648378 2.3 2.3 2.3 2.3 2.3 648398 2.4 2.4 2.4 2.4 2.4 648350 2.7 2.7 2.7 2.7 2.7
648383 2.0 2.0 2.0 2.0 2.0 648359 2.6 2.6 2.6 2.6 2.6 648375
648399 2.6 2.6 2.6 2.6 2.6 648363 2.7 2.7 2.7 2.7 2.7
Sannteed nml
-4
CO
oo
>
a
DuPont-6554
.dividual Dose Volumes
ige Gavage Gavage ml ml
77 Day 78 Day 79
Gavage ml
Day 80
Gavage ml
Day 81
Gavage ml
Day 82
Gavage ml
Day 83
2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.7 2.7 2.7 2.7 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.6 2.6 2.6 2.6 2.6 2.6 2.6
2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.7 2.7 2.7 2.7 2.7 2.7 2.7
483
H90--2D46ay78O: raSluGbcahvraogneicSTtuodxyiciintyRats
Gavage ml
Day 84
Gavage ml
Day 85
Female, X - 300 mg/kg/day
648407 2.4 2.4 648392 2.3 2.3 648435 2.9 2.9
648376 2.6 2.6 648347 2.4 2.4 648412 2.1 2.1 648438 2.5 2.5 648400 2.5 2.5 648388 2.5 2.5 648373 2.6 2.6 648358 2.2 2.2 648367 2.4 2.4 648391 2.3 2.3 648411 2.2 2.2 648355 2.1 2.1 648387 2.3 2.3 648419 2.3 2.3 648378 2.4 2.4 648398 2.4 2.4 648350 2.7 2.7 648383 2.1 2.1 648359 2.7 2.7 648375
648399 2.6 2.6 648363 2.7 2.7
Gavage ml
Day 86
2.4 2.3 2.9 2.6 2.4 2.1 2.5 2.5 2.5 2.6 2.2 2.4 2.3 2.2 2.1 2.3 2.3 2.4 2.4 2.7 2.1 2.7
2.6 2.7
Gavage ml
Day 87
2.4 2.3 2.9 2.6 2.4 2.1 2.5 2.5 2.5 2.6 2.2 2.4 2.3 2.2 2.1 2.3 2.3 2.4 2.4 2.7 2.1 2.7
2.6 2.7
Individual Dose Volumes
Gavage ml
Day 88
Gavage ml
Day 89
Gavage ml
Day 90
Gavage ml
Day 91
2.4 2.4 2.4 2.4 2.3 2.3 2.3 2.4 2.9 2.9 2.9 2.9 2.6 2.6 2.6 2.7 2.4 2.4 2.4 2.5 2.1 2.1 2.1 2.2 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.6 2.5 2.5 2.5 2.6 2.6 2.6 2.6 2.2 2.2 2.2 2.4 2.4 2.4 2.3 2.3 2.3 2.2 2.2 2.2 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.3 2.3 2.4 2.4 2.4 2.4 2.4 2.4 2.7 2.7 2.7 2.1 2.1 2.1 2.7 2.7 2.7
2.6 2.6 2.6 2.7 2.7 '2.7 2.8
Gavage ml
Day 92
2.' 2.' 2.1 2.` 2.' 2.: 2.! 2.i 2.i
2.1
DuPont-6554
AUeOUIQQ
w ' wk` " `H'"1
484
